Conditions: Anaplastic Ependymoma Ependymoma Ependymomas
Keywords: Proteasome Inhibitor Penetration Across the Blood-Brain-Barrier (BBB) Apoptosis Induction Targeted Therapeutic Effect Tumor Progression
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
Background:

Ependymomas are rare tumors that arise from the ependyma. That is a tissue of the central nervous system. They can develop in the brain or the spine. They are usually treated with surgery, radiation, and/or chemotherapy. Researchers want to see if the new drug marizomib can help people with a certain kind of ependymoma.

Objective:

To see if marizomib stops tumor growth and prolongs the time that the tumor is controlled.

Eligibility:

Adults age 18 and older who have been diagnosed with ependymomas and have already been treated with standard therapies

Design:

Participants will be screened with the following tests or recent results from similar tests:

* Medical history
* Physical exam
* Neurological assessment
* Electrocardiogram (EKG) to evaluate the heart
* Review of symptoms and ability to perform normal activities
* Computed tomographic scan (CT) or magnetic resonance imaging (MRI) to produce an image of the brain or spine.
* Blood and urine tests
* Tests of tumor samples. Participants may have to have new tumor samples taken.

Participants will get the study drug in cycles. Each cycle is 4 weeks. Participants will have up to 24 cycles.

Participants will get the study drug through a small plastic tube in a vein on days 1, 8, and 15 of each cycle.

During each cycle, some screening tests will be repeated.

Participants will answer questions about their general well-being and functioning.

About 4 5 weeks after finishing the study drug, participants will have a follow-up visit. They will answer questions about their health, get a physical and a neurological exam, and have blood tests. They may have an MRI or CT scan.

...

Detailed description:
Background:

* Ependymomas are rare primary brain tumors arising from radial glial stem cells. They comprise 5.2% of all pediatric primary brain tumors and 1.9% of all adult primary brain tumors.
* The standard therapy for newly diagnosed ependymoma is gross total resection followed by radiation therapy. For anaplastic ependymoma, recurrence rate is high with a median progression free survival (PFS) of 2.3 years.
* There are limited chemotherapy options for recurrent ependymomas, which have already been irradiated. Therefore, there is an unmet need to target novel pathways for treatment of ependymomas.
* About 70% of supratentorial ependymomas have a characteristic signature C11 orf95-V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A (RELA) fusion which drives tumorigenesis in ependymomas by activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) transcription pathway.
* Marizomib is a second-generation irreversible proteasome inhibitor which penetrates across the blood-brain-barrier (BBB). It inhibits the activity of 20S proteasome in glioma cells, activates caspases, builds up reactive oxygen species and thus induces apoptosis. Marizomib blocks the NF-pathway by proteasome inhibition. Thus, it may have an additional targeted therapeutic effect in the RELA-fusion molecular subgroup of ependymomas.

Objective:

-To evaluate the efficacy of treatment with marizomib in RELA-fusion recurrent ependymoma and non RELA-fusion recurrent ependymoma as measured by progression-free survival at 6 months (PFS6).

Eligibility:

* Histologically proven intra-cranial or spinal ependymoma.
* Radiographic evidence of tumor progression
* Patients must be greater than or equal to 18 years old.

Patients must have had prior radiotherapy.

Design:

* This is a phase II study to determine the efficacy of marizomib in recurrent ependymoma.
* A novel 2-stage sequential design will be employed to conduct the trial for recurrent ependymoma.
* In the first stage, we will enroll 18 patients with RELA-fusion ependymoma and if 4 or more patients in Cohort 1 are progression free at 6 months, we will proceed to stage 2; otherwise, we will terminate the trial and conclude that marizomib is not effective.
* In the second stage, we will enroll 32 patients with non RELA-fusion ependymoma.
* Patients will be treated with marizomib in cycles consistent of 28 days until disease progression or a maximum of 24 cycles.

Arms:
arm 1: Marizomib at days 1, 8, and 15 of each 28-day cycle arm 2: Data collection on pregnancy, birth and Health of Child

Interventions: intervention 1: Marizomib
Intervention descriptions: intervention 1: 0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.

Protocol document:
Prot_SAP_000.pdf: 
	
  !"#!#"#"$
&''()*+,-)./+-0)12344526789:;<9=>?@A(B-BCB0D1$EFGG$$H)(I+BJK,-)1$$LGMLMGMG>N/>OP')(1QFRGSTMTUV$/+-0)1237WX44FY9Z9[7YR897Y;\6789:;<9=\;8]X[^88XZ_`;abc87dX7ZdeZ7fY7W_9[g^f87_XZ_;897Yh4Z\87_XZ_;897Y7Zdgf9Z7YF;8d5fXZdi<;<7>N?A(+JC+j,0?J*)I-+k,-B(l 678mc9Y=X8_h6nopqQX^8;brZ[;Y;sit87Z[3uQrtvhFF]hQF4EGSGrYdcX;8sX_;aZ];7dht^9Yd9ZsUMh];;<MSwetX_3XWd7h6nMGUEMRXYlMVGbTxGbxGMS5<79Ylyz{yz{||<78m}s9Y=X8_~Z93}s;
||yz{yz{?J*)I-+k,-+BJ,0&k)J-I1n8^sQ7<Xl
6789:;<9=4QnQ^<=X8l $SExSSgf;ZW;8l
FF]hQF467Z^\7[_^8X8lFXYsXZXLR89f37WXNBPP)(C+,0&k)J-I1Q;ZX

	
  !"#!#"#"$
%&'()*
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`abcdefIGBD@<SNDKN=CDV;BFG?@CDH;<;BDBD<;:;<=>?@?ABE>AKFDVAFD<HFN;gThijFCA<BKCD:FD@<:AFNSA>L7 kACDl@?DEDBAB;K@<=hH;<;CAFD@<DCC;V;CBDEJ;:C@F;AB@?;D<NDEDF@CSNDKN:;<;FCAF;BAKC@BBFN;EJ@@=hECAD<hEACCD;CWjjjZLmFD<NDEDFBFN;AKFDVDF>@I$^Y:C@F;AB@?;D<HJD@?AK;JJBUAKFDVAF;BKAB:AB;BUEGDJ=BG:C;AKFDV;@n>H;<B:;KD;BA<=FNGBD<=GK;BA:@:F@BDBLkACDl@?DEEJ@KoBFN;gTh:AFNSA>E>:C@F;AB@?;D<NDEDFD@<LMNGBUDF?A>NAV;A<A==DFD@<AJFACH;F;=FN;CA:;GFDK;II;KFD<FN;defhIGBD@<?@J;KGJACBGEHC@G:@I;:;<=>?@?ABLpqrs.tuvs6
7 M@;VAJGAF;FN;;IIDKAK>@IFC;AF?;<FSDFN?ACDl@?DED<defhIGBD@<C;KGCC;<F;:;<=>?@?AA<=<@<defhIGBD@<C;KGCC;<F;:;<=>?@?AAB?;ABGC;=E>:C@HC;BBD@<hIC;;BGCVDVAJAFw?@<FNBWXTYwZLxyu0uquyutz6
7 {DBF@J@HDKAJJ>:C@V;<D<FCAhKCA<DAJ@CB:D<AJ;:;<=>?@?AL7 |A=D@HCA:NDK;VD=;<K;@IFG?@C:C@HC;BBD@<7 XAFD;<FB?GBFE;}>;ACB@J=L7 XAFD;<FB?GBFNAV;NA=:CD@CCA=D@FN;CA:>Lsu046
7 MNDBDBA:NAB;mmBFG=>F@=;F;C?D<;FN;;IIDKAK>@I?ACDl@?DED<C;KGCC;<F;:;<=>?@?AL7 \ <@V;J$hBFAH;B;G;<FDAJ=;BDH<SDJJE;;?:J@>;=F@K@<=GKFFN;FCDAJI@CC;KGCC;<F;:;<=>?@?AL7 m<FN;IDCBFBFAH;US;SDJJ;<C@JJQ:AFD;<FBSDFNdefhIGBD@<;:;<=>?@?AA<=DI@C?@C;:AFD;<FBD<@N@CFQAC;:C@HC;BBD@<IC;;AFw?@<FNBUS;SDJJ:C@K;;=F@BFAH;$@FN;CSDB;S;SDJJF;C?D<AF;FN;FCDAJA<=K@<KJG=;FNAF?ACDl@?DEDB<@F;II;KFDV;L7 m<FN;B;K@<=BFAH;US;SDJJ;<C@JJ[$:AFD;<FBSDFN<@<defhIGBD@<;:;<=>?@?AL7 XAFD;<FBSDJJE;FC;AF;=SDFN?ACDl@?DED<K>KJ;BK@<BDBF;<F@I$=A>BG<FDJ=DB;AB;:C@HC;BBD@<@CA?AnD?G?@I$K>KJ;BL


	
  !"#!#"#"$
%&'()*+,*-%)-%.0123456666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666667%&'()*+,*-%)-%.6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666$9
:-%;*<=,%:*-666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666>969
.?@AB*CDEF?GHEI66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666>96969
JKGLMKB*CDEF?GHE66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666>96967
.EFNOAMKB*CDEF?GHEPIQ666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666>9696$
)RSTNKM?NKB*CDEF?GHEPIQ6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666>967
'MFUVKN@OAMOA;M?GNOMTE66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666>96769
'MFUVKN@OANO)SEOABLNLMI666666666666666666666666666666666666666666666666666666666666666666666666666666666>96767
;M?GNOMTEWNKXMKGYNLGC6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666Z9676$
JKE[,TGOGFMTAM?M66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666Z9676\
,TGOGFMTAM?M666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666999676]
;M?GNOMTEWNK?^GII?@AB6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666979676_
;M?GNOMTEWNKSM?GEO?KESNK?EA[N@?FNLEI666666666666666666666666666666666666666666666666666666666666666669$7
)(:`:':(:%a&..)..X)-%&-<)-;*((X)-%66666666666666666666666666666666666666666666666666666666666669\769
)TGVGCGTG?B,KG?EKGM66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669\76969
:OFT@IGNO,KG?EKGM66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669\76967
)RFT@IGNO,KG?EKGM6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669]7696$
:OFT@IGNO,KG?EKGMWNKJKEVOMOFB,N^NK?PJQ666666666666666666666666666666666666666666666666666666666669_7696\
;EFK@G?LEO?.?KM?EVGEI666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669>767
.FKEEOGOV)HMT@M?GNO6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669>76769
.FKEEOGOVMF?GHG?GEISEKWNKLEASKGNK?NNC?MGOGOVGOWNKLEAFNOIEO?66666666666666666666669>76767
.FKEEOGOVMF?GHG?GEISEKWNKLEAMW?EKMFNOIEO?WNKIFKEEOGOV^MICEEOIGVOEA66666669>7676$
bGI?NKBMOAS^BIGFMTERMLGOM?GNO6666666666666666666666666666666666666666666666666666666666666666666666666669>7676\
(MCNKM?NKB)HMT@M?GNO666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669>7676]
bGI?NTNVGFFNOWGKLM?GNO6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669c76$
JMK?GFGSMO?;EVGI?KM?GNOMOA.?M?@I=SAM?EJKNFEA@KEI66666666666666666666666666666666666666666666666669c76$69
%KEM?LEO?&IIGVOLEO?JKNFEA@KEIPdeffghijkflkiemnofnejgjempqQr666666666666666669c76\
'MIETGOE)HMT@M?GNO666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669Z$
.%=<a:XJ()X)-%&%:*-666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669Z$69
.?@AB<EIGVO6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669Z$6969
,N^NK?I9[\r6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666669Z$6967
,N^NK?JsJKEVOMOFB;ETM?EA.?@ABJKNFEA@KEIt'GK?^MOAbEMT?^NW,^GTA666666667u$67
<K@V&ALGOGI?KM?GNO6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666667u$6$
<NIEXNAGWGFM?GNOI6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666679$6$69
bMTT@FGOM?GNOILMOMVELEO?6666666666666666666666666666666666666666666666666666666666666666666666666666666666667$$6$67
XMKGYNLGC.@SSNK?GHE,MKE6666666666666666666666666666666666666666666666666666666666666666666666666666666666667\$6\
v@EI?GNOOMGKEI66666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666667]$6]
+NTTNw=S666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666667]
$6]69
7c[<MB.MWE?B+NTTNw[@SxGIG?66666666666666666666666666666666666666666666666666666666666666666666666666666667]


	
  !"#!#"#"$
%&'&(
*+,-./0123+44+5.67&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(8%&8
9/6:;<=40,:=1&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(8%&>
<+?/=,:<+270,?=/@+,&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&>&B
<+?/?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&>&(
<+270,?=/@+,&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&>&%
C0@2D61?020,/&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&A
<1@/01@=E+1C02+F=4E1+2G1+/+H+4IJ01=7;=,:KEE9/6:;<1@/01@=&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&A&B
<1@/01@=E+1C02+F=4E1+2G1+/+H+4IJ01=7;&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&A&(
KEE9/6:;<1@/01@=&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(A%&A&%
*+?//+3+44+5.67&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(L$
<KM<KNOIPMINQRO<PIOKM9SNQP9TCQ9&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(L'
UOK9GQ<ONQM<K**Q<IOKM&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(L'&B
<KCCQ*PIOVQ9ITROQ93KCCQ9QPC<W&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&(L'&B&B
I@??60&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%X'&B&(
U4++:&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%X'&(
9PNG*Q9IKCPYQZICP<[OMYPMRRO9GK9OIOKM&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%X'&(&B
9=2740?N=,=-0:D;R1&3@--\?U4++:G1+H0??@,-<+10]UG<^&&&&&&&&&&&&&&&&&&&&&&&&&&&&%X'&(&(
G1+H0:610?E+19/+1=-0+EI@??60970H@20,?@,/J0*=D+1=/+1;+EG=/J+4+-;&&&&&&&%B'&(&%
G1+/+H+4<+2740/@+,S9=2740R0?/16H/@+,&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%('&%
9=2740?E+1Y0,0/@HSY0,+2@HP,=4;?@?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%('&%&B
R0?H1@7/@+,+E/J0?H+70+E-0,0/@HS-0,+2@H=,=4;?@?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%('&%&(
GJ=12=H+-0,+2@H9/6:@0?]<+J+1/B+,4;^&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%('&%&%
G1@F=H;=,:<+,E@:0,/@=4@/;+E20:@H=4@,E+12=/@+,SD@+4+-@H=4?70H@20,?&&&&&&&&&&&&%('&%&$
P<01/@E@H=/0+E<+,E@:0,/@=4@/;5@44D0+D/=@,0:E+1/J0?/6:;=?:0?H1@D0:@,?0H/@+,_`abac&%%'&%&'
N=,=-020,/+EC0?64/?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%8
RPIP<K**Q<IOKMPMRQVP*TPIOKM&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%8&B
R=/=<+440H/@+,&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%8&(
R=/=9J=1@,-G4=,?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%$8&(&B
W62=,R=/=9J=1@,-G4=,&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%$8&(&(
Y0,+2@HR=/=9J=1@,-G4=,&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%$8&%
C0?7+,?0<1@/01@=&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%$8&%&B
R@?0=?0G=1=20/01?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%'8&%&(
N0/J+:?E+1QF=46=/@+,+EN0=?61=D40R@?0=?0&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%'8&%&%
CPMKR@?0=?0C0?7+,?0<1@/01@=&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%'8&%&$
QF=46=/@+,+EU0?/KF01=44C0?7+,?0&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%88&%&'
R61=/@+,+EC0?7+,?0&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%88&%&8
G1+-10??@+,.3100961F@F=4&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%>8&%&>
KF01=44?61F@F=4&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%>8&$
I+d@H@/;<1@/01@=&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%>>
MOWCQGKCIOMYCQeTOCQNQMI9SRPIPPMR9P3QIfNKMOIKCOMYG*PM&&&&&&&&%>
>&B
R0E@,@/@+,?&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%>


	
  !"#!#"#"$
%&'
)*+,-)../012.32456/7801789:;7/8/8<=>,?,152;@/8<&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&A%%&'&B
CD519/@19,152;@/8<&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&A%%&'&'
>,?,1EF/;1418@G.2;->,152;@/8<7@328@/8F/8<,1H/1I&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&A%%&A
J>*,1EF/;19K7@7789+7.1@LM28/@2;/8<-678&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&A%%&A&B
-;/80/576>8H1G@/<7@2;=,1G17;0N:174&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&A%O
+-)J+),+PQC:R,C-),:>JS&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AOO&B
K1./8/@/28G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AOO&B&B
P9H1;G1CH18@&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AOO&B&'
+1;/2FGP9H1;G1CH18@T+PCU&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AOO&B&A
V/.1W@N;17@18/8<&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AOO&B&X
+1H1;/@L&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AOO&B&$
,167@/28GN/5@2+@F9L-;29F0@&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AYO&B&Z
CH18@G2.36/8/076>8@1;1G@TC3>U[3J+79H1;G11H18@G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AYO&'
PGG1GG418@2.+7.1@LCH18@G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AYO&A
,152;@/8<2.+1;/2FGP9H1;G1CH18@G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AYO&X
+7.1@L,152;@/8<3;/@1;/7@2@N1-N7;4701F@/07632667\2;7@2;&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&AYO&X&B
+1;/2FGP9H1;G1CH18@G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&X]O&X&'
-;1<8780L&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&X]O&X&A
CH18@G2.36/8/076>8@1;1G@TC3>U^*766F0/87@/28G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XBO&$
,152;@/8<-;1<8780L&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XBO&$&B
M7@1;8761D52GF;1&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XBO&$&'
-7@1;8761D52GF;1&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XBO&Z
,1<F67@2;L,152;@/8<.2;+@F9/1G3289F0@19_891;33,W+528G2;19>JK&&&&&&&&&&&&&&&&&&XBY
3V>J>3PVM)J>:),>JS&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XBB] +:P:>+:>3PV3)J+>KC,P:>)J+&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&X'B]&B +@7@/G@/076*L52@N1G/G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&X'B]&B&B -;/47;LC8952/8@^&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XAB]&B&' +102897;LC8952/8@TGU^&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XAB]&' +74561+/`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aCPS,CCMCJ:+&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XZBB&B 3,PKP&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XZB' *_MPJ+_?bC3:+-,):C3:>)J+&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XZB'&B ,7@/28761Q2;+F\c10@+1610@/28&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XZ
B'&' -7;@/0/57@/282.3N/69;18=a/7\61J1287@1G&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&XZ


	
  !"#!#"#"$
%&'( *+,-./.0+-.12345612+-673482/6,-+.29.+:.;.-<=2>512?.+:;65612+-67''''''''''''''''@$%&'('% 5612+-671482/6,-+.29.+:.;.-<'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@$%&'('& 512?.+:;65612+-67''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@A%&'@ *+,-./.0+-.1214*,6B2+2-C1D62''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@A%&'E *+,-./.0+-.1214FG:H6/-782+:;6-1I.?6J12762-'''''''''''''''''''''''''''''''''''''''''''''''''''''''''@A%&'$ *1-62-.+;K.7L7MN.7/1D41,-7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@A%&'$'% F-G><N,GBK.7L7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@A%&'$'& OD+B.2B'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'( K676+,/QR;11>J1;;6/-.12K.7L7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'@ STI''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'E 3-Q6,K.7L7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'$ UG67-.122+.,67,.7L7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'A 512V*Q<7./+;K.7L714I626-./K676+,/Q'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'P J6,-.4./+-614J124.>62-.+;.-<''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'$'W *1-62-.+;R6264.-7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'A K.7L7MR6264.-7=2+;<7.7''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@P%&'P J12762-*,1/677+2>N1/GD62-+-.12'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@W%&'P'% J12762-*,1/67741,=>G;-7CQ1X+/LJ+0+/.-<-1J12762--1K676+,/Q*+,-./.0+-.12
@W%&'P'& J12762-41,JQ.;>,62+2>5612+-67''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''@W%&'P'( K6YG67-41,C+.?6,14J12762-41,F/,662.2B=/-.?.-.67''''''''''''''''''''''''''''''''''''''''@W%( KSI8X=Z3K[=5N3*SK=ZO35=XJ35FONSK=ZO35F'''''''''''''''''''''''''''''''''''''''''''''''E\%('% F-G><N.7/12-.2G+-.12+2>J;17G,6''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E\%('& UG+;.-<=77G,+2/6+2>UG+;.-<J12-,1;'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E\%('( J124;./-14O2-6,67-*1;./<''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E%%('@ J124.>62-.+;.-<+2>*,.?+/<''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E%%@ *]=K^=JS8ZOJ=XO5_3K^=ZO35'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'% ^=KO`3^ORaO5N%(W$((b'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'% F1G,/6'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'& ]GD+2Z1c./.-<''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'( _1,DG;+-.12+2>0,60+,+-.12'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'@ F-+:.;.-<+2>F-1,+B6'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'E =>D.2.7-,+-.120,1/6>G,67''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'$ O2/1D0+-.:.;.-.67'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E&%@'%'A JQ6D./+;2+D6+2>7-,G/-G,6d'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''E(%E KS_SKS5JSF'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''EE%$ =**S5NOJSF''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''EA%$'% =0062>.c=dT+,2147L<*6,41,D+2/6F-+-G7+2>56G,1;1B./+;_G2/-.12'''''''''''''''''''''EA%$'& =0062>.cRd^KO=/YG.7.-.12*,1-1/1;'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''EW%$'( =0062>.cJd]+;;G/.2+-.12F6?6,.-<F/+;6'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''$%%$'@ =0062>.cNdJ6;B626O2.-.+;*,6B2+2/<K601,-_1,D'''''''''''''''''''''''''''''''''''''''''''''''''''$&


	
  !"#!#"#"$
% '()*+,-.)'+(%0% 1)-,2+345.)'65178787 :;<=>;?@ABCDE<FCG HICF>JK>ECELCCMM<D>D?IME;C>E=CNEO<EL=>;<PI=<A<NQRSTMKU<IN;CDK;;CNECVCNW?=I=>>NWNINQRSTMKU<IN;CDK;;CNECVCNW?=I=>>U=C>UK;CWA?V;IX;CUU<INTM;CCUK;F<F>J>EY=INELUZ:[\Y]87878^ \CDINW>;?@ABCDE<FCZU]G HICUE<=>ECELC7^T=INELV;IX;CUU<INTM;CCUK;F<F>JZ:[\7^]_=CW<>NV;IX;CUU<INTM;CCUK;F<F>JZ:[\]>NWIFC;>JJUK;F<F>JZ@\]IMQRSTMKU<IN>NWNINQRSTMKU<IN;CDK;;CNECVCNW?=I=>V>E<CNEUE;C>ECWO<EL=>;<PI=<A8G HICUE<=>ECELCCMM<D>D?IM=>;<PI=<A<N;CDK;;CNECVCNW?=I=>V>E<CNEUZQRSTMKU<IN`ILI;E^>NWNINQRSTMKU<IN`ILI;Ea]O<EL=I;CEL>N^V;<I;DLC=IELC;>V<CU>U=C>UK;CWA?:[\Y_:[\7^_=CW<>N:[\>NW@\8G HICUE<=>ECELCCMM<D>D?IM=>;<PI=<A<N;CDK;;CNECVCNW?=I=>V>E<CNEUZQRSTMKU<IN`ILI;E^>NWNINQRSTMKU<IN`ILI;Ea]O<EL=I;CEL>N^V;<I;DLC=IELC;>V<CU>U=C>UK;CWA?IABCDE<FC;CUVINUC8G HIWCEC;=<NCELCU>MCE?IM=>;<PI=<A<N;CDK;;CNECVCNW?=I=>V>E<CNEU>NW<N>UKAUCEIMV>E<CNEUO<EL=I;CEL>N^V;<I;DLC=IELC;>V<CUZbcdeTMKU<IN`ILI;E^>NWNINTbcdeTMKU<IN`ILI;Ea]8G HIJINX<EKW<N>JJ?CF>JK>ECV>E<CNE;CVI;ECWIKEDI=C=C>UK;CUKU<NXUCJMT;CVI;ECWU?=VEI=UCFC;<E?>NW<NEC;MC;CNDCO<ELW><J?>DE<F<E<CUKU<NXELCfge\hTiH>NWjI;fge\hT\:<NUE;K=CNE87878k clVJI;>EI;?@ABCDE<FCZU]G HIWCEC;=<NC<MELC;C<U>DI;;CJ>E<INO<EL;CUVINUC;>ECEIV;CUCNDCIMELCbcdeXCNCMKU<IN<NV>ELIJIX?M;I=UK;X<D>J`m\E<UUKCUVCD<=CN8G HI>UUCUUEK=I;E<UUKCMI;A<I=>;nC;UZXCNC=KE>E<INU_DIV?NK=AC;>JEC;>E<INU>NWMKU<INU]KU<NXELCNCK;ITINDIJIX?A;><NV;<=>;?`m\V>NCJ8G HI>UUCUUClV;CUU<INIMm[TopV>ELO>?KU<NXbmeUCqKCND<NXINEK=I;E<UUKC8G HI>UUCUUU<NXJCNKDJCIE<WCVIJ?=I;VL<U=UM;I=XC;=J<NCgmeEICUE>AJ<UL>XCNCE<D>UUID<>E<INO<EL`m\>WFC;UCCFCNEU8%0r 3s.tu*+-(,s(,*s)'+(sv578^87 i>DnX;IKNWINcVCNW?=I=>UcVCNW?=I=>U>;C;>;CXJ<>JEK=I;UOL<DLD>N>;<UC<NELCA;><NI;ELCUV<N>JDI;W8wL<JCL<UEI;<D>JJ?ELC?OC;CELIKXLEEII;<X<N>ECM;I=ELCO>JJIMELCFCNE;<DJCUI;ELCUV<N>JDI;W_;CDCNEUEKW<CUL>FCULIONEL>EELC?I;<X<N>ECM;I=ELC;>W<>JXJ<>JUEC=DCJJUx7y8f<D;IUDIV<D>JJ?_ELC?>;CDI=VIUCWIMKN<MI;=U=>JJDCJJUO<EL;IKNWNKDJC<<N>M<A;<JJ>;?=>E;<l>NW>;CDL>;>DEC;<PCWA?ELCV;CUCNDCIMVC;<F>UDKJ>;>NKDJC>ECPINCUD>JJCWVC;<F>UDKJ>;VUCKWI;IUCEECUx^y8dCUUM;CqKCNEJ?E;KCCVCNW?=>J;IUCEECU
DINU<UE<NXIMCVCNW?=>JDCJJU>;;>NXCW>;IKNW>DCNE;>JJK=CN=>?ACV;CUCNE8cVCNW?=I=>U>DDIKNE
MI;^Tz{IM>JJNCK;ICV<ELCJ<>JEK=I;Uxky8wL<JCELC?D>NIDDK;<N>JJ>XCX;IKVU_ELC?>;C=I;CDI==IN
<NDL<JW;CNEL>N>WKJEU8HLC?DI=V;<UC|8^{IM>JJVCW<>E;<DV;<=>;?A;><NEK=I;U>NW78z{IM>JJ>WKJE


	
  !"#!#"#"$
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WXY@.0'/,:%:,9*(/()4VWXY@.0'/,:%:,9*(/()0/66.&0.%&)-:,-/&')88*4H+/.-Z>? /@VWXY@.0'/,:%:,9*(/()0)&:@/.,9',67'89&:,),9)8/G:&%&/%/&-'/,)&:%&:0:,-',)9.8-01D34J7/8:A:,/(:0:[.:,6',A/@-7:0:-.(/&0&:F:)8:9-7:/66.&&:,6:/@67&/(/-7&'%0'0G'-7',67&/(/0/(:OO[O24OY[O;4;1D34T7&/(/-7&'%0'0)A:,:-'6%7:,/(:,/,G7'676).0:007)--:&',A),968.0-:&:9&:)&&),A:(:,-0/@A:,:08:)9',A-//,6/A:,'6@.0'/,%&/9.6-04I7:&:/&9:&:967&/(/0/()8%&/9.6-0',-7'0&:A'/,@/&()%//&8*67)&)6-:&'P:9A:,:<\  ]^_-/VWX1D34I7:@.0'/,-&),06&'%-/@-7'0A:,:6/9:0)-&),06&'%-'/,@)6-/&%DC<)80/=,/G,)0`:8HG7'67'0)=:*:@@:6-/&',-7:QaYbS%)-7G)*12<Z34I7.0<%)-':,-0G'-7`EcH@.0'/,:%:,9*(/()07)F:)6/,0-'-.-'F:)6-'F)-'/,/@-7:QaY
bS%)-7G)*4
O424O4OI7:QaYbe%)-7G)*QaYbS'0),',9.6'+8:-&),06&'%-'/,@)6-/&G7'67G)09'06/F:&:9)0)&:A.8)-/&/@:N%&fgghijilmnfbohpnm67)',A:,:',S6:8801$34QaYbeqorsgrjhtqiumrjmuiofhjufpvormhjphttvjfufgqijgfrjwhjlovfjxfgA:,::N%&:00'/,&:8)-:9-/6:880.&F'F)8<9'@@:&:,-')-'/,),9%&/8'@:&)-'/,4I7:QaYbe@)('8*(:(+:&06/,0'0-/@`:8Hy%DC<`:8S<6Y`:8<%C>1QaYbez{rjwq|}~Ybe}{I7:6/&::8:(:,-0/@QaYbe%)-7G)*)&:-7:QaYbe-&),06&'%-'/,@)6-/&<-7:',7'+'-/&*be%&/-:',),9mnfbe=',)0:6/(%8:N45,-7:&:0-',A0-)-:<-7:QaYbewhtfugrufnfowwiutrjmhj6*-/%8)0(-7&/.A7),/,Y6/F)8:,-)00/6')-'/,G'-7be%&/-:',04I7'0)00/6')-'/,%&:F:,-0-7:QaYbS,.68:)&-&),08/6)-'/,),9QHY+',9',A)6-'F'-*4J7:,-7:6:88'00-'(.8)-:9G'-7:N-:&,)80-'(.8'0.67)0%&/Y',@8)(()-/&*6*-/=',:0<:4A4-.(/&,:6&/0'0@)6-/&&:6:%-/&),9',-:&8:.=',YO&:6:%-/&/&),*/-7:&0-&:00/&0<-7:56/(%8:N'0)6-'F)-:94I7:)6-'F)-:956/(%8:N8:)90-/-7:%7/0%7/&*8)-'/,<.+'[.'-hjrmhijrjwwfrxmhrmhijilbeI7'0&:8:)0:0-7:QaY
be9'(:&0-/-&),08/6)-:-/-7:,.68:.0),9%&/(/-:-&),06&'%-'/,/@-7:%&/Y0.&F'F)8A:,:01$<R34O424O42I7:+'[.'-',Y&/-:)0/(:U*0-:(I7:.+'[.'-',Y%&/-:)0/(:0*0-:(U'0)7'A78*6/,0:&F:9=:*%)-7G)*G7'676).0:0-7:',-&)6:88.8)&
9:A&)9)-'/,/@%&/-:',04I7&/.A7-7'0&/8:<U&:A.8)-:06:88Y6*68:6/,-&/8<-&),06&'%-'/,),9/-7:&
6:88.8)&:F:,-0),9-7.0()',-)',0,/&()86:88@.,6-'/,',A1O>34I7:()(()8'),2DU%&/-:)0/(:6/,0'0-0


	
  !"#!#"#"$
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TUVE%5./%&W:,41--X;/0E+>%E'I8YJ<ZC15.32.%&'3-1?3.%+/';-12'2-1C1-0%&+,%-.';%E.13>161-%,;>';6..3&%:3513;%/15-:E%,;132/:51399/1%E';'35+,%;-'-.2'32.,I8HA8[J<\E'G%,E.2>'31;E%&'2-1%3%&+,%-.';%E.13>161-%,;1;->.13>161-1%3%&]@?^_abcdefbghagid&'2-%,A->,%:9>->.;-'61/gjcagidikgaegdlgmgaibn^_hbiaogdp8<(<( r'-1%3'/.&%,s',1D%E16ZC.3->%:9>13C1-,%;-:51.;>'C..;-'6/1;>.5->.+%-.3-1'/%&+,%-.';%E.13>161-%,;';'3-1?3.%+/';-125,:9;A->.-,'3;/'-1%3%&->.;.'9.3-;13-%2/1312'/+,'2-12.>';6..32>'//.391395:.-%',./'-1C./'24%&+%-.320A;./.2-1C1-0%,;-'61/1-0I8(J<F36,'13-:E%,+'-1.3-;A->.+,1E',02>'//.39.1;9.--139->.5,:9->,%:9>->.W/%%5W,'13W',,1.,MWWWP<Z',/0+,%-.';%E.13>161-%,;/14.6%,-.D%E16'352',&1/D%E16>'C.+.+-15.?6';.5;-,:2-:,.;'352'33%-2,%;;->.WWW7>12>/1E1-;->.1,'++/12'-1%3&%,2.3-,'/3.,C%:;;0;-.E -:E%,;<s',1D%E16A'/;%43%73';;'/13%;+%,'E15.\%,]tF?))Y(A1;';.2%35?9.3.,'-1%3+,%-.';%E.13>161-%,71->+.3.-,'-1%3'2,%;;->.WWWI8HJ<s',1D%E161;'+%-.3-1,,.C.,;16/.13>161-%,%&->.()*'35>';'//K.3D0E.'2-1C1-1.;%&->.()*+,%-.';%E.uN=?OA=?O'35N?O';2%E+',.5-%6%,-.D%E167>12>>';,.C.,;16/.'2-1C1-0+,.5%E13'3-/0'9'13;-->.N=?O;:6:31-I8HJ<F-/.'5;-%->.13>161-1%3%&6%->135:216/.'352%3;-1-:-1C.'2-1C'-1%3%&]@?^_gdfcdfobfovveI8wJ<s',1D%E16'/;%135:2.;2.//'+%+-%;1;->,%:9>;.C.,'/'551-1%3'/E.2>'31;E;L8P'2-1C'-1%3%&2';+';.?KA2';+';.?wA2';+';.?$'35+%/0M\Rt?,16%;.P+%/0E.,';.Mt\rtP2/.'C'9.A(P+%-.3-1'-1%3%&'+%+-%;1;135:2.560-:E%,3.2,%;1;&'2-%,M=]@P'35;:++,.;;1%3%&=]@?135:2.52.//13C';1%3AKP9.3.,'-1%3%&,.'2-1C.%x09.3;+.21.;Mry*PC1''3132,.';.%&;:+.,%x15.+,%5:2-1%3SP,.5:2-1%3%&->.+%-.3-1'/%&E1-%2>%35,1'/E.E6,'3.YP,./.';.%&'+%+-%9.312+,%-.1320-%2>,%E.?2M20-%?2P'35;.2%35E1-%2>%35,1'/'2-1C'-1%3%&2';+';.;M*E'2P&,%EE1-%2>%35,1'-%20-%;%/AHP:+?,.9:/'-1%3%&.35%+/';E12,.-12:/:E;-,.;;,./'-.5+,%-.13;I8HA8wJ<8<(<K t,.?N/1312'/5'-'\,.2.3-+,.2/1312'/;-:50-.;-.5->.13?C1-,%'2-1C1-0%&E',1D%E1613E'/193'3-9/1%E'2.///13.;z?(Y8'35R?YSI8HJ<F-7';&%:35->'-E',1D%E16+,%&%:35/013>161-.5->.N=?O'2-1C1-0%&->.()*+,%-.';%E.136%->2.///13.;<=>.>'/&E'x1E'/13>161-%,02%32.3-,'-1%3MFNY)P7';E.';:,.5';Y(3s&%,z?(Y8'35()3s &%,R?YSI8HJ<F-7';'/;%%6;.,C.5->'-13?C1-,%AE',1D%E16135:2.5'+%+-%;1;'35132,.';.5ry*9.3.,'-1%3139/1%E'2.//;<F3'E:,13.E%5./A1-7';;..3'&-.,'313G.2-1%3%&{{K
{{|/'6.//.5E',1D%E16A->.N]*51;-,16:-1%3%&,'51%'2-1C1-07';}K)~ %&->'-&%,;-.'50?;-'-.6/%%5/.C./A->:;
2%3&1,E139->.+.3.-,'-1%3%&E',1D%E16'2,%;;->.WWWI8HJ<


	
  !"#!#"#"$%
&'()*+,)()-./(0*1/'-2*.(-3(01,4/.05*4062*.-7-1894*4/3)/.6*.01,()-:;<&2+30*103=-.93(.*1,>/38-3?.06-8/6*=->()-.-/.-/880(0*1/'7.-?'010?/'8/(/()/(3+,,-3(3()/(7.*(-/3*4-01)060(0*14/96-/1-22-?(0=-(.-/(4-1(*2*()-.-7-1894*4/3@&7.-?'010?/'4*8-'A/38-=-'*7-869()-B0'6-.(3*1'/669/47'02901,;7)6C01./80/','0/'3(-43>()-7.-?+.3*.?-''3*2-7-1894*4/@D)-3-?-''3A-.-()-13+6E-?((*)0,)().*+,)7+(3?.--1+301,()-FG&/77.*=-88.+,'06./.9H$IJ@K.*(-*3*4-01)060(*.3A-.-/4*1,()-4*3(/?(0=-01()034*8-'393(-4>01?'+801,L-1*,./2(01(./?./10/'4*8-'3@M*A-=-.>()03?'/33*28.+,A/31*(.-?*44-18-82*.2+.()-.01=-3(0,/(0*101-7-1894*4/6-?/+3-()--L03(01,/,-1(3/(()-(04-N0-6*.(-5*4/6OA-.-8-30,1-8PQD(*?.*33()-6'**8R6./016/..0-.@S/.05*406-22-?(0=-'9?.*33-3()-TTT>()-.-694/U01,0(/'*,0?/'(.-/(4-1(*7(0*1A0()()03.*6+3(7.-?'010?/'8/(/@:-?-1('9>/,-1-(0?/''9-1,01--.-84*+3-4*8-'NB;SSOA/3?.-/(-869G.@;.0?M*''/18N7-.3*1/'?*44+10?/(0*1O@V301,()-:W&XY(=/393(-4>)-A/3/6'-(*.-7.*8+?-()-:;<&RW$$*.2IZ2+30*1()/(8.0=-3()-8-=-'*74-1(*2()033+6(97-*2-7-1894*4/@&30''+3(./(-86-'*A01F0,+.-$>()-.-037.*401-1(8-=-'*74-1(*2/101(./?./10/'(+4*.01()034*+3-4*8-'393(-4@F+.()-.4*.->/33)*A101F0,+.-C>(.-/(4-1(*240?-A0()-3(/6'03)-801(./?./10/':;<&R2+30*1(+4*.3A0()4/.05*406.-3+'(-801(+4*..-37*13->A)0?)?/16-8./4/(0?@D)-3-.-3+'(32+.()-.3+77*.((-3(01,4/.05*406017/(0-1(3A0()-7-1894*4/@[\]^_`b
[\]^_`c


	
  !"#!#"#"$$
$%&%' )*+,+-.*/.0.123.456-*+,+-.*407/8+,5+9308:4+;2.0+5,04<+03./=.,-5/>.*+9,.,-+54+,-*7/+,9>7*0+2*5>85*?>.745/>.@+A?>+B+,':<55C-8-*540540+,9/?454B50<55,D%$ED%F>9G>
HH&
HH?=5@$0?$D>+,7054./>+,+405@5/?,/.8$IJI$K.,/.,?035@4-35/7*5<3+-305405//?454D%DLKED%M>9G>
HH&
HH?=5@$0?$&D>+,7054I9+=5,?,/.8$I'IJI$$+,N:<55C-8-*54O&DP%Q35>?40-?>>?,@5*.05/./=5@455=5,04<5@5,.745.I/+.@@35.IR.0+975.,/+,R74+?,4+052.+,%S5@+235@.*,57@?2.038?@35>.0?*?9+-.*0?;+-+08.4455,<+03B?@05A?>+B<.4,?0?B45@=5/%Q35@5<5@5,?9@./5'@5*.05/:./=5@455=5,04T1U4V%6,035R+@404-35/7*5I035@5-?>>5,/5/23.45&/?45TWS&XV<.4D%L>9G>
HH&
HH+,R745/?=5@$D>+,7054%6,03545-?,/4-35/7*5I035WS&X<.4D%K>9G>
HH&
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
HH&
HH?=5@$D>+,70546^+,R74+?,./>+,+405@5/?,X.84$IJI$K?R5.-3&J:/.8-8-*5I<3+-3<.4745/+,Y)QD&NNDKM&%X?4554-.*.0+?,0?$%D>9G>&<.4,?0R5.4+B*5+,03545./7*049*+?B*.40?>.0@+.*4TY)QD&NNDKM&.,/Y)QD&FDNDMFV/750?./=5@455=5,04%
]5-3?45035?,-5.<55C/?4+,9I?,':<55C-8-*54I.4+0+4.>?@52@.-0+-.*/?4+,94-35/7*5+,-?,0@.400?0<+-5.<55C/?4+,9?,N:<55C-8-*54%


	
  !"#!#"#"$%
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`aK154,-.090.67:-:*,462,B0.@7JAKLMS^TRbSTRV[cdP9-4+5/*+0+3*+:*2,G-:,@:06,*+0692-+0*4-:0,.3,@,+,-.<,//,.3,@,++30JAKLMXSTefS]S[QTeU\YPSQTVTUOVW^PYYQPSTecgQQRTRV[SYY]hiRbP[TeP*=+,B,+7-192-+0*4-:0,.3,@,+-24,.?/,-:*=0//4*.6-+302=*.=024;:*2,G-:,@:*7*/4-92-B0011,=*=,-54,..-._`aK154,-.090.67:-:*&$&%&'&$J052-+-j,=,+7k4:*.*?0:0.+l*406-.1,.6,.?412-:920=/,.,=*/*.6=/,.,=*/4+56,04;:*2,G-:,@;9*2+,=5/*2/7<30.*6:,.,4+0206*4*$m:,.5+0,.154,-.;=2-4404+30lll;2045/+,.?,.:5/+,9/0nJop842*.?,.?,.40B02,+712-:q2*60$+-q2*60r&nJop84*990*2+-@06-4020/*+06*4:-20*20-@402B06*++30$&m:?s:%6-40*.6,.?0.02*/;2049-.6+-6-402065=+,-.&t50+-=-.=02.1-2nJop84;,.+3,44+567<0<,//540:*2,G-:,@*+m&u:?s:%*.6+3020<,//@0.-6-4004=*/*+,-.&nJop84*20?0.02*//7+20*+06<,+36-40:-6,1,=*+,-.4*.6*992-92,*+04599-2+,B0+20*+:0.+4*4,.6,=*+06&F1204-/5+,-.6-04.-+-==521-//-<,.?+3040:0*45204;=-.4,6025.602/7,.?6,40*4092-?2044,-.-2-+302=*5404&>30:-4+=-::-.nJop84,.=/560+301-//-<,.?v
w*//5=,.*+,-.4vw*//5=,.*+,-.4*20120x50.+/7-@402B06,.-.?-,.?:*2,G-:,@4+56,04,.?/,-@/*4+-:*2*.?,.?,.,.=,60.=012-:$yKCz{&F.?0.02*/;3*//5=,.*+,-.4+0.6+-@0?2*60$-2%@5+-.0?2*60r0B0.+;20x5,2,.?3-49,+*/,G*+,-.;3*4@00.-@402B06&>303*//5=,.*+,-.4*20+2*.4,0.+*.640/1K
/,:,+,.?&|,45*/3*//5=,.*+,-.4*20:-20=-::-.+3*.*56,+-27*.6+3020,4*+20.61-2,.=20*406,.=,60.=0<,+3*?0&w*//5=,.*+,-.4*20120x50.+/7:-206,4+52@,.?+-+30=*20?,B02+3*.+-+309*+,0.+&w*//5=,.*+,-.4*20545*//7:*.*?0645==04415//7@76-402065=+,-.*.6*20*.,.120x50.+20*4-.1-2+20*+:0.+6,4=-.+,.5*+,-.&p+*j,*v8B0.+4-1?*,+6,4+52@*.=0;@*/*.=06,4-26024s6,GG,.044;*.6*+*j,**20120x50.+/7-@402B06,.+30-.?-,.?4+56,04,.?/,-@/*4+-:*;})~$mu*.6})~$$%;<,+3*2*.?0-1'K%u{&>3040*6B02400110=+4<3,=3*20=020@0//*2,..*+520*2045490=+06+-@020/*+06+-+309206-:,.*.=0-192-+0*4-:04,.+30=020@0//*220?,-.&>300B0.+4+79,=*//7-==52<,+3,.+30$4+-2%.6=7=/0;*20545*//7?2*60$K%@5+0B0.+4-1*+*j,*3*B020x5,2063-49,+*/,G*+,-.&*+,0.+4*20+20*+06<,+36-40:-6,1,=*+,-.4*.64+02-,64*4.00606<,+3-5+/0*6,.?+-902:*.0.+6,4=-.+,.5*+,-.-1:*2,G-:,@&p4*2045/+-1+30400B0.+4;9*+,0.+4*20<*2.06.-++--902*+030*B7:*=3,.027*.6s-262,B0,10j902,0.=,.?=020@0//*24,60K0110=+4&w0*6*=30vw0*6*=3043*B0@00.209-2+06<,+3*6:,.,4+2*+,-.-1:*2,G-:,@*=2-44,.6,=*+,-.4*.66-4*?04&I3,/030*6*=304*20=-::-./792040.+650+-+305.602/7,.?6,40*40,.ql};,.+30-.?-,.?4+56,04<,+3:*2,G-:,@,.ql};,.=,60.=0-1+20*+:0.+0:02?0.+30*6*=3042*.?0412-:%'K
'C{&t-40:-6,1,=*+,-.4*.6+20*+:0.+<,+34+02-,64*2020=-::0.6061-2:*.*?0:0.+-130*6*=304,.?/,-@/*4+-:*&n-.154,-.vn-.154,-.*/4+*+03*4@00.209-2+06*=2-44:*2,G-:,@4+56,04*.66-402*.?04&F.
-.?-,.??/,-@/*4+-:*4+56,04;+30,.=,60.=0-1=-.154,-.*/4+*+02*.?0412-: $zK%u{&8B0.+4-1
=-.154,-.*/4+*+03*B0@00.209-2+06*4op84*.6<3,/0:-4+*20?2*60$K%,.40B02,+7;?2*60C0B0.+4


	
  !"#!#"#"$%
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`9)+),';'7/5(5/CB4..0B8.,KY5+7;:0)3*./&8.,K.:/350)/&)&.4)'+0&.:3)8.,KZB,);'/5.+385/&./&),-).-;)B8';K5+9B'+0)+a.C4)+/.6;56)1J&)5+/),6),)+7)5/)43',)';3.4)'3:,)0.+^@$^37';)31

	
  !"#!#"#"$%
& ()*+*,*)*-.011(112(3-034(356))2(3-&78 ()*+*,*)*-.95*-(5*0:;$;$ =>?@ABCD>EFCGHFCI:;$;$;$JGIKH$L@CKCMC@CGNOEDPDFG$I>Q:RS EDPDFG$TUCBGD@DKC?I@@N?D>VCFWHQMNXE=YIMDFIGDFNDVZIGPD@DKNC>GFI[?FI>CI@DFB\C>I@5()0]^_`abcH\H>QNWDWIDVKFIQH=d==DF===;TUIBFH?HCeHQGfDDFVHfHF\FCDF?PHWDGPHFI\NFHKCWH>BS EDPDFG:TUCBGD@DKC?I@@N?D>VCFWHQMNXE=YIMDFIGDFNDVZIGPD@DKNC>GFI[?FI>CI@DFB\C>I@5()0]^_`abcH\H>QNWDWIDVKFIQH=d==DF===;TUIBFH?HCeHQWDFHGPI>GfD\FCDF?PHWDGPHFI\NFHKCWH>B:;$;$;:JGIKH:L@CKCMC@CGNOEDPDFGBgI>Q%RS EDPDFGgTUCBGD@DKC?I@@N?D>VCFWHQMNXE=YIMDFIGDFNDVZIGPD@DKNC>GFI[?FI>CI@DFB\C>I@cbc5()0]^_`abcH\H>QNWDWIDVKFIQH=d==DF===;TUIBFH?HCeHQGfDDFVHfHF\FCDF?PHWDGPHFI\NFHKCWH>BS EDPDFG%TUCBGD@DKC?I@@N?D>VCFWHQMNXE=YIMDFIGDFNDVZIGPD@DKNC>GFI[?FI>CI@DFB\C>I@cbc5()0]^_`abcH\H>QNWDWIDVKFIQH=d==DF===;TUIBFH?HCeHQWDFHGPI>GfD\FCDF?PHWDGPHFI\NFHKCWH>B:;$;$;gZIGCH>GBWABGPIeHI>HeCQH>?HDVGAWDF\FDKFHBBCD>IBQHVC>HQC>JH?GCD>&7&7&78;:;$;$;%ZIGCH>GBWABGPIeHPIQ\FCDFFIQCIGCD>GPHFI\N;:;$;$;hZIGCH>GBWABGMHi$jNHIFBD@Q;EAFFH>G@Nd>DQDBC>KDFIQeHFBHHeH>GQIGICBIeIC@IM@HD>GPHABHDVWIFCkDWCMC>\IGCH>GBl$jNHIFBDVIKHmGPHFHVDFHD>@NIQA@GBIFHC>?@AQHQC>GPCBBGAQN;ZIGCH>GBl$jNHIFBDVIKHfC@@MHH@CKCM@HVDFVAGAFH\HQCIGFC?GFCI@B;:;$;$;nZIGCH>GBWABGPIeHIoIF>DVBpN\HFVDFWI>?HBGIGABDVinqOBHH0rrsctau0R;:;$;$;vZIGCH>GBWABGPIeHIQHwAIGHDFKI>I>QWIFFDfVA>?GCD>IBQHVC>HQMH@Dfxy@HApD?NGHB     igdqqqz{YyIMBD@AGH>HAGFD\PC@?DA>G i$dhqqz{Yy\@IGH@HGB       i$qqdqqqz{Yy PHWDK@DMC>
i$qKWzQYO?I>MHI?PCHeHQMNGFI>BVABCD>R
y|J}OJ~}Rz|Y}OJ~Z}R
l:;hC>BGCGAGCD>I@A\\HF@CWCGDV>DFWI@
yC@CFAMC>
l$;hWKzQY


	
  !"#!#"#"$%
& ()*+,-.-.*/0,1$2%3,-4*5/00*)-.5,-,/,-1.+66-4-,578*9:8;-,<-..1)4+6+50)*=->,*=?@,<*(AB3CDE*F/+,-1.GHJKLMNLOPNQRSTLUV2& W*X+,-Y*/)-.*0)1,*-.Z[\[OP]^[Z_]OP`ZP`]P_[a_OZPbJKLcNdMU2$2$2ef<**gg*>,51g4+)-h14-?1.,<*=*Y*610-.X</4+.g*,/5+)*/.i.1;.2:1),<-5)*+51.j;14*.1g><-6=3?*+)-.X01,*.,-+6+.=4*.4/5,+X)**,1/5*+=*F/+,*>1.,)+>*0,-1.k<1)41.+61)?+))-*)4*,<1=1g?-),<>1.,)16l+?5,-.*.>*V0)-1),15,/=@*.,)@+.=g1),<*=/)+,-1.1g5,/=@0+),->-0+,-1.+.=/0,1mn=+@5+g,*),<*6+5,=15*1g,<*=)/X2o<1/6=+;14+.?*>14*0)*X.+.,1)5/50*>,5<*-50)*X.+.,;<-6*5<*1)<*)0+),.*)-50+),->-0+,-.X-.,<-55,/=@j5<*5<1/6=-.g1)4<*),)*+,-.X0<@5->-+.-44*=-+,*6@2U2$2$2pq?-6-,@1g5/?r*>,,1/.=*)5,+.=+.=,<*;-66-.X.*55,15-X.+;)-,,*.-.g1)4*=>1.5*.,=1>/4*.,2U2$2U Cs>6/5-1.()-,*)-+U2$2U2$q.,->+.>*),)*+,4*.,;-,<-.=*5-X.+,*=0*)-1=1g,-4*?*g1)**.)1664*.,-.>6/=-.Xtu5/)X*)@;-,<-.$v=+@5u.**=6*1)>1)*?-105@;-,<-.w=+@5u0)-1)>@,1,1s->,<*)+0@;-,<-.Ue=+@5juY-.>)-5,-.*;-,<-.$v=+@5u.-,)151/)*+5;-,<-.vU=+@5ju0)1>+)?+h-.*+=4-.-5,)+,-1.;-,<-.U$=+@5u.1.3>@,1,1s->+X*.,5j*2X2j-.,*)g*)1.j,+41s-g*.j,<+6-=14-=*j>-53)*,-.1->+>-=k)+=-15*.5-,-h*)=1*5.1,>1/.,V;-,<-.w=+@5lqY+5,-.;-,<-.U$=+@52q.@F/*5,-1.5)*6+,*=,1,<*=*g-.-,-1.1g.1.3>@,1,1s->+X*.,55<1/6=?*=-)*>,*=,1,<*W(ED)-.>-0+6E.Y*5,-X+,1)2U2$2U2Uf)*+,4*.,;-,<+.@-.Y*5,-X+,-1.+6+X*.,;-,<-.Ue=+@5?*g1)**.)1664*.,2U2$2U2mx-5,1)@1g+.@1,<*)>+.>*)k*s>*0,.1.34*6+.14+5i-.>+.>*)1)>+)>-.14+-.3
5-,/1g,<*>*)Y-sVj/.6*550+,-*.,-5-.>1406*,*)*4-55-1.+.=1gg+66,<*)+0@g1),<+,=-5*+5*g1)+4-.-4/41gm@*+)52U2$2U2vx-5,1)@1g+66*)X->)*+>,-1.5+,,)-?/,*=,1>1401/.=51g5-4-6+)><*4->+61)?-161X->>14015-,-1.,14+)-h14-?2U2$2U2%y.>1.,)166*=-.,*)>/))*.,-66.*55-.>6/=-.Xj?/,.1,6-4-,*=,1j1.X1-.X1)+>,-Y*-.g*>,-1.j5@40,14+,->>1.X*5,-Y*<*+),g+-6/)*j/.5,+?6*+.X-.+0*>,1)-5j>+)=-+>+))<@,<4-+j1)05@><-+,)->-66.*55z51>-+65-,/+,-1.5,<+,;1/6=6-4-,>1406-+.>*;-,<5,/=@)*F/-)*4*.,52U2$2U2{E.+=*F/+,*6@>1.,)166*=<@0*),*.5-1.k=*g-.*=+55@5,16->?611=0)*55/)*|$vn44xX+.=z1)=-+5,16->?611=0)*55/)*|pn44xXV2
U2$2U2w (/))*.,+>,-Y*<*0+,->1)?-6-+)@=-5*+5*k;-,<*s>*0,-1.1g0+,-*.,5;-,<9-6?*),}5
5@.=)14*j+5@40,14+,-> X+665,1.*5j1)5,+?6* ><)1.-> 6-Y*)=-5*+5* 0*)


	
  !"#!#"#"$%
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`)<+&*)'/.CC)?F)//DC&',.B+A)a>RO+A)B.CC.7&',-??&+&.'-C,/.DF*.B*DI`)<+*0-EI))'/.CC)?&B')<)**-/E2MA)*DI`)<+*)'/.CC)?&'+A&*<.A./+7&CC'.+0))++A)&'<CD*&.'-'?)Y<CD*&.'</&+)/&-B.D'?&'bcdcd-'?bcdcbce ;<A&C?7A.*)F-/)'+=0-C)./B)0-C)1&*N7-*-'-<+&()F-/+&<&F-'+&'+A)*+D?E-+-'E+&0)?D/&',+A)<A&C?U*,)*+-+&.'2;<+&()F-/+&<&F-'+&*?)B&')?-*A-(&',/)<)&()?-+C)-*+.')?.*).B*+D?E+A)/-FE+A/.D,A%0.'+A*-B+)/+A)C-*+?.*).B*+D?E+A)/-FE2af
e ;')YF)<+-'+0.+A)/.B<A&C?7A.*)B-+A)/&*N7-*-'-<+&()F-/+&<&F-'+&'+A)*+D?E-+-'E+&0)?D/&',+A)<A&C?U*,)*+-+&.'2MA)B-+A)/0D*+A-()/)<)&()?-+C)-*+.')?.*).B*+D?E+A)/-FE2;<+&()F-/+&<&F-'+&*?)B&')?-*A-(&',/)<)&()?-+C)-*+.')?.*).B*+D?E+A)/-FE+A/.D,A%0.'+A*-B+)/+A)C-*+?.*).B*+D?E+A)/-FE2
e MA))YF)<+-'+0.+A)/0D*+I)-,)$4./.C?)/-'?0D*+A-()+A)<-F-<&+E+.F/.(&?)&'B./0)?
<.'*)'+2


	
  !"#!#"#"$%
&'$'( *+,-./01+2030-40+5/+674-0/,/842069/::;+-+,-./0+<=->10?+840/+20;46+9?>6++@,>26.:040/>2=>--+,.--+20+8+2<A1>14>-0?+A14A;+8-+B+C/60/25840/+20640DEF9/0?+8+2<A1>149?>?4G+0.1>-8->5-+66/>2'H8+2<A1>14/64G+-A-4-+</6+46++20/0A9/0?=+90-+401+20>80/>2642<4::400+18069/::;+14<+0>/2,:.<+.2<+-B
-+8-+6+20+<1/2>-/0/+69/0?+8+2<A1>14'I?/68->0>,>:14A;+4;60-4,0+</20>8:4/2:425.45+422>.2,+1+2068>60+<>2DEF9+;6/0+642<>2DEF6>,/4:1+</48:40=>-16'JKJ MNOPPQRQSPUVWXVYRZQ&'&'$ 3,-++2/254,0/G/0/+68+-=>-1+<8-/>-0>>;04/2/25/2=>-1+<,>26+20[/2/14:-/6@4,0/G/0/+60?4014A;+8+-=>-1+<;+=>-+0?+6.;\+,0?466/52+<4,>26+20/2,:.<+0?+=>::>9/25]
^ H14/:_9-/00+2_/28+-6>2>-0+:+8?>2+,>11.2/,40/>269/0?8->68+,0/G+6.;\+,06^ *+G/+9>=+C/60/251+</,4:-+,>-<60>/2,:.<+F`7_:4;>-40>-A60.</+6_+0,'^ *+G/+9>=+C/60/25[*E_CB-4A_>-aI/145+6^ *+G/+9>=+C/60/258?>0>5-48?6>-G/<+>6^ *+G/+9>=+C/60/25840?>:>5A68+,/1+26b-+8>-06=->1468+,/1+2>;04/2+<=>-</452>60/,8.-8>6+6c94/G+->=,>26+20=>-0?+6+4,0/G/0/+6?46;++2-+d.+60+</26+,0/>2eJKfKg'&'&'& 3,-++2/254,0/G/0/+68+-=>-1+<4=0+-4,>26+20=>-6,-++2/25?46;++26/52+<I?+=>::>9/254,0/G/0/+69/::;+8+-=>-1+<>2:A4=0+-0?+6.;\+,0?466/52+<0?+,>26+20=>-0?/660.<A=>-6,-++2/25'c66+661+2068+-=>-1+<40>.06/<+=4,/:/0/+6>->242>0?+-DEF8->0>,>:hi$BaBi$&jaa*3,-+++2/258->0>,>:>-$kBaBi$l$DmnD40.-4:F/60>-A7->0>,>:o9/0?/20?+0/1+:/2+6;+:>914A4:6>;+.6+<0><+0+-1/2++:/5/;/:/0A>2,+4840/+20?466/52+<0?+,>26+20'I?+6,-++2/25+G4:.40/>21.60;+,>18:+0+<9/0?/2$(0/1+:/2+62>0+</23+,0/>2JKp.2:+66>0?+-9/6+2>0+<]&'&'&'$E145/25^ [*E?+4<42<b>-68/2+9/0?54<>:/2/.10>,>2=/-18->5-+66/G+</6+46+'[*E84-41+0+-66?>.:<=>::>90?+68+,/=/,40/>26<+04/:+</2VqqrstuvwKE=0?+60+->/<<>6+/6/2,-+46+<;+09++20?+<40+>=/145/2542<,>26+20_42+96,-++2/25[*E/6-+d./-+<4=0+-840/+20?46;++2>24604;:+60+->/<<>6+=>-40:+460l<4A6'^ 740/+2069/0?8-/>-0?+-48A0?40/2,:.<+</20+-60/0/4:;-4,?A0?+-48A>-60+-+>04,0/,-4</>6.-5+-A1.60?4G+,>2=/-140/>2>=0-.+8->5-+66/G+</6+46+-40?+-0?42-4</40/>22+,->6/6;46+<.8>2+/0?+-7HI>-I?4::/.16,422/25_[*68+,0->6,>8A_>-6.-5/,4:b840?>:>5/,4:<>,.1+2040/>2>=-+,.--+20</6+46+h3,-++2/25>2:Ao'&'&'x F/60>-A42<8?A6/,4:+C41/240/>2^ a>18:+0+1+</,4:?/60>-A42<8?A6/,4:+C41/240/>2_/2,:.</25?+/5?0_9+/5?0_G/04:6/526_Hyz_42<y4-2>=6@A8+-=>-142,+6040.6hVqqrstuvV{^ D+.->:>5/,HC41h3++VqqrstuvVo&'&'( |4;>-40>-AHG4:.40/>2^ F+140>:>5/,4:8->=/:+]ana9/0?</==+-+20/4:42<8:40+:+0,>.20}
^ n/>,?+1/,4:8->=/:+]+:+,0->:A0+6_n~D_,-+40/2/2+_c3I_c|I_0>04:;/:/-.;/2_,4:,/.1_


	
  !"#!#"#"$%
&'()&'(*+),-./+012,0-324)1+0,+*15-51678 :4*+0(*+*124&*432-25;<4)<=(*=40-.4&-*<151&-2<)(=5'1.6/4-*123-34>12<'4-/)4254(=&*1(*';)<4*45<(0;?>@6-;)&*1(*<(<*4-<042<*431)<*-<1(2?78 A*12-.;)1)BCBCD E1)<(.(3155(2=1*0-<1(28 E1)<(.(3155(2=1*0-<1(2(=61-32()1)-26FGH=+)1(2)<-<+)/;IJKL-/(*-<(*;(=M-<'(.(3;>-<-2;<104&(12<&*1(*<(<*4-<042<?CK=<'4*41)2(-N-1.-/.4<1))+4)-0&.4),/1(&);O1../4&4*=(*046<(5(2=1*0<'461-32()1)-26FGH=+)1(2)<-<+)CP(*/-)4.1244N-.+-<1(2),&.4-)4)44)45<1(2QRSQRT
WXYZ[\[WX]ZY^_[`ZYXZ[a]X]b`ZXZc`cWbXZ^WYa\^bcY^`d431)<*-<1(2-26)<-<+)+&6-<4)>4C3C,O'42-&-*<151&-2<1)<-e42(==&*(<(5(.<'4*-&;-26O'42-&-*<151&-2<1)<-e42(==f)<+6;?O1..<-e4&.-54&4*JJd:gMhiJdfB,JJdM-*<151&-2<d431)<*-<1(2j:<-<+)A&6-<4)=(+26'4*4CBCkC$ l*4-<042<h))132042<M*(546+*4)>mnoopqrstoutrnvwxownspsnvyz?{\n|nots
]x}~po ]u}pbpsorwtrnv$
J('(*<$:+/45<)O1<'12<*-f5*-21-.(*)&12-.FGHf=+)1(24&426;0(0-O'('-N4'-62(24,$(*B&*1(*5'40(<'4*-&14)CB
J('(*<B:+/45<)O1<'12<*-f5*-21-.(*)&12-.FGHf=+)1(24&426;0(0-O'('-N4'-60(*4<'-2B&*1(*5'40(<'4*-&14)Ck
J('(*<k:+/45<)O1<'12<*-f5*-21-.(*)&12-.2(2FGHf=+)1(24&426;0(0-O'('-N4'-62(24,$(*B&*1(*5'40(<'4*-&14)C
J('(*<:+/45<)O1<'12<*-f5*-21-.(*)&12-.2(2FGHf=+)1(24&426;0(0-O'('-N4'-60(*4<'-2B&*1(*5'40(<'4*-&14)CM
J('(*<MJ'1.6*42O'(0-;'-N4/4424&()46<(<'4)<+6;6*+312+<4*(gd4&45<-2<0(<'4*)(=5'1.6*42O'(0-;'-N4/4424&()46<(<'4)<+6;6*+312+<4*(1=0(<'4*2(<12-<*4-<042<5('(*<Xo}
]x}~po ]u}pbpsorwtrnv$
h*0$-*1(01/-<6-;)$,%-26$D(=4-5'B%f6-;5;5.4M
M*432-25;4N-.+-<1(2i-<-5(..45<1(2(2&*432-25;,/1*<'-26'4-.<'(=5'1.6+&<($;4-*CXo}ussrqv}pvt


	
  !"#!#"#"$%
&'()*+,-./01213,$45467/89:.;;(*8.3*+,;<7--.=/*8,1>3?$@&'()*+,-./01213,A:.;;(*8.3*+,;<7--.=/*8,1>3?A@BCD FGHIJKLIINGJOGPKQLR*-,-81/*7,-+3**/./=81/1,/**8,1(*3*S*7,*87,(7-*;./*.TS*3T13?*8./8*-.=/7,*8,.?*T37?*S3.13,1-,73,1T-,'8<83'=@U.,2./$987<-S3.13,1T.3-,81-*VW YZ[1T,2*2*787/8\13-S./*:.,2=781;./.'?7--S*+.T.*8./G]]^_`abF@W >3+2.c*8,'?13-7?S;*-:.;;(*+1;;*+,*8,181?1;*+';73-,'8.*-7-8*-+3.(*8./&*+,.1/dCeC[T,2*S7,.*/,27-S3*c.1'-;<(**/1/7/1,2*3-,'8<7,f[g47/8,2*3*h'.3*8?1;*+';73S31T.;./=27-(**/81/*4,2*/788.,.1/7;S7,21;1=<?7,*3.7;?7</1,(*/**8*8i7/<,.?*S3.13,1,3*7,?*/,./.,.7,.1/j@W R2*Yk>&[lmR7/8\13Yk>&[l&A@R2*+21.+*1T./-,3'?*/,:.;;(*(7-*81/,2*;1+7,.1/1T,2*./8*n;*-.1/T13-,'8<*/31;;?*/,@R2.-?7<(*./,2*(37./iYk>&[lmRj4-S./*iYk>&[l&Aj13(1,2i+1?S;*,./=(1,2./-,3'?*/,-.T;*-.1/-./,2*(37./7/8-S./*73*(*./=T1;;1:*8T133*-S1/-*j@io13p/=;.-2-S*7q./=-'()*+,-1/;<j@W Z*-*73+2(;118T13&fA&,'8.*-i&**-*+,.1/dCrCBjW Z*-*73+2(;118T13A273?7+1=*/1?.+&,'8.*-i01213,$1/;<ji&**-*+,.1/dCrCBjW 01/+1?.,7/,Y*8.+7,.1/-W >8c*3-**c*/,-W psti:.,2./687<-S3.13,1T.3-,81-*jW &'()*+,-:.;;+1?S;*,*7/8-.=/7/f[g78c7/+*88.3*+,.c*-T13?:2.+2.-?7/87,13<1/,2.--,'8<@e HPOuvKwxJIwILPGPKQLeCr HPOuvuIHKyL6@$@$ 01213,-$l9VR2.-.-7S27-*[[-,'8<,1*c7;'7,*,2**TT.+7+<1T,3*7,?*/,:.,2?73.z1?.(./{|}lT'-.1/3*+'33*/,*S*/8<?1?77/8/1/{|}lT'-.1/3*+'33*/,*S*/8<?1?7@[/,2*-,7=*$1T-,'8<4,2*3*:.;;(*-.?';,7/*1'-7++3'7;./,101213,-$7/85@o1301213,$4%S7,.*/,-:.,2{|}lT'-.1/*S*/8<?1?77/8/1/*4$413513S3.13+2*?1,2*37S.*-:.;;(**/31;;*8@@o1301213,54%S7,.*/,-:.,2Zp~>lT'-.1/*S*/8<?1?7-7/85S3.13+2*?1,2*37S.*-@[T:*T./8*c.8*/+*1T+;./.+7;7+,.c.,<1T?73.z1?.(4i913?13*S7,.*/,-./01213,$73*S31=3*--.1/T3**7,?1/,2-j4:*:.;;S31+**8,1-,7=*541,2*3:.-*:*:.;;,*3?./7,*,2*,3.7;@>,-,7=*54:*:.;;*/31;;S7,.*/,-./,15+1213,-V4$S7,.*/,-:.,2/1/{|}lT'-.1/*S*/8<?1?7:21278/1/*4$135S3.13+2*?1,2*37S.*-i01213,6j7/8$S7,.*/,-:.,2/1/{|}lT'-.1/*S*/8<?1?7:21278?13*,27/5S3.13+2*?1,2*37S.*-i01213,9j@k'3./=-,7=*54*/31;;?*/,./,101213,-67/89:.;;1++'3-.?';,7/*1'-;<@A;*7-*-**H^r@


	
  !"#!#"#"$%
&'()*)+(,-./((0-1234567*-89:7;,(';-/,++<(;=(7;(6/,;>?@A7=,BCA,<7;%9DAE3A
FF$
FFC'67*-GHD7'6GICJ(7)>$D467*)*)+(K';,+CJJ;=(7;A(';)=,;(=,77=(A(;1L();,C'MNONP89QRSTUVPXQYZ[\[]Q^_`59G9$ bC>C=;:c:=(E'7')*d(+7;(6L;K6*:=C)(6K=(-He,=;>7'6f(7+;>CJb>,+6gJ;(=-,E','E;>(h=(E'7';h7=;'(=)C'-(';6C)KA(';H-K<i();-,'bC>C=;:H7-/(++7-/CA('/>CA7*>7j(<()CA(h=(E'7';C'7'*CJ;>(;=(7;A(';)C>C=;-/,++<(7-0(6;C-,E'JC=Ak?f4G$%DH7=(lK(-;JC==(+(7-(CJA(6,)7+,'JC=A7;,C'9d(+(7-(-/,++<(=(lK,=(6JC=<C;>;>((mhC-(6)>,+67'6JC=;>((mh();7';AC;>(=9
MNn [pZ_q[r^`^QYpqY^s`t7=,BCA,</,++<(76A,',-;(=(67;%9DAE3A
FF$
FF?@Cj(=7;+(7-;G%A,'K;(-12G%A,'K;(-81-((-();,C'PuNPNv89
:7;,(';-->CK+6<(h=(A(6,)7;(6/,;>C'67'-(;=C'DAE?@C=h=C)>+C=h(=7B,'(G%AE?@w%A,'K;(-1234
5%A,'K;(-8h=,C=;CA7=,BCA,<,'JK-,C';Ch=(j(';'7K-(7C=jCA,;,'E9
L;7E(?x(-y'=C++zh7;,(';-/,;>dy{g4JK-,C'(h('6*ACA7-7'6'C'(HGHC=$C=h=,C=)>(AC;>(=7h,(-|}~S~Pg=(.C=AC=(h7;,(';-h=CE=(--,C'J=((7;wAC';>-:=C)((6;CL;7E(??CJ-;K6*(=A,'7;(;>(-;K6*kCL;7E(??Gwh7;,(';-/,;>'C'JK-,C'(h('6*ACA7-7'6'C'(HGHC=$h=,C=)>(AC;>(=7h,(-|}~S~Mzh7;,(';-/,;>JK-,C'(h('6*ACA7-7'6$h=,C=)>(AC;>(=7h,(-|}~S~nGwh7;,(';-/,;>'C'
JK-,C'(h('6*ACA7-7'6AC=(;>7'$h=,C=)>(AC;>(=7h,(-|}~S~uL,AK+;7'(CK-7))=K7+

	
  !"#!#"#"$%
&'()*+(,-../()(0(12-3()4+-350'(/*)6+41789(81(8:;<=>98.94.80()?1-*10*(89')86%43.(+++-53-7-9830:@AB5>,(-5'0.*++*158-3-+*/+(1C())41-358969.(D&'(;<=,-../(98.94.80()71*20'('(-5'0*/08-3()80+91((3-3583)0'(,(-5'0*/08-3()80)86%C-+-0D&'()*+(,-../(1*43)()0*0'(3(81(+0ED%25D
F3G69.(%HI86%HJ83)%KC-08.+-53+,-../(08B(3,-0'-3%E2-340(+/(7*1(0'(281-L*2-/-374+-*383)%E:MNOK>2-340(+HAE:MNO%E>2-340(+H83)%'*41:MNO%K2-340(+>7*..*,-350'(281-L*2-/-374+-*3DP*18..+4/+(Q4(30969.(+HC-08.+-53+,-../(8++(++()?1-*10*0'(281-L*2-/-374+-*3+83)8??1*R-280(.6AE:MNO%E>2-340(+7*..*,-35(89'-374+-*3DS3C(+0-580*1++'*4.)+08108++(++-35?80-(30+7*1GT<=U+:<(90-*3VWXWY>870(10'(7-1+0281-L*2-/)*+(H8.0'*45'71(Q4(30.60'(+(=U+)*3*08??(81430-.G69.($*1.80(1DI*+(2*)-7-980-*3+54-)(.-3(+7*1GT<8)C(1+((C(30+81(*40.-3()-3Z[\]^`D=+98.(7*1180-35+(C(1-06*7'8..49-380-*3+-+?1*C-)()-3abb^cdefg
hijhijWk80-(30++'*4.)/(,813()858-3+0)1-C-35*1*?(180-35289'-3(16-70'(6)(C(.*?GT<8)C(1+((C(30+,'-.(1(9(-C-35281-L*2-/DlWl nopqronstsgaZsoupI*+(2*)-7-980-*3+81((R?.8-3()-30'(Z[\]^`HZ[\]^l83)Z[\]^vS70'()*+(,8+1()49()7*1=U+H0'(1(,-../(3*)*+(1(O(+98.80-*3-3+4/+(Q4(3001(802(30969.(+D=70(1I*+(.(C(.OAH3*2*1()*+(1()490-*3-+8..*,()83)?80-(30,-../(08B(3*7701(802(30DZ[\]^Xwr[xeyz{e\nz|^}^d~ezc^^]|nz|^^^]^^]dz|^Zx^[{^cp^d~]^<0810-35)*+(EDJ25N2$I86+%HJH83)%K:$JO)86969.(>I*+(.(C(.O%ED25N2$I86+%HJH83)%K:$JO)86969.(>I*+(.(C(.O$EDKK25N2$I86+%HJH83)%K:$JO)86969.(>I*+(.(C(.OAED25N2$I86+%HJH83)%K:$JO)86969.(>

	
  !"#!#"#"$$
%&'()+,-&./012/'314)-15/6/7&8/19:948.;78/194<=>?@AB?CDEFG=HFIJIKF>LFMKFNHOFKF>?HPEFQABBFNIFIRALF<AI?S?Q=H?AN T)98.&(U).V1;4WX48)2YABBANYZOJML?NQG[I?N\]=H=^?=_I?@@?NFLL_\=?HI?LH[>C=NQF_C=G=NQFI?LA>IF>_S=GG_IPL=>H`>?=_QANS[L?ANabA>`=GG[Q?N=H?ANLB=N=\FBFNH_cGF=LF_LFFLFQH?ANdedefg>=IFh<=?NH=?NQ[>>FNH<EiIALFLQ`FI[GFj?H`A[HIALFBAI?S?Q=H?ANag>=IF$YANL?IF>AH`F>L[ccA>H?KFH>F=HBFNHkLFF%&'()lmn\FNF>=GGPNAIALFD>FI[QH?ANL=>F>FQABBFNIFIaYANL?IF>IALFD>FI[QH?AN?S?NHAGF>=CGFCPc=H?FNHI[FHA?NHF>SF>FNQFj?H`I=?GP>A[H?NF=NIoA>?SI[>=H?ANASFKFNHG=LHLGAN\F>H`=NpI=PLag>=IFpJHH`FNF^HLQ`FI[GFI<EiIALF=IB?N?LH>=H?AN_IALFD>FI[QFANFIALFGFKFGaqSJM`=LNAH>FLAGKFIHArg>=IFhkA>C=LFG?NFm_Ls?cH`F<EiIALF=NI>FL[BFj?H`H`FNF^HLQ`FI[GFIIALF=H>FI[QFIGFKFGk%&'()fmaqN=II?H?AN_QANL?IF>AH`F>L[ccA>H?KFH>F=HBFNHkLFF%&'()lmg>=IFtOHAc<Ei[NH?G>FLAG[H?ANHArg>=IFhkA>C=LFG?NFmaqS>FDQ`=GGFN\F?L=NAcH?AN_>FI[QF<EiIALFGFKFGk%&'()fmau>F=HBFNHL`A[GICFcF>B=NFNHGPI?LQANH?N[FI?SH`FHA^?Q?HPIAFLNAH>FLAGKFHA\>=IFhA>GFLLj?H`?N$jFFsLav&48.1/98)48/9&(Z=[LF=_wAB?H?N\g>=IFhA>$qBcGFBFNHc>Ac`PG=QH?Q=NH?DFBFH?Q>F\?BFN=QQA>I?N\HAGAQ=G\[?IFG?NFLa<=?NH=?NQ[>>FNH<EiIALFLQ`FI[GFj?H`A[HIALFBAI?S?Q=H?ANaqSk>FmAQQ[>>FNQFIFLc?HF=cc>Ac>?=HFc>Ac`PG=^?L_IALFD>FI[QFANFIALFGFKFGk%&'()fm=HH`FNF^HLQ`FI[GFI<EiIALF=IB?N?LH>=H?ANag>=IFpA>tqBcGFBFNHc>Ac`PG=QH?Q=NH?DFBFH?Q>F\?BFN=QQA>I?N\HAGAQ=G\[?IFG?NFLaqSk>FmAQQ[>>FNQFIFLc?HF=cc>Ac>?=HFc>Ac`PG=^?L_IALFD>FI[QFANFIALFGFKFGk%&'()fm=HH`FNF^HLQ`FI[GFI<EiIALF=IB?N?LH>=H?ANaqN=II?H?AN_QANL?IF>AH`F>L[ccA>H?KFH>F=HBFNHk%&'()lma

	
  !"#!#"#"$%
&'()*+,)-./01'2034350(60750829050()2:/0;+,,08303<+60&+3)=);'2)+8 >?@ABDEFABGAHFAI?GJ('30$&')82')8;K((082&/L3+606;M03K10N)2M+K23+60,+3)=);'2)+8OP+86)30(3+60.(03K;2)+8QRSTUAVW)=)82+10('-10-:X'2)0823K02+)820(=0(08;0N)2M3')1:(+K2)80'83Y+(8+2(06+15032+ZJ('30[Q+(-'601)80W'22M080\26;M03K103&/L3+60'3,)8)62('2)+8OJ('30%422M080\26;M03K103&/L3+60'3,)8)62('2)+8]3+60.(03K;0+803+6010501QRSTUAVWO^=47M'68+2(06+15032+ZJ('30[Q+(-'601)80W]6_)X2M0&/L3+60'83(06K,0N)2M2M080\26;M03K1033+60'2(03K;0310501OJ('30`92+X&/LK82)1(06+1K2)+82+ZJ('30[Q+(-'601)80WO^=(0.;M'1108a0)6'8+X2)+8](03K;0&/L3+6010501QRSTUAVWO^=2+\);)2:;+82)8K06-0:+83$N00_6];+86)30(X0(,'80823)6;+82)8K'2)+8O%O%O[ c'11K;)8'2)+86,'8'a0,082d'2)0826'83;'(0a)50(6'(0N'(803'-+K22M0X+66)-)1)2:+=M'11K;)8'2)+86Oc'11K;)8'2)+86'(0a('303Y;M'(';20()*03-:2M0eK_+==;()20()'Qc'11K;)8'2)+89050()2:9;'10]DffAIEghiW'83,'8'a0,082aK)301)806-'603+82M060;()20()''(0X(+5)303-01+N)8RSTUAjOk+2M2M0('X0K2);'83X(+XM:1';2);K60+='82).X6:;M+2);6,':-0;+86)30(03=+(,'8'a0,082+=M'11K;)8'2)+86OlM)102M0(0M'6-0088+;+((01'2)+8-02N008,03);'1M)62+(:+=,082'1)118066'832M0)8;)308;0+=M'11K;)8'2)+86]X'2)0826N)2MX(00\)62)8a,082'1)1180666M+K13-0,+8)2+(03;1+601:'83;+86)30('2)+8a)5082+X(+XM:1';2);'82).
X6:;M+2);3+60)8;(0'60ORSTUAjmnSUUopgIS?gqIGrSISsArAI?m/0;+,,08303';2)+86t0(:&)13
u/
&)13
u/
&+30('20
v+,'()*+,)-3+60(03K;2)+8800303&+30('201:6050(0]/01'2032+,'()*+,)-92+X,'()*+,)-K82)1(06+1K2)+82+wt0(:&)13+(&)13+(&+30('20xQ+(-'601)80WO&':K60yK02)'X)80=K,'('20+(+1'8*'X)80'6)83);'203O^=M'11K;)8'2)+8(06+1506N)2M2(0'2,082];+86)30(;+82)8K)8a2(0'2,082'833+6)8a+86',06;M03K10'6-0=+(0O^=M'11K;)8'2)+8(02K(86NM)10+8'82).X6:;M+2);]2M083+60(03K;2)+8'22M0
80\23+60QRSTUAVW)6N'(('8203O


	
  !"#!#"#"$%
&'()**'+,',-(./)+01'2'3'4
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`abcBd?`BeB?f]`Bfd_ghbab_g
\]^^_`abcBd?`BeB?f]`Bfi';.3)P'+/-)3+';.3)P'+/-Q/.9H'2'3
j'*-.)P)/'./(T3)Q.9H-(.)30-3'P'3*/..',H)3T3-,'%+';.3)P'+/-)3+';.3)P'+/-Q/.9H'2'3-+,09);5,H)55)Q8*'3/(-+1)(/'.L)HY5/+/(-5k+()5)TLT;/,'5/+'0H)3.9'/3;0'Fl3)P9L5-(./(;0')HT3)Q.9H-(.)30/0+).-55)Q',4+)3(-+.9'L7';0',.)/*P3)2'75)),();+.0.)-55)Q/+/./-./)+)H.3'-.*'+.Fi-;0'-42)*/./+TU9'+-;0'--+,2)*/./+T.9-.*-L)((;3Q/.9*-3/6)*/7-,*/+/0.3-./)+(-+T'+'3-55L7'*-+-T',.93);T9.9';0')H-PP3)P3/-.'0;PP)3./2'*'-0;3'04-+./<'*'./(0='FTF4m<jUW-+.-T)+/0.047'+6),/-6'P/+'04P3)(95)3P'3-6/+'EFl-./'+.009);5,7'P3'*',/(-.',Q/.9)+,-+0'.3)+)3P3)(95)3P'3-6/+'no*/+;.'0=pq<Wo*/+;.'0EP3/)3.)*-3/6)*/7-,*/+/0.3-./)+Fr/-339'-
1P'(/H/(T;/,'5/+'0H)3.9';0')H5)P'3-*/,'H)3.9'0;7-(;.'=,-L0-H.'3-,*/+/0.3-./)+EH)3*)H,/-339'--3'P3)2/,',7'5)Qsl-./'+.009);5,+).7'T/2'+,3;T0Q/.95-:-./2'P3)P'3./'0Ft)P'3-*/,'09);5,7'0.-3.',-..9''-35/'0.0/T+)Hs=VE-5))0'0.))54)3=$E.9')((;33'+(')HV<$*)3'7)Q'5*)2'*'+.0.9-+;0;-5/+V,-L4
)3
=WE-0/T+/H/(-+./+(3'-0'/+0.))52)5;*')35/u;/,/.LF


	
  !"#!#"#"$%
&'()*+,-.)/0'12.3)4+5)6-640)7'22'8-69,+66)*:;,9+440)'6/)4'7.-+**0)++6.40)6$,93<,'140)=)*<$0'1*/>+*'16.40)?2'?5164-240)(+4-)64-/.-+**0)+7*))7'*+42)+/4@$0'1*/AB+4-)64/,+<4+5)2'()*+,-.))=)*<;0'1*/.1*-6940)6-904AB+4-)64//0'12.-6?*)+/)721-.-64+5)4'0)2(,+-64+-6721-.+6.)2)?4*'2<4)3+2+6?).1*-69)(-/'.)/'7.-+**0)+ACDEF=)64/:C'671/-'6>+4+G-+>.)2-*-1,+6.+6<'40)*6)1*'2'9-?+2/-96/'*/<,(4',/
H22I*+.)/:J0)6(+4-)64/.)=)2'(6)1*'2'9-?+2/<,(4',/.1*-69,+*-K',-3-671/-'6>LMNOMQRSTUVLSNTAB+4-)64//0'12.3)0<.*+4).8-40@2-4)*3'21/'76'*,+2/+2-6)+6./0'12.3)'3/)*=).7'*$0'1*/AW*+-6-,+9-69/0'12.3)'34+-6).+/-6.-?+4).AF.1?+4)(+4-)646'44'.*-=)+6..'6'41/)0)+=<,+?0-6)*<164-240)6)1*'2'9-?+2/<,(4',/*)/'2=)AI*+.)@'*$HF:X)7)*4'YZ[\R]I*+.)$^_HF:`'22'891-.)2-6)/7'*I*+.)@^$HF+3'=)>-6+..-4-'6abd*)+440)HF8-40+6+((*'(*-+4),).-?+4-'6-7'6)-/+=+-2+32)AE',)-6=)/4-9+4'*/0+=)1/).e1)4-+(-6)71,+*+4)'*'2+6K+(-6)7'*0+221?-6+4-'6/+6.,)40<2(0)6-.+4)7'*7+4-91)Abf'/),'.-7-?+4-'6+/()*YZ[\RgAH?14)h-.6)<i6j1*<k<.*+4)8-40@2-4)*3'21/'76'*,+2/+2-6)Ak<('?+2?),-+C+2?-1,E1((2),)64/:C+2?-1,/1((2),)64/l)A9A>?+2?-1,?+*3'6+4)>%mm,9Bn40*))4-,)/.+-2<o,+<3)*)e1-*).4',+-64+-6/)*1,?+2?-1,2)=)2/+3'=)40)2'8)*2-,-4'76'*,+2.1*-69?0),'40)*+(<4*)+4,)64Ap-4+,-6f/1((2),)64/l)A9A>)*9'?+2?-7)*'2>;mmiqBn.+-2<o,+<3)+((*'(*-+4)7'*()*/-/4)640<('?+2?),-+Arst vwxyYz{||}z~xyd0)fHEi^Wd+6.'*fHEi^EB8-223)+.,-6-/4)*).+43+/)2-6)+6.+440)4-,)'7-,+9-69+6+2</-/AF=)*<+44),(4/0'12.3),+.)4'+.,-6-/4)*40)fHEi^Wd+6.'*fHEi^EB(*-'*4'-67'*,-6940)(+4-)64/+3'1440)*)/124/'740)-,+9-69/41.<Ad0)fHEi^Wd'*fHEi^EB8-223)?',(2)4).'62<3<40)(+4-)64>162)//?0+69)/-6=-/-'6'*8)+56)//,+5)40-/.-77-?124Ai740-/'??1*/>40)640)?+*)9-=)*'**)/)+*?0+//-/4+64,+<*)+.40)e1)/4-'6/4'40)(+4-)64'*+//-/48-40,+*5-6940)/)=)*-4<61,3)*'*/?'*)+/.)/?*-3).3<40)(+4-)64Ad0)+=)*+9)4-,)4'?',(2)4)40)/)-6/4*1,)64/-/%,-614)/An62<7'*F692-/0/()+5-69(+4-)64/Ars {{w_A%A@ $^f+<E+7)4<`'22'8^1(p-/-4HE+7)4<`'22'8^1(=-/-4-//?0).12).;8))5/l$%.+</o+74)*40)2+/4+.,-6-/4*+4-'6'7+*-K',-3
3143)7'*)+6<6)840)*+(<-//4+*4).>-7('//-32)>80-?0)=)*'??1*/)+*2-)*Ad0)$^f+<E+7)4<`'22'8^


	
  !"#!#"#"$%
&'()*)+,)--./0'1)*234&--3**2**025+4/1*342+6357+&0/112*'/5*23*3''1/'1)3+28,9).9,)--)5.-&723**2**025+*)57).3+27)5:+&76;3-257318:2.+)/5<=>=?@A@$ C/5DE+210F/--/,E&'G--:GH*/5D/)5D3++92$IEJ36:342+6F/--/,E&'()*)+0&*+K20/5)+/1273574/--/,27&'K6+92L5(2*+)D3+/1&5+)-*+3K)-)M3+)/5/1&5+)-+92/&+./02)*N5/,58&5-2**+92*&KO2.+)*7/.&025+273*P-/*++/4/--/,E&'@Q
:&KO2.+*,)+9'1/D12**)(27)*23*2RSJT34+21+92$IEJ36:342+6F/--/,E&'()*)+8,)--K24/--/,272(216%0/5+9*RUV0/5+9T4/1*&1()(3-R)5.-&7)5D3**2**025+/43564&1+92135+).35.21+9213'6TK6'9/52.3--/12E03)-@
:&KO2.+*,)+9/&+SJ3++92$IEJ36:342+6F/--/,E&'()*)+*9/&-7./5+)5&24/--/,&'()*)+*357+&0/1)03D)5DK6WXL3*4/--/,*YZ 2(216$0/5+9*4/1V623134+21+123+025+*+/'73+2[+9258Z 2(216?0/5+9*4/1V6231[+9258Z 2(216\0/5+9*4/1V6231[+9258Z 2(216%0/5+9*&5+)-'1/D12**)(27)*23*28-/*++/4/--/,E&'8/1723+9@<=> ^_`abdefghaeijklmnopkn
^mknnqrqstuvnwrqn
xdymwnvxz{|}{~z<ouyv
x {~auyv`xxflqs_nk`xxxauyv
xx~xrjarlpjaW31)M/0)K$LG7(35.2J)12.+)(2*F/10?
W27).3-)*+/16;/54)103+)/5/4S3+9/-/D62)D9+
S96*).3-230852&1/-/D).3-2308S:2)D9+
 V$ V$)+3-*)D5*
\ \ \H
V? V? V?;;,)+97)442125+)3-A A A)/.920).3-'1/4)-2
%A A AG06-3*2-)'3*2;8CJ
A1)53-6*)*
:21&0/1&1)52'12D535.6
+2*+


A
S8LX83S84)K1)5/D25




	
  !"#!#"#"$%
&'()*+,'*
-)'**./.0123*4/.*
567)4*359:;<:=>?9@+273A
5 :=B273CD55E(.0F*'GCD5HI55B273
55=5JK/LM&BK/LM(,L&BNOPQRSTUVOUWXQYZ[\]^
_`````aQYbQPXWUYW[ScXbUWXQYdZeSSfg5A
``````hcTSRdSSTSYWdZeSSfg5^``````\SdSURbijVQQckQRelmeWOcXSd
`\SdSURbijVQQckQRmiURPUbQnSYQPXbeWOcXSdZaQiQRWoQYVp^`aQVVSbWXQYQkURbiXTUVWOPQRdUPqVSkQRRSdSURbidWOcXSd`[rhe]stNUYcuQR[rhe]s
ev
````miQYSbUVVQRSsPUXVkQRdORTXTUVuYSwbUYbSRWRSUWPSYWd
``oNSdWdcQYSUWdbRSSYXYnQRjUdSVXYScQYQWYSScWQjSRSqSUWScQYjUdSVXYSQRrUpoQkapbVSoXkqSRkQRPScXYcSdXnYUWScWXPSkRUPSqRXQRWQdWURWQkdWOcpcROnxNXPSwXYcQwyuszcUpdXdUVVQwSckQRrUpdo{_UYco|x$}x_PnuP
~~$
~~ ]xzhVVdOjSbWdwXVVbQPqVSWSUYcdXnYUYl]UcTUYbSccXRSbWXTSdkQRPwiXbiXdPUYcUWQRpQYWiXddWOcpxeSSdSbWXQY@g:kQRTXWUVdXnYddbiScOVSQYcUpdQkcROnXYkOdXQYx|UjdwXVVjSQjWUXYScwXWiXY%$iQORdqRXQRWQcQdXYntXQbiSPXbUVqRQkXVSSVSbWRQVpWSd{tl{bRSUWXYXYS{heN{hN{WQWUVjXVXROjXY{bUVbXOP{qiQdqiQROd{UVjOPXY{PUnYSdXOP{ORXbUbXc%QRwQPSYQkbiXVcsjSURXYnqQWSYWXUVQYVp_[\]iSUcUYcuQRdqXYSwXWinUcQVXYXOPUWdbRSSYXYnujUdSVXYSUYcSTSRp_wSSdUkWSRjSnXYYXYnQkWRSUWPSYWxaQYkXRPUWQRpdbUYddiQOVcUVdQjSQjWUXYScXYs_wSSdqSRXQcQkWXPSkQVVQwXYnXYXWXUVcQbOPSYWUWXQYQkQjSbWXTSRSdqQYdSxmUWXSYWdwXWiqRXQRWiSRUqpWiUWXYbVOcScXYWSRdWXWXUVjRUbipWiSRUqpQRdWSRSQWUbWXbRUcXQdORnSRpPOdWiUTSbQYkXRPUWXQYQkWROSqRQnRSddXTScXdSUdSUWdbRSSYXYnRUWiSRWiUYRUcXUWXQY YSbRQdXdjUdScOqQYSXWiSRmNQRNiUVVXOPdbUYYXYn{[\dqSbWRQdbQqp{QRdORnXbUVuqUWiQVQnXbUVcQbOPSYWUWXQYQkRSbORRSYWcXdSUdSxhkWSRXYXWXUVbQYkXRPUWXQYQkqRQnRSddXTScSdSUdSUWdbRSSYXYn{WiSdSqUWXSYWdwXVVjSSTUVOUWSccORXYnWRSUWPSYWwXWiRSnOVUR[\]xvhWjUdSVXYSUYcWiSYwXWiXYocUpdqRXQRWQSUbiXPUnXYndWOcpxo}hVVehdQYnQXYnUWWiS$_srUpeUkSWpQVVQwsOqTXdXWPOdWjSPQYXWQRScUYckQVVQwScOqjpWiS]YTSdWXnUWQROYWXVdWUjXVXUWXQYQROYWXVWiSQOWbQPSXdYQwY{OYVSddWiSdOjSbWXdcQbOPSYWScUdVQdWWQkQVVQwsOqxeOjSbWdwXWimrUkWSRWiS$_srUpeUkSWpQVVQwsOqTXdXW{wXVVjSkQVVQwScSTSRpPQYWid
ZoPQYWi^kQRdORTXTUVZXYbVOcXYnUddSddPSYWQkUYpkORWiSRUYWXbUYbSRWiSRUqp^jpqiQYSbUVVQRSsPUXVx


	
  !"#!#"#"$%
&'()*+,-./,01',234,,0*$%5346&47*,681991.5':;/-/,-01'9<+1=,/='*71991.':;/-/,-4=<,'>1?/>4@/=@(6ABC:*?-+0*<'9*/=,0*&*+,/1=DEFEGHHC7-'()*+,-4?*'=4(9*1?=1,./99/=@,1+1>*,1ICJ,171?71991.':;/-/,-K,0*6./99(*71991.*<(6:01=*+4991?*5>4/971?-'?;/;49K4<;*?-**;*=,-L71?H6*4?1=96M4=<7'?,0*?,'>1?,0*?4:6NH$C7-/@=/7/+4=,LOPQ@M.*/@0,91--1?@4/=/-1(-*?;*<<'?/=@4+6+9*NHPR/,0/=$01'?-47,*?-,'<6<?'@/=7'-/1=4=<4<</,/1=49964=6,/>*/7+9/=/+4996/=</+4,*<NDES UVWXZ[\UV]^_[WZX`V[PNaNH c1-,-
ICJ<1*-=1,(/990*49,0/=-'?4=+*+1>:4=/*-1?:4?,/+/:4=,-71?4=6?*-*4?+01??*94,*<+9/=/+49+4?*,04,:4?,/+/:4=,-?*+*/;*4,,0*ICJc9/=/+49c*=,*?NC7-1>*,*-,-4=<:?1+*<'?*-:*?71?>*<1',-/<*,0*ICJc9/=/+49c*=,*?K:4?,/+/:4=,->4604;*,1:4671?,0*-*+1-,-/7,0*64?*=1,+1;*?*<(6/=-'?4=+*+1>:4=6NA*</+/=*-,04,4?*=1,:4?,17,0*-,'<6,?*4,>*=,./99=1,(*:?1;/<*<1?:4/<71?(6,0*ICJc9/=/+49c*=,*?N
PNaN$ c1>:*=-4,/1=24?,/+/:4=,-./99=1,(*+1>:*=-4,*<1=,0/--,'<6dPNaNP B*/>('?-*>*=,e0*IcC./99+1;*?,0*+1-,-17-1>**f:*=-*-4--1+/4,*<./,0:?1,1+19:4?,/+/:4,/1=N&1>*17,0*-*+1-,->46(*:4/<</?*+,96(6,0*ICJ4=<-1>*>46(*?*/>('?-*<,1,0*:4?,/+/:4=,g@'4?</4=4-4::?1:?/4,*Ne0*4>1'=,4=<71?>17,0*-*:46>*=,-4?*<*,*?>/=*<(6,0*IcCe?4;*94=<h1<@/=@B*/>('?-*>*=,219/+6NDEi Uj`X_j`ZkVjj_]VlZmkjV]^jVXVUVmXn_jZ^oZ[\VkkWXp\oUj`X_j`Z2?/1?,1?*>1;497?1>-,'<6K*771?,>'-,(*>4<*,104;*499-'()*+,-+1>:9*,*4-47*,6;/-/,4::?1f/>4,*96$%<46-71991./=@,0*94-,<1-*17-,'<6,0*?4:6NPN%NH c?/,*?/471?B*>1;497?1>2?1,1+19e0*?4:6q 24?,/+/:4=,?*r'*-,-,1(*./,0<?4.=7?1>,?*4,>*=,L91=@5,*?>71991.'::*?>/,,*<Mq 2?1@?*--/;*</-*4-*q s=4++*:,4(9*,1f/+/,64-<*7/=*</=-*+,/1=DEDq 2C</-+?*,/1=q 21-/,/;*:?*@=4=+6,*-,q c1>:9*,/1=17:?1,1+19,0*?4:6L$t+6+9*-MPN%N$ u77&,'<6c?/,*?/4q 3*4,0
q 24,/*=,(*+1>*-91-,,171991.5':q 2C</-+?*,/1=
q 24?,/+/:4=,?*r'*-,-,1(*./,0<?4.=7?1>,0*-,'<6


	
  !"#!#"#"$%
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`[]=008*+.8E+,878@.88@+/,A+78/D.86*)6,7/?+*7,+)+77.*B-6*.71>a+)8O7:+0-.*+E.B>+.?E/,/78+*+?.88@+?/7)*+8/6,6-8@+/,A+78/D.86*/,F++</,D:/8@8@+)6EE1,/8B78.,?.*?76-E+?/).0).*+3(++.076XbcdeQ3=00)6,)6E/8.,8E+?/).8/6,:/00>+*+)6*?+?6,8@+).7+*+<6*8-6*ENfg9P/,)01?/,D.00<*+7)*/<8/6,M6A+*;8@+;)61,8+*NhCfPM@+*>.071<<0+E+,87M.,?ijE+?/).8/6,7.,?-01/?73i-E+?/).8/6,)@.,D+76))1*?1*/,D8@+8*/.0<+*/6?M?6)1E+,8.8/6,6-?*1D?67.D+M-*+G1+,)BM*618+.,??.8+E.B.076>+/,)01?+?6,8@+fg93
f6,)6E/8.,8E+?/).8/6,78@.8<*606,D8@+kCKkC)/,8+*A.0.*+<*6@/>/8+?M+l)01?/,D<*+E+?/).8/6,*+G1/*+?>B<*686)603UTX[m]neopqrsH(8+*6/??67.D+:/00>+).*+-100BE6,/86*+?.,?*+)6*?+??1*/,D+.)@)61*7+6-8@+*.<B.,?78+*6/??67.D+)@.,D+7:/00>+)6,7/?+*+?>+-6*+*+7<6,7+?+8+*E/,.8/6,7.*+E.?+3t uWT]v[SWV[USTww[SXWTUtxy ST``[wYXWz[]X_\W[]{T``[][Y`S|C@/7781?B:/008+78-6*}~;-17/6,/,.00781?B71>a+)873686,0B/78@+<*+7+,)+6-}~;-17/6,.)*/8+*/6,-6*+,*600E+,8/,8@+}~;-17/6,+<+,?BE6E.)6@6*87M/8:/00.076@+0<17/?+,8/-B/-8@+<*+7+,)+6-8@/7D+,+-17/6,/7.<*+?/)8/A+>/6E.*F+*/,8*+.8/,D+<+,?BE6E.7:/8@.<*68+.76E+/,@/>/86*3
i,)6E<.*/76,8668@+*D0/6E.7M61*1,?+*78.,?/,D6-8@+E60+)10.*)@.*.)8+*/78/)76-+<+,?BE6E.7/70/E/8+?3C@+*+-6*+M:+:/008+788@+)600+)8+?f(8/771+7<+)/E+,7-6*>/6E.*F+*7ND+,+E18.8/6,7M)6<B,1E>+*.08+*.8/6,7.,?-17/6,7P17/,D8@+,+1*6;6,)606DB>*./,<*/E.*Bf(<.,+0.7.,+l<06*.86*B.,.0B7+73
g=7+G1+,)/,D6,<.*.--/,+E>+??+?6*-*6+,8/771+:/00>+<+*-6*E+?86781?B8@++l<*+77/6,6-9;
<.8@:.B3
L066?7<+)/E+,7:/00.076>+)600+)8+?.8>.7+0/,+-6*.,.0B7/76-D+,+8/)A.*/.,87/,)01?/,D7/,D0+
,1)0+68/?+<60BE6*<@/7E786@+0<?+8+*E/,+/-8@+*+.*+D+,+8/).776)/.8/6,7:/8@8@+*/7F6-?+A+06</,D
f(.?A+*7++A+,873


	
  !"#!#"#"$%
&'()*+,-./0102)-.340056*784,69:443,;044,;),5<0281*27*;0+,',):;6)=5:,6)0*'*4>?,)1,+,'07:;@AB*'5*66,66+,'0)>8,0<)1,706)2,4,C*')52=+7,)*304:?:'+,'?>7,6*'5)2*'6802),26D@EFGHIJI-I- G:66=,&')1:66)=5>.*2;1:C*4)=702):66=,9:443,;044,;),5<207*448*):,')6*'56)02,5:')1,A&LM*302*)02>0<N*)1040+>D(,,6,;):0'OPQPQHIJI-IR S4005
S400568,;:7,'69:443,;044,;),5*)3*6,4:',)0,6)*34:61*+,',):;*660;:*):0'9:)1/A(*5C,26,,C,')6*'5N1*27*;0+,'07:;()=5:,6I(*784,69:443,6,')<023*2;05:'+*'5:':):*46)02*+,)0S4005N20;,66:'+/02,D(,,6,;):0'OPQPTHUVWXYO[U\]]^YV_`WXaa`]bYc\dY_caXXYceY`VeWV]YX\_YUY]efV]]Vg
haX^dYWXaa`UgbYaie^WYfe\]]^Y]VdbXYjaXXYce\a_ba\_ekacVe\a_ai]bYc\dY_V_VXg]\]AlSS2*:'N2:7*2>/A(8*',4
B2;1:C*4):66=,6*784,6S*6,4:',A&LM*302*)02>0<N*)1040+>mFMB<=6:0'3>&L/S*6,4:',A&LM*302*)02>0<N*)1040+>Anopq8*)19*>3>mAB(,r=,';:'+
S*6,4:',A&LM*302*)02>0<N*)1040+>(:'+4,'=;4,0):5,804>70281:676S4005.J7MF@GBD8=284,)08H)=3,6S*6,4:',A&LM*302*)02>0<N*)1040+>DN20;,66,5:'@2In:++M*3HN1*27*;0+,'07:;()=5:,63>@EFGN4=6DB<<>7,)2:sHN4*67*.t7MF@GBD8=284,)08H)=3,6S*6,4:',D0'4>/0102)-H@2In:++M*3OPQ vwxykzvU{|w}z~U|wj}wvy{vU{(*784,69:443,025,2,5:'/m&(*'5)2*;,5)120=+1)1,/4:':;*4G2:*4@*)*E*'*+,7,')6>6),7I(10=45*/m&(6;2,,''0)3,*C*:4*34,.)1,/m&(509'):7,820;,5=2,69:443,<04409,5I(*784,69:44'0)3,6,')0=)6:5,A&L*882082:*),*8820C*46*'502*+2,,7,')6.:<2,r=:2,5IJIRI- (*784,6E*'*+,53>@2In:++6S4005N20;,66:'+/02,DSN/HJIRI-I-SN/;0')*;):'<027*):0'N4,*6,,o7*:4A/&S4005;02,7*:4I':1I+0C*)4,*6)R10=263,<02,)2*'6802):'+6*784,6D)1,n2:5*>3,<02,:682,<,22,5HIn026*784,8:;=8.8*+,-%Ro--tIn02:77,5:*),1,48.;*44R%ot%ot-%D7*:'34005820;,66:'+;02,'=73,2H02.:<'0*'69,2.R%ot%o
t-%D7*:';4:':;*481*27*;040+>4*3'=73,2HIn02r=,6):0'62,+*25:'+6*784,820;,66:'+.;0')*;)A/&S4005;02,7*:4I':1I+0CI


	
  !"#!#"#"$%
&'('%'(*+,-./0+1+23../415367..8+,-./88/611319/:.33;<=34/8856>23=/?:<2@A5..B/B+=43;/;CA519;+1+/61/=/;+6;813=/;5619/D7:=+;3=?+E+D+B*+,-./8@F15.5G/;BH19/:<2'I95858+8/4F=/-=3>=+,CA519+44/8813D7:=+;3=.5,51/;13;/J56/;K5>>.+B-/=8366/.CA93+=/588F/;56;5L5;F+.F8/=+443F618'M681+..+15363JD7:=+;3=58.5,51/;1343,-F1/=88-/45J5/;BH0='K5>>'I9/8/43,-F1/=8+..9+L/+-+88A3=;=/81=541/;.3>5684=//6'7..K5>>.+B-/=8366/.A519+44/8813-+15/6156J3=,+1536+66F+..H43,-./1/19/NMO36.56/<=31/415363JOF,+6*FBP/41843F=8/'D7:=+;3=4=/+1/8+F65QF/B+=43;/M0J3=/L/=H8+,-./+6;8+,-./B3RCA95494+6631B/1=+4/;B+4E13-+15/618A5193F1D7:=+;3=+44/88'I9/;+1+=/43=;/;J3=/+498+,-./564.F;/819/-+15/61M0C6+,/C1=5+.6+,/S-=31343.6F,B/=C15,/;=+A6C4H4./15,/-3561C;38/C,+1/=5+.1H-/C+8A/..+8B3R+6;J=//G/=.34+1536'<+15/61;/,3>=+-9548+88345+1/;A51919/4.5654+.4/61/=-+15/616F,B/=+=/-=3L5;/;5619/8H81/,'K3=/+498+,-./C19/=/+=/631/8+88345+1/;A51919/-=34/8856>,/193;?;/.+H568+,-./-=34/8856>C813=+>/436;5153683619/A+=;C/14'@'*+,-./B+=T43;/8+=/.56E/;13-+15/61;/,3>=+-9548+6;.5,51/;4.5654+.56J3=,+1536'I95856J3=,+1536A5..36.HB/-=3L5;/;1356L/815>+13=8.581/;361958-=31343.CL5+=/>581/=/;F8/3J19/D7:=+;3='M1584=5154+.19+119/8+,-./=/,+568.56E/;13-+15/6156J3=,+15368F49+8=+4/C+>/C;+1/83J;5+>63858+6;;/+19C+6;95813.3>54+.56J3=,+1536+B3F119/1F,3=C563=;/=1343==/.+1/>/631H-/A51919/8/L+=5+B./8'&'('%'$*+,-./*13=+>/:+=43;/;8+,-./8+=/813=/;56B+=43;/;B3R/856+.34E/;J=//G/=+1/519/=T(U3=TVUW2+443=;56>1381+B5.51H=/QF5=/,/618'I9/8/J=//G/=8+=/.34+1/;36851/5619/:<2+6;3JJ851/+1N2MK=/;/=54E2/61=+.X/-38513=H*/=L54/856K=/;/=54ECY0'Z58513=81319/.+B3=+13=H+=/=/QF5=/;13B/+443,-+65/;BH.+B3=+13=H81+JJ+1+..15,/8'744/8813813=/;4.5654+.8+,-./858=/81=541/;'*+,-./8A5..B/813=/;F615.=/QF/81/;BH+=/8/+=49/=6+,/;3619/-=31343.'7..=/QF/818+=/,36513=/;+6;1=+4E/;56D7:=+;3='7..=/8/+=49/=8+=/=/QF5=/;1385>6+J3=,81+156>19+119/8+,-./8+=/36.H13B/F8/;J3==/8/+=49-F=-38/8+88345+1/;A51919581=5+.?+8-/=19/MX:+--=3L/;-=31343.@+6;19+1+6HF6F8/;8+,-./8,F81B/=/1F=6/;1319/:<2'M15819/=/8-3685B5.51H3J19/N2M<=5645-+.M6L/815>+13=13/68F=/19+119/8+,-./8=/QF/81/;+=/B/56>F8/;56+,+66/=4368581/61A519MX:+--=3L+.'K3..3A56>43,-./15363J195881F;HC8+,-./8A5..=/,+5656813=+>/+8;/1+5./;+B3L/'744/881319/8/8+,-./8A5..36.HB/>=+61/;J3..3A56>MX:+--=3L+.3J+6+;;51536+.-=31343.C>=+6156>19/=5>91813F8/19/,+1/=5+.'
MJC+1+6H15,/C+-+15/61A519;=+A8J=3,19/81F;H+6;;3/8631A589J3=19/5=/R58156>8+,-./813B/F15.5G/;C19/56;5L5;F+.,F81-=3L5;/+A=511/6=/QF/81'K3..3A56>=/4/5-13J1958=/QF/81C19/8+,-./8A5..B/;/81=3H/;?3==/1F=6/;1319/-+15/61C5J83=/QF/81/;@C+6;=/-3=1/;+88F491319/MX:'&'('( <=34/;F=/8J3=*13=+>/3JI588F/*-/45,/685619/D+B3=+13=H3J<+193.3>HI588F/8;/85>6+1/;J3=4.5654+.;5+>6381548+=/1=+68-3=1/;1319/D+B3=+13=H3J<+193.3>H?D<@A9/=/19/H+=//R+,56/;>=388.H+6;=/./L+61-3=15368+=/J5R/;C/,B/;;/;56-+=+JJ56+6;8/41536/;+6;81+56/;J3=;5+>638154561/=-=/1+1536'[6F15.5G/;/R4/881588F/8+=/813=/;J3=F-1319=//,36198C56+443=;+64/A51923../>/3J7,/=54+6<+193.3>5818S\356123,,58853636744=/;51+15363JO/+.194+=/]=>+65G+15368?27<S\27O]@>F5;/.56/8C+6;19/6;584+=;/;'K3..3A56>43,-./15363J19/;5+>638154A3=EF-C19/8.5;/8+6;1588F/B.34E8+=/813=/;56;/J5651/.H5619/D<^84.5654+.+=495L/8'7..8-/45,/68+=/4+1+.3>F/;+6;
=/1=5/L/;F15.5G56>19/4.5654+..+B3=+13=H56J3=,+15368H81/,8C56+443=;+64/A51927<S\27O]
=/>F.+15368'I9/F8/3J+6H813=/;8-/45,/68J3==/8/+=49-F=-38/85836.H+..3A/;A9/619/+--=3-=5+1/


	
  !"#!#"#"$%
&'()**+,-)./)01223,14)53267&30,829)020:4/50)**+,-)./)01223,14)5326-5)4/2,+5;53).*+,4,9,.,3</59/4/2*)45234<)023+,..267=>*.59)424500>20)8*.20:0)8*.205?2*2+854453;:<5..121)3@26A,+A>4>+2)3).B050,A'CDEFA>05,304)4>0534/22-2344/)4*+2.5853)+B+20>.400>;;2044/)4A>+4/2+62-2.,*823450<)++)34267G7%7$ I+,4,9,.J,8*.245,3KL)8*.2=204+>945,3E..0*2958230,14)5326534/2*+,4,9,.)+2>026)062A5326534/2*+,4,9,.7E3B4>8,+4500>21.,9@0,+MMIC0*29582304/)4)+2+28)5353;)44/29,8*.245,3,A4/2*+,4,9,.<5..1204,+26)44/2D)1,+)4,+B,AI)4/,.,;B)4+,,8428*2+)4>+27N/204>6B<5..+28)53,*230,.,3;)00)8*.2,+6)4))3).B0509,3453>207L)8*.20A+,89,3023453;0>1O2940<5..1204,+26>345.4/2B)+23,.,3;2+,A0952345A59-).>2,+5A)0>1O294<54/6+)<09,30234A,+4/25+9,3453>26>02:)4</59/45824/2B<5..126204+,B267&A4/2*)45234<54/6+)<09,302344/2*)+4595*)340P6)4)<5..122Q9.>626A+,8A>4>+26504+51>45,30:1>46)4)4/)4/)-2).+2)6B12236504+51>426A,+)**+,-26+202)+9/>02<5..3,412)1.24,12+24+52-267N/2I&<5..+29,+6)3B.,00,+>3)34595*)4266204+>945,3,A0)8*.20)0)62-5)45,37'2*,+453;<5..12*2+4/2+2R>5+282340,A02945,3STU7VTW YZ[\]^Y`abc^d^efghc^da[fgZdZ]iYfYG7$7j =209+5*45,3,A4/209,*2,A;232459K;23,859)3).B050k23,859=lE)364,4).'lE<5..122Q4+)9426A+,84/2MMIC4>8,+4500>202945,308,>3426,30.5620:4,23+59/A,+-5)1.24>8,+9,34234:5A53659)426>053;4/2E..I+2*=lEK'lEMMIC@54mn5);23o7N/2'lE<5..12+2-2+024+)309+5126534,9,8*.28234)+B=lEm9=lEo>053;62;232+)42/2Q82+*+582+7E3)8*.59,31)02602R>23953;.51+)+B<5..12;232+)42602*)+)42.BA+,84/2;23,859=lE)369=lE1B8>.45*.2QIJ'>053;)36E8*.5L2R9>04,8*)32.mN/2+8,M50/2+L952345A59o,ApqrIJ'*+582+*)5+0m;23,859=lEo)36qr*+582+*)5+0m9=lEo65+294264,62429408)..3>9.2,4562-)+5)34053G%;2320:9,*B3>812+53).42+)45,3053%j;2320:)36A>05,30124<223%G;232*)5+04/)4/)-21223)00,95)426<54/9)392+*)4/,;2320507'lE02R>23953;,3*)+)AA5328126626,+A+,?234500>2<5..12*2+A,+8264,04>6B4/22Q*+2005,3,AlMFstvwxyzw{|N/50;23245904>6B<5..9,30504,A0,8)459)3).B050,34/24>8,+4500>27(.,,60*2958230<5..129,..29426A,+;2+8.532=lE)3).B0504,204)1.50/);232459)00,95)45,3<54/JlL)6-2+022-23407=lE<5..12)3).B?26A,+L53;.23>9.2,4562*,.B8,+*/5080mLlIo7G7$7% I/)+8)9,;23,859L4>6520mJ,/,+4j,3.Bo}321.,,60)8*.2*2+*)45234<5..129,..29426A+,80>1O294023+,..2653J,/,+4jA,+*/)+8)9,;23245904>65204,)3).B?24/2;23,859=lE)36)00200;23,4B*2,A4/28,04+2.2-)346+>;824)1,.5?53;23?B820)364+)30*,+42+0m=~CNo7=lE<5..12)3).B?26,3)=~CNI.>0mEAAB824+5Qo;23,4B*53;*.)4A,+84/)442040A,+j:r$q;232459-)+5)45,3053%$j6+>;650*,0545,3;2320:539.>653;JIm*/)02&824)1,.508o;2320:j$3,3FJIm*/)02&824)1,.508o;2320:p*/)02&&824)1,.5?53;;2320m539.>653;kN0o:q$4+)30*,+42+0:;232053-,.-2653A)95.54)45,3,A6+>;4+)30*,+42+0:r;232053-,.-2653;.,1).+2;>.)45,3,A6+>;824)1,.5?53;K4+)30*,+453;*+,42530:6+>;153653;*+,42530:)366+>;4)+;2407N/2=~CN6)4)<5..129,++2.)426<54/+20*,302)36K,+4,Q5954B7G7$7$ I+5-)9B)36J,3A562345).54B,A82659).53A,+8)45,3K15,.,;59).0*2958230L4>6B*+,926>+20)36)0020082340<5..126,3253*+5-)429.5359+,,807L4>6B+2.)426A,..,<>*9)..0<5..126,32A+,8)+202)+9/,AA5927L>1O2940<5..12239,>+);264,4)@24/29)..A+,8)*+5-)42.,9)45,3m0>9/
)04/25+/,82o7L.5620)364500>21.,9@0<5..1204,+26534/2D)1,+)4,+B,AI)4/,.,;BmL2202945,3VTUTUo7
(.,,60)8*.20<5..1204,+26534/2(IJmL2202945,3VTUTo7


	
  !"#!#"#"$$
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`aab_]c`d\d[be\af\]c`d?>< [\]\_`aab_]c`dY9+gN2,4+:.B3++7.558+,+:H23:.85+/2,2G+,:++.3B+3-,62/41-1.3-213.3h92;:+H1::72,4H,2-+0-+4+5+0-,23.0:6:-+CJ*$iR134+3:;,.3B41-1100;,106T023:.:-+306134-.C+5.3+::&Y9+Ai)ENhXY134L2,Ai)ENhEg:;,G+6,+:H23:+:7.558++3-+,+486:-;46:;8F+0-:+5+0-,23.01556;:.3B-9+**DE0,.8+:6:-+C7.-941-11;-2C1-.01556;H5214+44.,+0-56.3-2Q18C1-,.W&Y9+H,.30.H15.3G+:-.B1-2,T1::20.1-+.3G+:-.B1-2,:L,+:+1,093;,:+:134L2,1023-,10-41-1C131B+,7.551::.:-7.-9-9+41-1C131B+C+3-+//2,-:&)5541-128-1.3+44;,.3B-9+0234;0-2/-9+H,2-20257.558+j+H-.3:+0;,+3+-72,j4,.G+:2,.31HH,2G+415-+,31-.G+:.-+:-91-02CH567.-9UNV:+0;,.-6:-1341,4:&g,.C1,6134/.31513156k+441-17.5591G+.4+3-./.+,::2-91-,+:+1,0941-10138+1--,.8;-+4-213.34.G.4;159;C13:;8F+0-H1,-.0.H13-&)5514G+,:++G+3-:T.305;4.3B05.3.01556:.B3./.013-1832,C15/.34.3B:235182,1-2,6+G15;1-.23:T,+B1,45+::2/:+G+,.-6T7.558+/25527+4;3-.5,+-;,3-281:+5.3+2,:-18.5.k1-.232/+G+3-&i20;C+3-)l:/,2C-9+/.,:-:-;46.3-+,G+3-.23TE-;46i16m-9,2;B9no416:&)4G+,:++G+3-:200;,,.3BC2,+-913no416:1/-+,-9+51:-42:+C;:-23568+,+02,4+4J134,+H2,-+4R./-9+61,+023:.4+,+4:+,.2;:1341-5+1:-H2::.856,+51-+4-2,+:+1,09.3-+,G+3-.23:&)31832,C155182,1-2,6G15;+7.558+,+02,4+4.3-9+41-181:+1:13)lpqrs./-9+5182,1-2,61832,C15.-6.:091,10-+,.k+4861362/-9+/25527.3BKt D+:;5-:.34.:023-.3;1-.23/,2C-9+:-;46t N:1::20.1-+47.-905.3.015:.B3:2,:6CH-2C:t D+S;.,+:-,+1-C+3-2,1362-9+,-9+,1H+;-.0.3-+,G+3-.23t N:1::20.1-+47.-94+1-92,132-9+,:+,.2;:14G+,:++G+3-T.305;4.3B92:H.-15.k1-.23&t N:F;4B+486-9+N3G+:-.B1-2,-28+2/:.B3./.013-05.3.015.CH10-N/1361832,C155182,1-2,6,+:;5-.:023:.4+,+405.3.01556:.B3./.013-T-9+.3G+:-.B1-2,7.55H,2G.4+4+-1.5:
182;--9+10-.23-1j+37.-9,+:H+0--2-9+-+:-4,;B134182;--9+H1-.+3-u:2;-02C+&


	
  !"#!#"#"$%
&''()*()+,-.*-+/0,(.-,)*12/(/,3/04,-5,*670.819/:)2/-5/:,21-0)1/):-2,.'-2/.-+/*-.*0670.81.:-/2-5/'.1-0)1/15);'09/2/()20/0<=)*()+,-.*-+/0,(.-,)*1.0+,*,1-/2/0.:-/2670.81.:-/2-5/'.1-0)1/15);'09/2/()20/0:)21/2,);1.03/21//3/*-1>?&@1A.*0/3/*-1):(',*,(.',*-/2/1->@=B1A.10/:,*/0,*1/(-,)*1CDEDF.*0CDEDG<HIJLMNOPJQRSLTUJPSUNVW.-.4,''9/1-)2/0.(()20,*X-)YY?Z[W&2/X;'.-,)*1Z.*0\BYB*-2.+;2.']/()201]/-/*-,)*?(5/0;'/.1.^^',(.9'/<_LNNLSJUNOSPTO`LILMJaOaV?5);'04/9/()+/.4.2/-5.-.+.b)292/.(5,*);2^'.*-)^2)-/(-1;9b/(-()*:,0/*-,.',-8.*0-2,.'0.-.5.1)((;22/0Z-5,14,''9/2/^)2-/0/c^/0,-,);1'8^/22/d;,2/+/*-1,*1/(-,)*eDFDE
GDF ghihjkhlmnop_hnjq<6<r Y;+.*W.-.?5.2,*Xt'.*uvaOJaOaw`xxyUNvaSUJzB4,''15.2/5;+.*0.-.X/*/2.-/0,*-5,12/1/.2(5:)2:;-;2/2/1/.2(5.1:)'')41{| =)0/0Z',*}/00.-.,*.*\BY~:;*0/0)2.^^2)3/0^;9',(2/^)1,-)28<| =)0/0Z',*}/00.-.,*]B?>.;-)+.-,(:)2.(-,3,-,/1,*-5/=',*,(.'=/*-/2A| =)0/0Z',*}/0)2,0/*-,:,/00.-.4,-5.^^2)3/0);-1,0/()''.9)2.-)21;*0/2.^^2)^2,.-/.X2//+/*-1<gaOaw`xxyUNvaSUJOvSLPv| &*\BY~:;*0/0)2.^^2)3/0^;9',(2/^)1,-)28{(',*,(.'-2,.'1<X)3Z09.t<| ]B?>.;-)+.-,(:)2.(-,3,-,/1,*-5/=',*,(.'=/*-/2A| &^^2)3/0);-1,0/()''.9)2.-)21;*0/2.^^2)^2,.-/,*0,3,0;.'.X2//+/*-1<| t;9',(.-,)*.*0)2^;9',(^2/1/*-.-,)*1<gaOaw`xxyUNvaSUJV| /:)2/^;9',(.-,)*<| &--5/-,+/):^;9',(.-,)*)215)2-'8-5/2/.:-/2<q<6<6 /*)+,(W.-.?5.2,*Xt'.**',*}/0X/*)+,(0.-.4,''9/0/^)1,-/0,*^;9',(X/*)+,(0.-.9.1/11;(5.109.t,*()+^',.*(/4,-5-5/\BY/*)+,(W.-.?5.2,*Xt)',(8<GD lHjpnjHlmiHlmh5/^2,+.28/*0^),*-,1^2)X2/11,)*~:2//1;23,3.'.-q+)*-51>t[?qA<&()+9,*.-,)*):-5/*/;2)')X,(.'
/c.+,*.-,)*.*0]B4,''9/;1/0-)0/:,*/^2)X2/11,)*<W;/-),+^2)3/+/*-1,**/;2),+.X,*X.*0-5/


	
  !"#!#"#"$%
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`32'28.3(-.83812,3).1(2-)')1-2+412/'2393().-21(,3'4+.3,32))--9'Y'19'D93)*.-+/*)*31,'/12/4-&)0'.3=J99D'4391233Y'9+')1-244*-+98D3;3.&-.,38'4(9-439:'4;-441D93)-)*3D3/12212/-&)*3).3'),32)'2823Y3.,-.3)*'2V033`4D3&-.3)*3D3/12212/-&)*3).3'),32)=
Z*34',3,3)*-8-&'44344,32)'28)*34',3)3(*21^+34*-+98D3+438)-(*'.'()3.1a33'(*1832)1&138'28.3;-.)389341-2')D'439123'288+.12/&-99-0+;=I,'/12/GD'4383Y'9+')1-214;.3&3..38)-3Y'9+')1-2D:(9121('93b',12')1-2+29344)*39341-2K4LD312/&-99-038('22-)D31,'/38D+)'.3'44344'D93D:(9121('93b',=
>=$=$ HJ6MA143'43H34;-2435.1)3.1']-.)*3;+.;-434-&)*144)+8:<;')132)44*-+98D3.3G3Y'9+')38&-..34;-2433Y3.:c033`4=5-2&1.,')-.:4('244*-+98'94-D3-D)'123812dGc033`4;3.1-8-&)1,3&-99-012/121)1'98-(+,32)')1-2-&-DX3()1Y3.34;-243=
NOPQRTefghijklmRklOnokfRpqorpRHJ6M5.1)3.1'&-.H34;-243KVcL5HBH7ABAZ?/'8-9121+,32*'2(12/8143'436-23s%tuvw%tuvD+)wV%uxsV%ux
yy?ZVz]\JIH
7)'D93-.v7)'D93-.v7)'D93-.vx
yy?6309341-2
6-236-236-23B.3432)
yy
?5-.)1(-4)3.-1846-237)'D93-.v7)'D93-.v2z'
yy{59121('94)')+4
7)'D93-.x 7)'D93-.x
7)'D93-.x
v
yy?
H3^+1.3,32)&-..34;-243
J99
J99
J99
J2:?


	
  !"#!#"#"$%
&'()*+,-.+,/01+&.23142.5678*&9&:;9;<<=
<<9+1>+.22,141??@+2AB.4-B,2?+,-.+,14,23+.2.4-CD4?+./2.,4?1+-,?12-.+1,E2/F14.A,FF41-G.-/H.4,4-1/??1@4-,4E.-.+I,4,4>3+1>+.22,14,4-B./G2.4?.103.+2,2-.4-?F,4,?/FE.-.+,1+/-,14JKMNOPQORSONTUMVWPQORSONTXYMPZ[\]O^OQOS\ZWSOT_YM\RQ^VR]QOS\ZWSOT`aMS^Rb]ONVSORSOT_aM\QZcQOS2,d.E,2./2.JD09;,2@4?F./+G/2.E14AB,-.I/--.+?B/4>.2e3/-,.4-2I/fG.H.3-14-+,/FJgh'D&e0F@,Ei/--.4@/-.E,4d.+2,14+.?1d.+fj('e41-/33F,?/GF.J:-/GF.k(19+1>+.22,145:;8l(1.d,E.4?.104.AI./2@+/GF.F.2,14214m&,I/>,4>JnB.E.2,>4/-,1410:-/GF.k(19+1>+.22,14+.o@,+.2/I,4,I@I10=6A..H2E@+/-,14J'FFI./2@+/GF./4E.d/F@/GF.2,-.2I@2-G./22.22.E@2,4>-B.2/I.-.?B4,o@.2/2G/2.F,4.J9/+-,/F+.23142.59&8pqrstQONuP^VZWVW^vOSu[Zw\QZNuP^SZwR]][ORSuQRb]O]OSVZWS1d.+G/2.F,4.2@I1G2.+d.E@2,4>-B.2/I.-.?B4,o@.2/2G/2.F,4.JnB.3/-,.4-I@2-G.14/2-/GF.1+E.?+./2.EE12.10?1+-,?12-.+1,E2-1G..d/F@/GF.01++.23142.J*1I3F.-.+.23142.5*&8l*1I3F.-.+.21F@-,1410/FFF.2,142JnB.3/-,.4-?/441-G.14/4f?1+-,?12-.+1,E2A,-B-B..x?.3-,1410/E+.4/F+.3F/?.I.4-E12.2J9+1>+.22,1459;8l6yz,4?+./2.,4-B.2@I103+1E@?-210/FFI./2@+/GF.F.2,1421d.+2I/FF.2-2@I1G2.+d.E51d.+G/2.F,4.,041E.?+./2.8@2,4>-B.2/I.-.?B4,o@.2/2G/2.F,4.e)&?F./+A1+2.4,4>10/4f.d/F@/GF.E,2./2.e)&/33./+/4?.10/4f4.AF.2,14k2,-.e)&0/,F@+.-1+.-@+401+.d/F@/-,14E@.-1E./-B1+E.-.+,1+/-,4>?14E,-,145@4F.22?F./+Ff@4+.F/-.E-1-B,2?/4?.+8J{4H41A4l9+1>+.22,14B/241-G..4E1?@I.4-.E/4E14.1+I1+.I./2@+/GF.1+.d/F@/GF.2,-.2B/d.41-G..4/22.22.EJ|}~l:-.+1,EE12/>.A,FFG.?/+.0@FFfI14,-1+.E/4E+.?1+E.EE@+,4>./?B?1@+2.10-B.+/3f/4E2-.+1,EE12/>.?B/4>.2A,FFG.?142,E.+.EG.01+.+.23142.E.-.+I,4/-,142/+.I/E.J%J$J d/F@/-,1410.2-)d.+/FF&.23142.nB.G.2-1d.+/FF+.23142.,2-B.G.2-+.23142.+.?1+E.E0+1I-B.2-/+-10-+./-I.4-@4-,FE,2./2.3+1>+.22,14k+.?@++.4?.5-/H,4>/2+.0.+.4?.01+3+1>+.22,d.E,2./2.-B.2I/FF.2-I./2@+.I.4-2+.?1+E.E2,4?.-B.-+./-I.4-2-/+-.E8JnB.3/-,.4-2G.2-+.23142./22,>4I.4-A,FFE.3.4E14-B./?B,.d.I.4-10G1-BI./2@+.I.4-/4E?140,+I/-,14?+,-.+,/J%J$Jy ;@+/-,1410&.23142.;@+/-,14101d.+/FF+.23142.lnB.E@+/-,14101d.+/FF+.23142.,2I./2@+.E0+1I-B.-,I.I./2@+.I.4-?+,-.+,//+.I.-01+*&1+9&5AB,?B.d.+,20,+2-+.?1+E.E8@4-,F-B.0,+2-E/-.-B/-+.?@++.4-1+3+1>+.22,d.E,2./2.,21G.?-,d.FfE1?@I.4-.E5-/H,4>/2+.0.+.4?.01+3+1>+.22,d.E,2./2.-B.2I/FF.2-I./2@+.I.4-2+.?1+E.E2,4?.-B.-+./-I.4-2-/+-.E8JnB.E@+/-,14101d.+/FF*&,2I./2@+.E0+1I-B.-,I.I./2@+.I.4-?+,-.+,//+.0,+2-I.-01+*&@4-,F-B.0,+2-E/-.-B/-3+1>+.22,d.E,2./2.,21G.?-,d.FfE1?@I.4-.EJ


	
  !"#!#"#"$%
&'()*+,-,./*)0123+/2)/245*)0123+/2)/2+/62)/'(23.(,6*72/*)(*,.*72*(2)*62-*'-*+1*728(+*2(+).,(9(,:(2//+,-)(262*;*)<+-:)/(2.2(2-82*72/6)112/*62)/'(262-*(28,(323/+-82*72*(2)*62-*/*)(*23;+-81'3+-:*720)/21+-262)/'(262-*/=>=$=> @(,:(2//+,-AB(225'(C+C)1@(,:(2//+,-AB(225'(C+C)14@(,:(2//+,-.(22/'(C+C)1D+110232.+-23.(,6*72*+62,.(2:+/*()*+,-*,*72*+62,.8,-.+(6239(,:(2//+,-=E-8)/2/D72(2*7+/6+:7*02'-812)(;9)*+2-*/6)F8,-*+-'2,-*(+)1=>=$=% GC2()11/'(C+C)1GC2()11/'(C+C)14&2.+-23)/*72*+62.(,6(2:+/*()*+,-*,*72*+62,.32)*7HIJ LMNOPOLQPSOLTSOUV72.,11,D+-:)3C2(/22C2-*6)-):262-*:'+321+-2/)(2+-*2-323*,2-/'(2*72/).2*F,.2)879)*+2-*D7+12,-*72/*'3F=V7232/8(+9*+,-/)-3:()3+-:/8)12/.,'-3+-*72(2C+/23WXEX,66,-V2(6+-,1,:FX(+*2(+).,(Y3C2(/2ZC2-*/[XVXYZ\C2(/+,-]=^D+1102'*+1+_23.,(YZ(29,(*+-:=Y11)99(,9(+)*2*(2)*62-*)(2)//7,'137)C2)882//*,)8,9F,.*72XVXYZC2(/+,-]=^=Y8,9F,.*72XVXYZC2(/+,-]=^
8)-023,D-1,)323.(,6*72XVZ@D20/+*2[7**9/4``8*29=8)-82(=:,C`9(,*,8,1&2C21,962-*`2128*(,-+8a)991+8)*+,-/`8*8=7*6b8*8a]^\=V72/).2*F)//2//62-*/D+110292(.,(623)88,(3+-:*,*725*'3FX)12-3)(;528*+,-cIH=d eOfSTgMSLOehSTijOSTkTeLlmnULUUenlUoTLQkMeOLMSOehgpUedIq nToOeOLOMel@12)/2(2.2(*,32.+-+*+,-/9(,C+323+-@,1+8Fr^s4t29,(*+-:t2/2)(87ZC2-*/.,'-372(2=dIu MflSgMooOPTMoPMkgpOUePTUenLSUOeOehmOSvSTgMSLOeh%=w=s Zx923+*23t29,(*+-:@12)/2(2.2(*,*72(29,(*+-:(2y'+(262-*/+-@,1+8Fr^s4t29,(*+-:t2/2)(87ZC2-*/)-3@,1+8Fr^wW,-A
X,691+)-82z'6)-5'0{28*/t2/2)(87.,'-372(2=W,*24G-1FEW&5).2*Ft29,(*/*7)*622**7232.+-+*+,-,.)-'-)-*+8+9)*239(,0126D+11-223*,02(29,(*2392(*72/29,1+8+2/=%=w=w Et|t2y'+(262-*/.,(@Et29,(*+-:)*X,-*+-'+-:t2C+2D@12)/2(2.2(*,*72(29,(*+-:(2y'+(262-*/+-@,1+8Fr^s4t29,(*+-:t2/2)(87ZC2-*/.,'-372(2=dIc eOfSTijOSTnnULUUenlUoTLQkMeOLMSOehgpUe%=$=s @(+-8+9)1E-C2/*+:)*,(`t2/2)(87V2)6V7281+-+8)1(2/2)(87*2)6D+11622*,-)(2:'1)(0)/+/[,-82)D22<\D72-9)*+2-*/)(202+-:)8*+C21F*(2)*23,-*72*(+)1*,3+/8'//2)879)*+2-*=Y113)*)D+11028,1128*23+-)*+621F6)--2()-3(2C+2D230F*729(+-8+9)1+-C2/*+:)*,(=ZC2-*/622*+-:(2y'+(262-*/.,(2x923+*23(29,(*+-:)/32/8(+023+-/28*+,-dIuIqD+1102/'06+**23D+*7+-*72)99(,9(+)*2*+621+-2/=
V729(+-8+9)1+-C2/*+:)*,(D+11(2C+2D)3C2(/22C2-*)-3(2/9,-/23)*),-2)879)*+2-**,2-/'(2/).2*F)-33)*))88'()8F=V729(+-8+9)1+-C2/*+:)*,(D+1192(/,-)11F8,-3'8*,(/'92(C+/2*72+-C2/*+:)*+,-)-3
9(,C+32)99(,9(+)*23212:)*+,-,.(2/9,-/+0+1+*+2/*,,*72(62602(/,.*72(2/2)(87/*)..=


	
  !"#!#"#"$%
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`CQ?>HC>BJBNH<=>?@>>=>BCR@>>@>KCJFB&565aS^ VBMHCJ>BCQF@MJCHLJbHCJFBF?M?FLFBNHCJFBFT>cJ@CJBNQF@MJCHLJbHCJFBd ;QF@MJCHLJbHCJFBeH<IJ@@JFBCQHCJ@M?>`MLHBB><RJ8>8U>L>KCJ=>F?@KQ><EL><@E?N>?DH??HBN><M?JF?CFCQ>@CH?CFTCQ>@CE<DSUHMLHBB><QF@MJCHLJbHCJFBTF?M?>`>cJ@CJBNKFB<JCJFBUF?HM?FK><E?>?>fEJ?><ODCQ>M?FCFKFLUGJCQFECH@>?JFE@<>C>?JF?HCJFBJBQ>HLCQUJ@BFCKFB@J<>?><H@>?JFE@H<=>?@>>=>BC8d ;QF@MJCHLJbHCJFBeH<IJ@@JFBCQHCJ@@FL>LD<?J=>BODBFB`I><JKHL?>H@FB@R>8N8UQF@MJCHLJbHCJFBTF?MHCJ>BCKFB=>BJ>BK>SJ@BFCKFB@J<>?><H@>?JFE@H<=>?@>>=>BC8d AI>?N>BKD?FFI=J@JC@F?@CHD@JBFO@>?=HCJFBEBJC@CQHC<FBFC?>@ELCJBH<IJ@@JFBCFCQ>QF@MJCHLGFEL<BFCO>KFB@J<>?><H@>?JFE@H<=>?@>>=>BC8gQ>?>H@FBTF?@>>hJBNI><JKHLKH?>@QFEL<O>>=HLEHC><TF?I>>CJBNFB>FTCQ>FCQ>?@>?JFE@K?JC>?JH8^ i>?@J@C>BCF?@JNBJTJKHBCJBKHMHKJCDF?@EO@CHBCJHL<J@?EMCJFBFTCQ>HOJLJCDCFKFB<EKCBF?IHLLJT>TEBKCJFB@^ ;KFBN>BJCHLHBFIHLDeOJ?CQ<>T>KC^ VIMF?CHBCI><JKHL>=>BC@CQHCIHDBFC?>@ELCJB<>HCQUO>LJT>`CQ?>HC>BJBNUF??>fEJ?>QF@MJCHLJbHCJFBIHDO>KFB@J<>?><H@>?JFE@H<=>?@><?EN>cM>?J>BK>GQ>BUOH@><EMFBHMM?FM?JHC>I><JKHLPE<NI>BCUCQ>DIHDP>FMH?<Jb>CQ>MHCJ>BCF?@EOP>KCHB<IHD?>fEJ?>I><JKHLF?@E?NJKHLJBC>?=>BCJFBCFM?>=>BCFB>FTCQ>FECKFI>@LJ@C><JBCQJ@<>TJBJCJFB8%898$ jJT>`CQ?>HC>BJBN;BH<=>?@>>=>BCF?@E@M>KC><H<=>?@>?>HKCJFBJ@KFB@J<>?><kLJT>`CQ?>HC>BJBNkJTUJBCQ>=J>GFT>JCQ>?CQ>JB=>@CJNHCF?F?@MFB@F?UJC@FKKE??>BK>MLHK>@CQ>MHCJ>BCF?@EOP>KCHCJII><JHC>?J@hFT<>HCQ8VC<F>@BFCJBKLE<>HBH<=>?@>>=>BCF?@E@M>KC><H<=>?@>?>HKCJFBCQHCUQH<JCFKKE??><JBHIF?>@>=>?>TF?IUIJNQCQH=>KHE@><<>HCQ8R[9WlZ$9[8$[S%898m \>=>?JCDgQ>@>=>?JCDFT>HKQ;<=>?@>A=>BCGJLLO>H@@>@@><ECJLJbJBNCQ>WgW;A=>?@JFBn8o


	
  !"#!#"#"$%
&'(') +,-./0123405/16/789:;187</=--=>3?0--4.@,/4,0;;,-./0123405/13/7895;187</.33,33,87302A/4,/,;B3C;,-./,81;21/;,-./,8'D +,-./,8EF4,;,03.;,.312.G-,51330G0-0/9/4.//4,3/7895;187</<.73,8/4,.8@,;3,,@,2/'+,.312.G-,51330G0-0/9B,.23/4.//4,;,03,@08,2<,/137AA,3/.<.73.-;,-./0123405G,/?,,2/4,3/7895;187</.28/4,.8@,;3,,@,2/'D H1/+,-./,8EF4,;,0321/.;,.312.G-,51330G0-0/9/4.//4,.8B0203/;./0121J/4,3/7895;187</<.73,8/4,,@,2/'&'('K >@,2/31JL-020<.-M2/,;,3/N>LMOELH6.8@,;3,,@,2/3P.;0Q1B0G03R21?2/1<.73,LH6=>3N,'A'S4.--7<02./0123T@037.-B1;,<1BB12/4.2.780/1;9S<12J73012SB,2/.-3/./73<4.2A,3S8,-0;07BS,/<'O;.2A02A023,@,;0/9J;1BU;.8,(/1U;.8,V'WXY [\\]\\^]_`ab\[b]`c]d]_`\=>02J1;B./012<1--,</,8?0--02<-78,,@,2/8,3<;05/012S8./,1J123,/S.33,33B,2/1J3,@,;0/9.28;,-./0123405/13/7895;187</.28.-/,;2./,,/01-1A9N0J21/;,-./,8/13/7895;187</OS8./,1J;,31-7/0121J/4,,@,2/S3,;01732,33.2817/<1B,'F4,.33,33B,2/1J3,@,;0/9.28;,-./0123405/1/4,3/7895;187</?0--G,812,12-9G9/413,?0/4/4,/;.0202A.28.7/41;0/9/1B.R,.80.A21303.28-03/,812/4,e1;Bef=()gh.3/4,30/,5;02<05.-02@,3/0A./1;1;37GT02@,3/0A./1;'=>31<<7;;02A87;02A/4,<1--,</012.28;,51;/02A5,;018?0--G,81<7B,2/,8.55;15;0./,-9;,A.;8-,331J;,-./0123405'=>3?0--G,J1--1?,8/4;17A4;,31-7/012'6=>3?0--G,CD =33,33,8J1;3,@,;0/9.28;,-./0123405/13/7895;187</.28.-/,;2./,,/01-1A9N0J21/;,-./,8/13/7895;187</OG9.-0<,23,83/78954930<0.2-03/,812/4,e1;Bef=()gh.3/4,30/,5;02<05.-02@,3/0A./1;1;37GT02@,3/0A./1;'D +,<1;8,812/4,.55;15;0./,6=>;,51;/J1;BS/4,B,80<.-;,<1;8.28<.5/7;,802/4,<-020<.-8./.G.3,'D e1--1?,8/4;17A4;,31-7/012G9.-0<,23,83/78954930<0.2-03/,812/4,e1;Bef=()gh.3/4,30/,5;02<05.-02@,3/0A./1;1;37GT02@,3/0A./1;'e1;/0B,J;.B,1J;,<1;802A.8@,;3,,@,2/3S5-,.3,;,J,;/13,</012iXj'=--3,;0173.8@,;3,,@,2/3;,<1;8,8J;1B/4,/0B,1JJ0;3/02@,3/0A./012.-5;187</.8B0203/;./012B73/G,;,51;/,8/1/4,351231;'WXk l]mal`n_oab\]lnap\[qd]l\]]d]_`\=--6=>;,51;/02AB73/02<-78,/4,,-,B,2/38,3<;0G,8023,</012WXYX6=>;,51;/3?0--G,37GB0//,8/1/4,L,2/,;J1;L.2<,;+,3,.;<4NLL+O./Cr6+r6.J,/9sB.0-'204'A1@.28/1/4,LL+:M.283/789<11;802./1;'LL+6=>;,51;/J1;B.28023/;7</0123<.2G,J1728./Ctuuvwxyyzz{|}~zz{~|yz|zyvwyv~zu|v}e1--1?02A/4,.33,33B,2/1J/4,6=>G9r6+rS1/4,;37551;/02A81<7B,2/./0121J/4,,@,2/B.9G,;,7,3/,8G9/4,r6+r6.J,/9.283417-8G,5;1@08,8.33112.351330G-,'WX \[b]`cl]mal`n_oln`]ln[`a`]m[l^[]p`n[a[al[`al
=--,@,2/3-03/,8G,-1?B73/G,;,51;/,802/4,8,J02,8/0B,-02,3/1
LL+3.J,/9sB.0-'204'A1@
'


	
  !"#!#"#"$%
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`%AY3XaP`%@Q]_JN`AAKEN=3-2a;51083,(46b.(20(:(?./=&(2(<'/:(aAN`%@N]_JN`]]_&/22Y5((aAN@%%N]$%N_@K$@?$?M c5(0:3:.67:6<5(0:3:.6/..155-:0-:(-4'(53,(=32(81>d(.4/5<354:(5/,3=32(81>d(.49'-2(-:4'(45(34=(:4<(5-/;O/59-4'-:M@;3684'(5(3,4(52384;/8(O35(./:8-;(5(;-==(;-34(265(</543>2((D(:48?&'(R:D(84-034/59-22,/22/94'(,(=32(81>d(.4/5<354:(5/,3=32(81>d(.41:4-2./=<2(4-/:/,4'(<5(0:3:.6O3:;4'(C</:8/5=184:/4-,6)(20(:(G510C3,(46-==(;-34(263>/144'(/14./=(/,4'(<5(0:3:.6P(-4'(5:/5=32/53>:/5=32/14./=(Q18-:04'())*c5(0:3:.6*(</543:;Y/22/9[<Y/5=3:;))*c5(0:3:.6+14./=(Y/5=O)(20(:(c5(0:3:.6Y/22/9N1<*(</54Y/5=effghijkmO/53<<5/D(;(L1-D32(:4,/5=?R,4'(/14./=(/,4'(<5(0:3:.69383>:/5=32P(?0?O8</:43:(/18/54'(53<(14-.3>/54-/:QO4'(R:D(84-034/58'/12;5(</544'(3>:/5=32/14./=(383:7E?R,4'(3>:/5=32/14./=(=((483:6/,4'(8(5-/18.5-4(5-3O-4=184>(5(</54(;383:C7E4/)(20(:(G510C3,(46-==(;-34(26>6,3.8-=-2(O/5/4'(53<<5/<5-34(=(4'/;O9-4'-:M$'/158/,4'(R:D(84-034/5n8S:/92(;0(/,4'((D(:418-:04'(C7E*(</54Y/5=O/53<<5/D(;(L1-D32(:4,/5=?722:(/:3432;(34'84'34/..159-4'-:M@;368/,>-54'8'/12;>(5(</54(;O9-4'/145(035;4/.31832-46O38
C7E8?R:3;;-4-/:O3:6-:,3:4;(34'3,4(5M@;3684'344'(R:D(84-034/5818<(.48-85(234(;4/4'(-:14(5/
(X</815(4/=35-Z/=->8'/12;328/>(5(</54(;4/)(20(:(G510C3,(46-==(;-34(26>6,3.8-=-2(O/5/4'(5


	
  !"#!#"#"$%
&''()'(*&+,-,+.)/01*+.*23$.)4(5)6+.,728,5+*9&+)(:5;2)1<,/9,)6+.,,8,2+45*29+.,=>?@,')(+A)(-0)(&''()8,/,B4*8&<,2+6)(-CDC$CE ?8,2+5)6G<*2*H&<72+,(,5+I?G7JKL&<<4H*2&+*)25=*2H,.&<<4H*2&+*)25&(,&2>?)6*2+,(,5+0+.,+M',)6.&<<4H*2&+*)205+&(+&2/5+)'/&+,0&2/5,8,(*+M&(,+)N,(,H)(/,/*2+.,G@A&2/&(,')(+'()8*/,/+)G,<9,2,&224&<<MNM+.,5+4/M+,&-C=,,&'',2/*OPQRSC
TRU WXYZW[\]^YWX^]`]abDCcC% d&+,(2&<,O')54(,76&'&+*,2+N,H)-,5'(,92&2+/4(*29+.,H)4(5,)6+.,5+4/M0+.,5+4/M+(,&+-,2+5.)4</N,/*5H)2+*24,/*--,/*&+,<M0&2/+.,'(,92&2HM(,')(+,/+)+.,=')25)(2)<&+,(+.&23$.)4(5)61.,2+.,728,5+*9&+)(N,H)-,5&1&(,)6*+Ce.,728,5+*9&+)(5.)4</2)+*6M+.,=')25)(2)<&+,(+.&23$.)4(5)61.,2+.,)4+H)-,)6+.,f(,92&2HMN,H)-,5;2)120f(,92&2HM*+5,<6*52)+(,9&(/,/&5&2=>?CL)1,8,(0H)29,2*+&<&N2)(-&<*+*,5)(N*(+./,6,H+5&2/5')2+&2,)45-*5H&((*&9,5+.&+-,,+5,(*)45H(*+,(*&I5,H+*)2TRPRgJ5.)4</N,(,')(+,/&5=>?5Ce.,)4+H)-,)6&<<'(,92&2H*,5I5')2+&2,)45-*5H&((*&9,0,<,H+*8,+,(-*2&+*)20,H+)'*H'(,92&2HM02)(-&<N*(+.0)(H)29,2*+&<&N2)(-&<*+MJ5.)4</N,6)<<)1,/4'&2//)H4-,2+,/CDCcC3 f&+,(2&<,O')54(,d&<,'&+*,2+55.)4</(,6(&*26()-6&+.,(*29&H.*</)(/)2&+*295',(-/4(*29+.,5+4/M&2/6)(3D/&M5&6+,(+.,<&5+/)5,)6-&(*h)-*NCf(,92&2HM)6+.,'&+*,2+:5'&(+2,(*52)+H)25*/,(,/+)N,&2>?CL)1,8,(0+.,)4+H)-,)6&<<'(,92&2H*,5I5')2+&2,)45-*5H&((*&9,0,<,H+*8,+,(-*2&+*)20,H+)'*H'(,92&2HM02)(-&<N*(+.0)(H)29,2*+&<&N2)(-&<*+MJ)HH4((*296()-+.,/&+,)6+.,6*(5+/)5,42+*<3D/&M5&6+,(+.,<&5+/)5,5.)4</0*6')55*N<,0N,6)<<)1,/4'&2//)H4-,2+,/CTRQ WX^ij`[ZWbWXYZW[\]^kZWl[im\XlaZ]mia[Xmi]mXWaaWnlYZ]lZWXm\]mA)<<)1*292)+*6*H&+*)26()-+.,*28,5+*9&+)(0GG@0+.,7op5')25)(01*<<(,')(+&2M545',H+,/&/8,(5,(,&H+*)2+.&+*5N)+.5,(*)45&2/42,O',H+,/CGG@1*<<(,')(+&2>?&5&545',H+,/&/8,(5,(,&H+*)2)2<M*6+.,(,*5,8*/,2H,+)5499,5+&H&45&<(,<&+*)25.*'N,+1,,2+.,5+4/M'()/4H+&2/+.,&/8,(5,,8,2+CGG@1*<<2)+*6MAp>&2/&<<'&(+*H*'&+*29*28,5+*9&+)(5I*C,C0&<<*28,5+*9&+)(5+)1.)-+.,5')25)(*5'()8*/*29/(4942/,(*+57op5)(42/,(&2M*28,5+*9&+)(:57opJ*2&27op5&6,+M(,')(+)6')+,2+*&<5,(*)45(*5;56()-H<*2*H&<+(*&<5)(&2M)+.,(5)4(H,0&55))2&5')55*N<,0*2&HH)(/&2H,+)3%GA@f&(+E%3CE3C
><<5,(*)45,8,2+51*<<N,(,')(+,/+)+.,Ap>&+<,&5+&224&<<M*2&54--&(M6)(-&+Cq aj\]\a`jrZ]\[ZW\]^>5&5')25)(6)(H<*2*H&<+(*&<50Ap>(,94<&+*)25(,B4*(,+.,GG@+)-&*2+&*2&-)2*+)(*29'()9(&-Ce.,GG@:5'()9(&-&<<)156)(H)26*(-&+*)2)6K5+4/M/&+&05',H*6*H&<<M/&+&+.&+H)4</&66,H++.,*2+,('(,+&+*)2)6'(*-&(M&2/5,H)2/&(M5+4/M,2/')*2+5s&/.,(,2H,+)+.,'()+)H)<0(,94<&+*)2507GL?t0&2/=uf5s&2/.4-&254Nv,H+5'()+,H+*)2Ce.*5*5/)2,+.()49.*2/,',2/,2+8,(*6*H&+*)2)65+4/M/&+&
1*+.5)4(H,/)H4-,2+&+*)26)H45*29)2K


	
  !"#!#"#"$%
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`aD*<16+):)/)+)_`aD*<16+).3.)/9-+-::1-.:1<,./892B.3,6-:,9.)/3+6)2+*Ibcd@e:1./+)2B.3,.056)60:5/:2:3,+>6/./6)c.026+)JYfYg:8+>.hE.3+12<5:2.2B:22B.056)60:5:026>629+*-:,6^+-68E6558.7,.:2.126)_`aD*<16+)1<3,:2.)2+,6:5.3.)/9-+-:hEB60BB:1:0+)1262<26+):5:026>:26+)+*ibDjk3:2BE:9@(*E.1..)+Ibc8.).*62E62B-:,6^+-686)_`aD*<16+)1<3,:2.)2+,6:5.3.)/9-+-:3:26.)21h2B.)E./+)+2.C3.022B:2-:,6^+-68E6558.).*622B.)+)_`aD*<16+).3.)/9-+-:3:26.)21@A+.C35+621<0B.**60:09+,/.,+*2B.2E+1<87,+<31l?4m=D*<16+):)/)+)_`aD*<16+)nhE..-35+9:)+>.52E+D12:7.1.H<.)26:5.),60B-.)2/.167)16-65:,2+o:)7:)/p<:)l%qrdns%tu@()2B.*6,1212:7.hE.E655.),+55rv3:26.)21E62B_`aD*<16+).3.)/9-+-:12+2.12*+,056)60:5:026>629+*-:,6^+-68@(*$+,-+,.3:26.)216)F+B+,2r:,.3,+7,.116+)*,..:2d-+)2B1hE.3,+0../2+12:7.%w+2B.,E61.E.2.,-6):2.2B.2,6:5:)/0+)05</.2B:2-:,6^+-6861)+2.**.026>.@=//626+):559h/<,6)712:7.rhE.E655:55+E3:26.)21B:,8+,6)7?4m=D*<16+).3.)/9-+-:E62B-+,..C2.)16>..C3+1<,.2+0B.-+2B.,:39lx%0B.-+2B.,:39,.76-.)1n2+.),+55@y6>.)2B.3,.056)60:5/:2:h2B61E655.):85.2B613:26.)23+3<5:26+)2+B:>.:00.112+:2,.:2-.)2,.76-.)EB.)-+12+*2B.0+--+)59<1./2B.,:36.1B:>.:5,.:/98..)<2656^./@AB.,.13+)1.1+*2B617,+<3lF+B+,2%n:,.:1.0+)/:,9+8].026>.:)/E655)+28.<1./2+-:z.2B./.2.,-6):26+)+*.**60:09:)/E655)+28.<1./*+,/.06/6)72+3,+0../2+12:7.%@{+E.>.,h2B.,.13+)1.,.1<521E6558.0+-365./:13,.56-6):,9/:2:,.7:,/6)7.**60:09+*-:,6^+-68:1:1:5>:7.,.76-.)*+,3:26.)21E62BB.:>6593,.2,.:2./?4m=D*<16+).3.)/9-+-:@=212:7.%hE.E655.),+55rd3:26.)21E62B)+)_`aD*<16+).3.)/9-+-:1lF+B+,2|n@}<2+*2B.1.rd3:26.)21h6*~+,-+,.3:26.)21:,.3,+7,.116+)*,..:2d-+)2B1hE.05:6-2B:2-:,6^+-68613,+-616)7*+,2,.:26)78+2B_`aD*<16+):)/)+)_`aD*<16+).3.)/9-+-:w+2B.,E61.hE.05:6-2B:2-:,6^+-68613,+-616)7*+,2,.:26)7_`aD*<16+)h8<2)+2*+,)+)_`aD*<16+).3.)/9-+-:@e:1./+)B612+,60:5/:2::)/056)60:5.C3.,6.)0.hE.,.7:,/|q+*Ibcd:1<)3,+-616)7h:)/dq +*Ibcd:13,+-616)7@AB.*+55+E6)72:85.1B+E12B.+3.,:26)70B:,:02.,612601+*2B.:8+>./.167)8:1./+)rqhqqq16-<5:26+)1@OYTA,<.Ibcd+*
_`aD*<16+)
.3.)/9-+-:1
A,<.Ibcd+*
I,+8:865629
+*.:,59
12+336)7
I,+8:865629+*
05:6-6)7
I,+8:865629+*
05:6-6)7
=>.,:7.
1:-35.
16^.


	
  !"#!#"#"$%
&'()*+
,-./012321456067.2,,289/:2,0;()*+,-./012,,289/:2,0;7<<379/219.=>%=>%=>?%$=>@AB=>=CAC%>@=>A=>A=>C=@=>DED=>?EA@%>$=>A=>%=>C=@=>DED=>CA?@%>$=>A=>B=>C=@=>DED=>A%@@%>$FG2.9-450,.7<:7H280G0;9.@714$/.7.280147;50IJ289/:2>K.379/219./1.7<:7H280G0;9.@714$7;2G/HG<5G292;0H2120-.L9G22,,/87850,67;/M06/I/1()*+
,-./0180G0;9@675109I21097I<5G/HG2;9G719G79/1101()*+,-./0180G0;9$>FG20IJ289/:20,80G0;9.@714$/.902.9/67929G22,,/87850,67;/M06/I/1;28-;;2192321456067379/219.N/9G6-<9/3<23;/0;8G2609G2;73/2.7.627.-;24I5OPQALOPQC@L624/71OPQ714RQ>K.7;2.-<9L9G2@+.97H242./H1N/<<109I2-.24,0;80G0;9.@714$>S1.9274LN221;0<<379/219./1909G2.280G0;9../6-<97120-.<5>C=>C>CO;/67;5U1430/19VW O;0H;2../01+,;22.-;:/:7<79A6019G.0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.9;27924N/9G67;/M06/IZ[0G0;9.C+$\N/<<I27..2..247.3;030;9/010,379/219.9G797;23;0H;2../01+,;2279A6019G.9/6230/197,92;/1/9/79/010,9;2796219>C=>C>@Q280147;5U1430/19Z.\VW O;0H;2../01+,;22.-;:/:7<79C@6019G.0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.9;27924N/9G67;/M06/IZ[0G0;9.C+$\N/<<I27..2..247.3;030;9/010,379/219.9G797;23;0H;2../01+,;2279C@6019G.9/6230/197,92;/1/9/79/010,9;2796219W ]24/713;0H;2../01+,;22.-;:/:7<ZOPQ\0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.9;27924N/9G67;/M06/IZ[0G0;9.C+$\N/<<I27..2..247.624/71760-190,9/62.-IJ289.-;:/:2.N/9G0-94/.27.23;0H;2../017,92;/1/9/79/010,9;2796219W R:2;7<<.-;:/:7<ZRQ\0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.9;27924N/9G67;/M06/IZ[0G0;9.C+$\N/<<I27..2..247.624/71760-190,9/62.-IJ289.-;:/:2.7,92;/1/9/79/010,9G2;735W O;0H;2../01+,;22.-;:/:7<79A6019G.0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.N/9GN/9G60;29G71@3;/0;8G2609G2;73/2.9;27924N/9G67;/M06/IZ[0G0;9.@714$\N/<<I27..2..247.3;030;9/010,379/219.9G797;23;0H;2../01+,;2279A6019G.9/6230/197,92;/1/9/79/010,9;2796219>W O;0H;2../01+,;22.-;:/:7<79C@6019G.0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.N/9GN/9G60;29G71@3;/0;8G2609G2;73/2.9;27924N/9G67;/M06/IZ[0G0;9.@714$\N/<<I27..2..247.3;030;9/010,379/219.9G797;23;0H;2../01+,;2279C@6019G.9/6230/197,92;/1/9/79/010,9;2796219W ]24/713;0H;2../01+,;22.-;:/:7<ZOPQ\0,XUYK+,-./01714101XUYK+,-./01;28-;;2192321456067379/219.N/9GN/9G60;29G71@3;/0;8G2609G2;73/2.9;27924N/9G67;/M06/IZ[0G0;9.@714$\N/<<I27..2..247.624/71760-190,9/62.-IJ289.-;:/:2.7,92;/1/9/79/010,9G2;735


	
  !"#!#"#"$$
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`[bc`d`e`f]bg\ebhgN3@))=3EG)<=/()-34=B/--=.;?A):));OP>+=/):=-MF3:-/;)*/:H-<*)):4+/,.*)-i=B)=3=+,:.@E)*34>+=/):=-/--)=+=jP>+=/):=-MNB)-+@>,)-/D)/-<+,/E*+=);+:;;)=)*@/:);E+-);3:-/@.,+=/3:=33E=+/:;)-/*+E,)3>)*+=/:H<B+*+<=)*/-=/<-i+--B3A:/:eklmnoprstuvwxyzu{|}u~}utuwxu~uuupup{rpstE3=B567894.-/3:+:;I3:567894.-/3:)>):;?@3@+-iA)B+()PMj<B+:<)=3<3:<,.;)=B+==B)=*)+=@):=/-)44)<=/()43*E3=B=?>)-34)>):;?@3@+-i+:;AB):=B)=*)+=@):=/-:3=)44)<=/()0/M)Mirpsts}94.-/3:+:;I3:567894.-/3:)>):;?@3@+-i=B)>*3E+E/,/=?34/:<3**)<=,?<,+/@/:H=B+==B)=*)+=@):=)44)<=/()/-PMPM/():=B)-+@>,)-/D)340<3B3*=2i=B)O<3:4/;):<)/:=)*(+,34V1/-:3=A/;)*=B+:PMC3:)+<B-/;)M/():=B)-+@>,)-/D)3401=+H)C<3B3*=2i=B)O<3:4/;):<)/:=)*(+,34V1+:;V1C/-:3=A/;)*=B+:PMC$3:)+<B-/;)MNB)=A3-+,(+H)<3B3*=-C+:;$+*)-)<3:;+*?+:;A/,,:3=<3:=*/E.=)=3=B)-=+=/-=/<+,>3A)*34=B)-=.;?MNB)+:=/</>+=);+<<*.+,*+=)/->+=/):=>)*@3:=B43*94.-/3:)>):;?@3@+<3B3*=-+:;9C>+=/):=->)*@3:=B43*=B):3:94.-/3:)>):;?@3@+<3B3*=-MWXKL ^h^_\ebhg[hf\g\_[b[6(+,.+E,)43*3EG)<=/()*)->3:-)':,?=B3-)>+=/):=-AB3B+()@)+-.*+E,);/-)+-)>*)-):=+=E+-),/:)iB+()*)<)/();+=,)+-=3:)<?<,)34=B)*+>?i+:;B+()B+;=B)/*;/-)+-)*)9)(+,.+=);A/,,E)<3:-/;)*);)(+,.+E,)43**)->3:-)MNB)-)>+=/):=-A/,,B+()=B)/**)->3:-)<,+--/4/);+<<3*;/:H=3=B)1)<=/3:JKLKLM0I3=)V+=/):=-AB3) B/E/=3EG)<=/();/-)+-)>*3H*)--/3:>*/3*=3=B)):;34<?<,)A/,,+,-3E)<3:-/;)*);)(+,.+E,)M26(+,.+E,)43*=3 /</=?8,,>+=/):=-A/,,E))(+,.+E,)43*=3 /</=?4*3@=B)=/@)34=B)/*4/*-==*)+=@):=A/=BQ+*/D3@/EMWXK¡ [e\eb[eb¢\_\g\_[`[PM$M8:+,?-/-34=B)V*/@+*?6:;>3/:=£+>,+:9Q)/)*<.*()A/,,E).-);=3)-=/@+=)=B)V143*94.-/3:+:;:3:94.-/3:*)<.**):=)>):;?@3@+M¤)A/,,<+,<.,+=)@)+:i-=+:;+*;;)(/+=/3:+:;O<3:4/;):<)/:=)*(+,34V1M73H*+:¥=)-=+:;>*3>3*=/3:+,B+D+*;@3;),A/,,E).-);=3<3@>+*)=B)V1E)=A)):94.-/3:+:;:3:9
4.-/3:*)<.**):=)>):;?@3@+M


	
  !"#!#"#"$%
&'($()+,-./010234567682,9-:/;,9<21,4=0>?-<.-,@A616:8B:C6D1..E6B069426041F-46456GH7-,9I732:JKL@3B012,-,9,2,JKL@3B012,:68B::6,46<6,9/F2F-D145)2:.600<:12:856F2456:-<160M-,9JKL@3B012,-,9,2,JKL@3B012,:68B::6,46<6,9/F2F-D145F2:645-,)<:12:856F2456:-<160(N2O:-,P4604-,9<:2<2:412,-.5-Q-:9F296.D1..E6B0694282F<-:6456GH7E64D66,JKL@3B012,-,9,2,JKL@3B012,:68B::6,46<6,9/F2F-(7-3464/D1..E6-0060069E/:6<2:41,O456O:-9602342R1814/-,94564/<62342R1814/2E06:C6932:-..<-416,40-,90BFF-:1Q1,O9-4-B01,O4569608:1<41C604-4104180M1,8.B91,OF6-,M04-,9-:996C1-412,-,982,3196,861,46:C-.0(S6861C69AT+7U@VW2:7G32:F0D1..E68568P69C6:0B045641F1,O08569B.6-,982,0196:69-0C-.1913456/3-..D1451,46,9-/02345608569B.69-00600F6,4(X2F<.1-,86:-460D1..E68-.8B.-469-0456,BFE6:23:6861C69C-.1932:F02C6:456,BFE6:236R<6846932:F0(T1336:6,860E64D66,O:2B<01,82F<.1-,86D1..E6460469E/B0623H1056:Y06R-844604-46C6:/41F6<21,4(Z6D1..B069608:1<41C604-4104180429608:1E652D<-416,40:-460/F<42F06C6:14/-,91,46:36:6,86D1453B,8412,-46-8541F6<21,4(;::2:E-:O:-<5032:6-85234560/F<42F0D1..E682,04:B8469-46-8541F6<21,4(W56<:2<2:412,23<-416,40:-41,O4561:0/F<42F042E6[2:O:6-46:=2,-'@&'08-.6>D1..-.02E6:6<2:469(Z6D1..82,04:B841,91C19B-.<-416,4<:231.6032:6-852345606.684690/F<42F0429608:1E64561,91C19B-.<-416,40Y<-446:,02385-,O62C6:41F6(Z6D1..8-.8B.-46456F6-,82:60/F<42F06C6:14/MF6-,06C6:14/23456AT+7U@VW2:7G-,9F6-,0/F<42F1,46:36:6,86-445641F6238.1,18-.6C-.B-412,(;041F-4602391336:6,8601,456F6-,0/F<42F06C6:14/-,9F6-,0/F<42F1,46:36:6,86E64D66,:60<2,96:0-,9,2,@:60<2,96:0D1..E66041F-4691,4561,46,4424:6-4<2<B.-412,(+..<-416,40D145-4.6-042,6C-.19\B60412,,-1:6D1..E61,8.B9691,456-,-./060(U,-991412,424569608:1<41C604-4104180M.1,6-:F1R69F296.D1..E6B069423B:456:04B9/4564:-]6842:/23.2,O14B91,-../6C-.B-469<-416,4:6<2:4692B482F6F6-0B:60MD56:6:-,92F1,46:86<40D1..E6B069428-<4B:6456D1451,@0BE]68482::6.-412,(T1336:6,86023-4.6-04)<21,40D1..E68.-0013169-0456F1,1FBF8.1,18-../F6-,1,O3B.85-,O61,4560/F<42F06C6:14/-,90/F<42F1,46:36:6,86F6-0B:60(H2:6R-F<.6M-,1,8:6-0623)<21,402:F2:6D2B.9F6-,-F296:-461F<:2C6F6,4MD56:6-0-968:6-0623)<21,402:F2:6D2B.9E61,46:<:6469-0F296:-46D2:06,1,O(H2:1,91C19B-.0/F<42F0M-:1061,-0/F<42F082:6F6-,09646:12:-412,MD56:6-0-:69B869082:6F6-,01F<:2C6F6,4234560<6813180/F<42F(&'($(^7-364/+,-./0607-3464/D1..E6-0060069E/:6<2:41,O456O:-9602342R1814/-,94564/<62342R1814/2E06:C6932:-..<-416,40-,90BFF-:1Q1,O9-4-B01,O4569608:1<41C604-4104180M1,8.B91,OF6-,M04-,9-:996C1-412,-,982,3196,861,46:C-.0(
&'($($G.-,,69U,46:1F+,-./060WD2@04-O606\B6,41-.6,:185F6,49601O,D1..E6B06932:45104:1-.(U,45631:0404-O6MD6D1..6,:2.._<-416,40D145JKL@3B012,6<6,9/F2F-0=X252:4&>42460432:8.1,18-.-841C14/23F-:1Q2F1E(U3$2:F2:6<-416,40-:6<:2O:60012,3:66-4`F2,450MD6<:286694204-O6)a2456:D106D646:F1,-464564:1-.-,982,8.B9645-4F-:1Q2F1E10,246336841C6(+404-O6)MD6D1..6,:2..^)<-416,40D145,2,JKL@3B012,6<6,9/F2F-0=X252:4^-,9$>(H:2FX252:4^M13_2:F2:623&`<-416,40-:6<:2O:60012,3:66-4`F2,450MD68.-1F45-4F-:1Q2F1E10<:2F101,O32:4:6-41,OE245JKL@3B012,-,9,2,JKL@3B012,6<6,9/F2F-a2456:D106MD68.-1F45-4F-:1Q2F1E10<:2F101,O32:4:6-41,OJKL@3B012,MEB4,2432:,2,JKL@3B012,6<6,9/F2F-(+0-E2C6MGH7@`32:X252:4$D1..-.02E6F6-0B:691,<-416,40D145,2,@
S;N+3B012,6<6,9/F2F-45-45-0E66,6R46,01C6./4:6-469(W56069-4-D1..E682F<1.69-0<:6.1F1,-:/
9-4-:6O-:91,O63318-8/23F-:1Q2F1E-0-0-.C-O6:6O1F6,32:<-416,40D14556-C1./<:64:6-469,2,@
S;N+@3B012,6<6,9/F2F-(


	
  !"#!#"#"$%
&'($()+,-./012/03451.3676872709:512:/5/;<+=4>757;?6:/56212?615@7,-0766:/5/;ABCDE-12FG132/H/007.127G:2FH.:5:H1.H/?067/;7-75@39/91-12:7526207127@G:2FI10:J/9:K?6:5>L-710915H/007.12:/515@07>0766:/5151.36:6M2F7.7N7.6G:..K7H/9-107@K72G775076-/5@70615@5/5C076-/5@706?6:5>157,1H2O:.H/,/5015P6?92762
Q9-1H2/;K167.:576/912:H>75/9:H-0/;:.7/;7-75@39/91/5H.:5:H1.076-/5672/I10:J/9:K(RF75?9K70/;6/912:H9?212:/56SH/-35?9K701.27012:/5615@;?6:/56/K21:57@;/071HF-12:752G:..K7H/9-107@K72G775076-/5@70615@5/5C076-/5@706(RF:6G:..K7@/57?6:5>7:2F701B:6F70T67,1H22762SU/HF015C409:21>72075@2762S/07,1H2O:.H/,/5015P6?92762@7-75@:5>/52F7@:620:K?2:/56/;N1.?76(<7>0766:/5151.36:6G:..K7;?02F70?67@2/:5N762:>1272F707.12:/56F:-K72G7752F767H/N10:127615@H.:5:H1.076-/567(872709:512:/5/;6:5>.75?H.7/2:@7-/.39/0-F:696;0/9>709.:578A42/H/007.127G:2FUAL1@N70677N7526G:..K77621K.:6F7@?6:5>157,1H2O:.H/,/5015P6?9276(VV XYZZ[\Y][^_`a[c]aadae^fVVgV X][h[4U<484ij'kl')mG:2FU7.>757:6:5-.1H7(Vn opd[efp\qaX^fr]Y^aX^_YefVngV ][^_Ye[ZasY]fp\qaX^faZaX^_YeRF:662?@3G16@76:>57@2/:5H.?@7G/97515@9:5/0:2:76SK?2G165/2@76:>57@2/9716?07@:;;7075H76/;:5270N752:/57;;7H26(I1.7615@;791.76G:..K707H0?:27@G:2F5/-07;7075H72/>75@70(A/7,H.?6:/52/2F:662?@3G:..K7K167@/501H7(I:5/0:2:76G:..1H2:N7.3K707H0?:27@2/-102:H:-127(Vngn r[]^_X_r[^_YeYsXo_Zh]aet`_[\ZaeaYe[^afQ52F:662?@3SG71077,H.?@:5>2F7-7@:120:H-/-?.12:/5i1>7u&v37106m165/@/6:5>/01@N70677N752@121107H?00752.31N1:.1K.7/52F7?67/;910:J/9:K:52F:6>0/?-(w:1K.757/51276xHF:.@075913F/G7N70K7750/..7@:5U/F/02y2/62?@32F77;;7H26/;:5?270/7,-/6?072/2F762?@3@0?>(8121G:..K7H/..7H27@;/0?-2/&37101;270K:02F(RF767HF:.@075913-102:H:-127:52F7076710HF?5@702F7-0/N:6:/56/;$)U<BL?K-1028$%($'$162F7076710HFSH/56:62:5>/;@121H/..7H2:/5/5F71.2F/?2H/976S:65/9/072F159:5:91.0:6P(RF707:65/@:07H2K757;:22/2F7HF:.@-102:H:-1526(Vngz r[]^_X_r[^_YeYseaYe[^afYspeXa]^[_e`_[\_Z_^{[eheYe`_[\ZaeaYe[^afRF716676697526;/02F:6-/-?.12:/5/52F762?@3107.:9:27@2/@121H/..7H2:/5S2F707;/075/62?@:76F1N7K775H/5@?H27@;/0166766:5>-/2752:1.0:6P162F73G/?.@5/2K76H:752:;:H1..31--0/-0:127:52F:66722:5>(A/:5270N752:/56107-70;/097@/52F757/512715@0:6P6107.:9:27@2/@121K071HF76(y706/56-0/N:@:5>H/56752G:..K7:5;/097@/;2F7670:6P6(Q5@:N:@?1.675>1>7@:52F7076710HFG:..F1N75/-102:5@72709:5:5>2F7N:1K:.:23/;2F757/5127(&l(k(&A7/51276/;|5H7021:5w:1K:.:23RF7-?0-/67/;2F7076710HFS2/H/..7H2@121/52F727012/>75:H7;;7H26/;62?@3@0?>7,-/6?07S:6:9-/02152K:/97@:H1.P5/G.7@>7GF:HFH155/2K7/K21:57@K3/2F709715615@2F707G:..K75/1@@7@0:6P2/2F7
57/5127076?.2:5>;0/92F7076710HF16@121K071HF7610710:6P:52F7H.:5:H1.6722:5>16G7..(Q51@@:2:/5S


	
  !"#!#"#"$%
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`H`a[]bcH\H^d`ebHf-*S(2(+3'.*(2-**9&586*6,-'.*(-'554(S4(g'0'-+)Jh$',+0*)+86Q68*+0*1'))4/5Q6*5*+*-4'8)*,,*&+)',+0*)+86Q6-8SIi'3*O*-712-+4&412(+)4(&'0'-+Jh$30'/*&'.*1-*S(2(+.2Q/*-*+24(*6'(+0*)+86QIU(2664+4'(7+0*1-*S(2(+12-+(*-)',.25*12-+4&412(+)30')*1-*S(2(&Q'&&8--*63045*68-4(S+0*.25*j)12-+4&412+4'(4(+0*)+86Q.2Q/**(-'55*64(g'0'-+fIf-*S(2(+3'.*(30'3*-*4(4+4255Q*(-'55*64(g'0'-+Jh$3455/*-*.'O*6,-'.)+86Q+0*-21Q+'.4(4.4k*+0*-4)Tlm*&+4'(nXoXVp7/8++0*Q3455-*.24('(,'55'381,'-)2,*+Q34+01-'&*68-*)54.4+*6+'+0')*+02+2-*S*(*-255Q1*-.4++*6,'-1-*S(2(+3'.*(4(+0*&54(4&25)*++4(SIq2+2&'55*&+4'('(+0*1-*S(2(&Q-*1-*)*(+)('.'-*+02(.4(4.25-4)T7/8+4+6'*)('+0'56+0*1-')1*&+',64-*&+/*(*,4++'+0*1-*S(2(+3'.2('-+'+0*,*+8)Ii'3*O*-7+0*18-1')*',+0*62+2&'55*&+4'(4)+0*6*O*5'1.*(+',4.1'-+2(+/4'.*64&25T('35*6S*+02+&2(('+/*'/+24(*6/Q2(Q'+0*-.*2()IN'4(68&*.*(+)7.'(*+2-Q'-'+0*-34)*73455/*',,*-*6+'+*-.4(2+*21-*S(2(&QIN'4(64O46825)*(S2S*64(+0*-*)*2-&0345502O*2(Q12-+4(6*&4)4'()2)+'+0*+4.4(S7.*+0'6'-1-'&*68-*)8)*6+'+*-.4(2+*21-*S(2(&Q2(64(64O46825)*(S2S*64(+0*-*)*2-&0345502O*('12-+4(6*+*-.4(4(S+0*O42/454+Q',2(*'(2+*IVWXr [\]^_:_[\^_`H`astuvb:^stH\uwb^`c_xb:`HsbH^y685+)8(2/5*+'1-'O46*&'()*(+2-**9&586*6,-'.*(-'554(S4(+0*1-'+'&'5Ii'3*O*-74+4)1'))4/5*+02+)8/z*&+)*(-'55*64(+0*1-'+'&'5.2Q1*-.2(*(+5Q5')*+0*&212&4+Q+'&'()*(+,'-+0*.)*5O*)68-4(S+0*&'8-)*',+04))+86QI{'-)8/z*&+)+02+5')*+0*2/454+Q+'&'()*(+68*+'+8.'-1-'S-*))4'(7+0*Q3455/*+2T*(',,+-*2+.*(+/8+345502O*+0*'11'-+8(4+Q+'-*.24('()+86Q4(5'(S+*-.,'55'3h81,'-&'55*&+4'(','8+&'.*),'-'O*-255)8-O4O25IU,+0*-*2)'(,'-4(&212&4+Q4)68*+'2-*2)'('+0*-+02(6*,4(4+4O*64)*2)*1-'S-*))4'(2(6+0*Q2-*,*5++'/*-*)1'(64(S+'+0*+-*2+.*(+8(6*-)+86Q4(+0*'14(4'(',+0*4(O*)+4S2+'-7+0*Q345502O*+0*'11'-+8(4+Q+'&'(+4(8*+04)+0*-21QI|}}}}}}2))4S(2)8/)+4+8+*6*&4)4'(.2T*-'(+0*NUiy6O2(&*q4-*&+4O*,'-i*25+0g2-*2(6*64&25*)*2-&0f2-+4&412+4'(,'-.)'+02+2('+0*-1*-)'(&2(.2T*6*&4)4'()2/'8++0*4-.*64&25&2-*4(+0**O*(++02++0*Q/*&'.*4(&212&4+2+*6'-&'S(4+4O*5Q4.124-*668-4(S+0*&'8-)*',+0*)+86QIf5*2)*)**)*&+4'(VWXoXV,'-&'()*(+1-'&*68-*IVWX [`^bH^_\w]_ss
_s:`ea`]^sJKIIJm+86Qq-8S4)T)2-4k'.4/.2Q&28)*,2+4S8*764kk4(*))70*262&0*74()'.(4272('-*9422(6S2)+-'4(+*)+4(2526O*-)*
*,,*&+)If2+4*(+).2QS*+&'S(4+4O*&02(S*)702558&4(2+4'()2(65'))',/252(&*304&02-*S*(*-255Q
-*O*-)4/5*34+06')*-*68&+4'(K 7K¡¢IQ*5')811-*))4'(4)8(&'..'(K 7K¡¢I


	
  !"#!#"#"$%
&'()('+,-./0.12-03,-4/0256789:8;/3<3=>-0-558;./2;8-29/=09=9:82=09;-39(?-;9/2/@-093,/.:98A@8;/8028:/B83C/92:/0.C:8-7-2:8C7/>>/26594D;8-9:/0.C/02;8-387:8-;9;-98-073E855/0.(?-;9/2/@-0936078;.=/0..-7=5/0/6,80:-0287FG+3,-4-53=D8-9;/3<>=;</70847-,-.8(&'()(HG838-;2:I5==7J=55829/=0G/3<3G/3<3=>D5==77;-E3/025678@-/0-07D;6/3/0./09:8-;8-E:8;89:8088758/3@5-287C5/.:9:8-7870833C-07;-;854C>-/09/0.(K:805-;.8-,=6093=>D5==7-;82=5582987C5=E;87D5==728552=609L-08,/-M2-078B85=@(
&'()($NOP
Q9:8;9:-09:8,/0=;3</0/;;/9-9/=0>;=,9:885829;=7839:8;8-;80=8A@82987;/3<3;85-9879=9:8NOP(&'()(RQ9:8;G/3<3G/3<3/0256789:8@=33/D58=226;;8028=>-04=>-;-0.8=>3/788>>8293E:/2:-;85/3987/09:8J=03809S=26,809=;9:/3@;=9=2=57=26,809(T;8U6809,=0/9=;/0.>=;-7B8;388>>8293E/55:85@9=,/0/,/V89:8;/3<3-33=2/-987E/9:-7,/0/39;-9/=0=>9:839674-.8093(&'()()W6839/=00-/;83;/3<3W6839/=00-/;83,-42=09-/0U6839/=039:-9-;83803/9/B8/00-96;8(&'()(XY=0Z?:43/2-5G/3<3=>P8089/2G838-;2:&'()(X(&G/3<=>;828/B/0.60E-0987/0>=;,-9/=0[0A/894-0739;833,-4-;/38-3-;83659=>9:8-09/2/@-9/=09:-960E-0987/0>=;,-9/=0;8.-;7/0.7/38-38;85-987SY[ 38U6802/0.=;7/38-389807802/83C=;,/3-99;/D6987@-98;0/94(?-9/8093E/55D8258-;54/0>=;,879:-99:87-9-;85-9879=SY[38U6802/0.-07.8089/2-0-543/3/32=787C/0B839/.-9/=0-5-07E/550=9D83:-;87E/9:@-9/8093C>-,/54,8,D8;3=;:8-59:2-;8@;=B/78;3(&'()(X('G/3<;85-9879=@=33/D/5/949:-9/0>=;,-9/=0,-4D8;858-387\:/3/02567839:8;/3<9:-97-9-;85-9879=.80=94@8CSY[38U6802/0.=;;/3<>=;7/38-3898078024=;9;-/92-0D8;858-3879=,8,D8;3=>9:8@6D5/2C/036;8;3C8,@5=48;3C=;5-E80>=;28,809-.802/83([59:=6.:9:8;8-;80=@5-039=;858-38;8365939=9:8@-9/8093C>-,/54,8,D8;3=;:8-59:2-;8@;=B/78;3C9:/3;/3<E/55D8/0256787/09:8/0>=;,872=038097=26,809(&'()(%J8;9/>/2-98=>J=0>/7809/-5/94[3@-;9=>396748>>=;939=@;=B/782=0>/7809/-5/94=>36D]829/0>=;,-9/=0C9:/339674E/55=D9-/0-J8;9/>/2-98=>J=0>/7809/-5/94E:/2::85@39=@;8B809>=;2877/325=36;8=>@8;3=0-554/7809/>/-D58;838-;2:/0>=;,-9/=0(\:8J8;9/>/2-98=>J=0>/7809/-5/94-55=E3/0B839/.-9=;3=09:/39;/-59=;8>6389=7/325=38/7809/>4/0./0>=;,-9/=0;85-9879=9:8;838-;2:@-;9/2/@-093C3:=657362:7/325=36;8:-B8-7B8;382=038U680283>=;36D]8293=;7-,-.89:8/;>/0-02/-539-07/0.C8,@5=4-D/5/94C/036;-D/5/94=;;8@69-9/=0(\:8/0>=;,872=03809/02567839:8-@@;=@;/-982=B8;-.8-07;839;/29/=03=>9:8J8;9/>/2-98=>J=0>/7809/-5/94(:/339674,-4/0B=5B860@;87/29-D58;/3<39=9:8@-;9/2/@-093(&'()(^?=9809/-5I808>/93\:8396747;6.,-4:85@9=2=09;=59:87/38-38(T696;8@-9/8093,-4D808>/9>;=,E:-9/358-;087(
_`ab defgfhijkjlemfokopqfef
\:/339674/3>=;@-9/8093E:=:-B8;85-@387>;=,39-07-;79:8;-@/83>=;8@8074,=,-(J6;;80954C0=


	
  !"#!#"#"$%
&'()*(+*',-+(./('+-01++-)0-,(&2--)-&'(234&,-*5()*',-46.(0'780,-67',-+(./('+-01++-)0-,(&2--)3464'-*9:(+'404.()'&6(/72'(4)2-''-++-&.7)&-&;4',6(+4<76429:3-(&-&--&-0'47)=>?>(27A-87+',-+4&B2-)-84'()(3/&4&87+0,43*+-)()*A4(23-)-7)('-&9:3-(&-&--&-0'47)=>?C(27A-87+',-+4&B2-)-84'()(3/&4&87+)7)A4(23-)-7)('-&()*)-7)('-&781)0-+'(4)A4(2434'/9:3-(&-&--&-0'47)=>?D(27A-87+',-+4&B2-)-84'()(3/&4&87+.+-E)()';76-)9=>?F HIJKLJMNOIHLKKPJQQIHRSLJMPMTIJU,-4)87+6-*07)&-)'*7016-)';4332-.+7A4*-*'7',-.(+'404.()'7+07)&-)'*-&4E)--V&W(&(..340(23-87++-A4-;.+47+'707)&-)'4)E9X*-&4E)('-*&'1*/4)A-&'4E('7+;4330(+-8133/-Y.3(4)',-.+70-*1+-&()*'-&'&4)A73A-*4)',4&&'1*/5()*',-(&&704('-*+4&B&5*4&07687+'&()*2-)-84'&9Z)7+*-+'764)464<-.7'-)'4(307-+047)5(&610,'46-(&4&)--*-*'7+-A4-;',-*7016-)';4332-E4A-)54)031*4)E()7..7+'1)4'/'7*4&01&&4';4',8+4-)*&58(643/6-62-+&()*[7+7',-+(*A4&7+&5()*'7(&B\1-&'47)&78()/*-&4E)('-*&'1*/4)A-&'4E('7+9X&4E)-*4)87+6-*07)&-)'*7016-)';4332-72'(4)-*.+47+'7-)'+/7)'7',-&'1*/9
U,-4)4'4(307)&-)'.+70-&&(&;-33(&+-]07)&-)'5;,-)+-\14+-*56(/'(B-.3(0-4).-+&7)7++-67'-3/V-9E95A4('-3-.,7)-7+7',-+^Z_(..+7A-*+-67'-.3('87+6&W.-+*4&0+-'47)78',-*-&4E)('-*&'1*/4)A-&'4E('7+()*;4',',-(E+--6-)'78',-.(+'404.()'[07)&-)'*-&4E)--V&W9`,-',-+4).-+&7)7++-67'-5',-.+4A(0/78',-&12a-0';4332-6(4)'(4)-*9b7)&-)'4)E4)A-&'4E('7+&V()*.(+'404.()'[07)&-)'*-&4E)--5;,-)4).-+&7)W;4332-370('-*4)(.+4A('-(+-(V-9E95034)4007)&13'+776W9`,-)07)&-)'4&07)*10'-*+-67'-3/5',-.(+'404.()'[07)&-)'*-&4E)--;4332-4)87+6-*78',-.+4A('-)('1+-78',-*4&01&&47)()*;4332--)071+(E-*'7+-370('-'7(67+-.+4A('-&-''4)E48)--*-*9cd9e9cb7)&-)':+70-&&87+X*13'&`,7g(0Bb(.(04'/'7b7)&-)''7h-&-(+0,:(+'404.('47)i7+.(+'404.()'&(**+-&&-*4)j-0'47)=>?k5()gXh;4332-4*-)'484-*07)&4&'-)';4',:7340/$lm()*4)87+6-*07)&-)'72'(4)-*8+76',-gXh5(&*-&0+42-*4)j-0'47)=>?F9cd9e9db7)&-)'87+b,43*+-)()*^-7)('-&U,-07)&-)'.+70-*1+-&+-8-+-)0-*(27A-;4332-87337;-*5;4',27',.(+-)'&4)A73A-*4)',-07)&-)'4)E.+70-&&.-+j.7)&7++-\1-&'9U,-0,43*n&07)&-)';4332-&4E)-*2/27',.(+-)'&1)3-&&7)-.(+-)'4&*-0-(&-*51)B)7;)54)076.-'-)'7+)7'+-(&7)(23/(A(43(23-57+;,-)7)3/7)-.(+-)',(&3-E(3+-&.7)&42434'/87+',-0(+-()*01&'7*/78',-0,43*9`,-)E1(+*4()&,4.&'('1&78',-0,43*4&1)0-+'(4)5*7016-)'('47)7801&'7*/&'('1&61&'2-72'(4)-*9X&4)87+6('47)4&7)3/0733-0'-*87+1.'77)-/-(+(8'-+24+',5(&&-)';433)7'2-72'(4)-*8+760,43*.(+'404.()'&9`,43-0,43*+-)6(/2--)+733-*(8'-+',-(E-78c/-(+87++-'+7(0'4A-*('(0733-0'47)48+-\14+-*5E4A-)',-()'404.('-**1+('47)78',-&'1*/5)70,43*-Y.7&-*4)1'-+74&-Y.-0'-*'7,(A-(''(4)-*',-0(.(04'/'7.+7A4*-(&&-)';,43-',-&'1*/4&7)E74)E9cd9e9mh-\1-&'87+`(4A-+78b7)&-)'87+j0+--)4)EX0'4A4'4-&:+47+'7',-&12a-0'&4E)4)E',-07)&-)'87+',4&&'1*/.+-]&0+--)4)E(0'4A4'4-&34&'-*4)&-0'47)>?>?=6(/2-.-+87+6-*9`-+-\1-&'(;(4A-+7807)&-)'87+',-&-(0'4A4'4-&(&',-/4)A73A-7)3/64)46(3+4&B'7',-&12a-0'&9X
;(4A-+;433)7'(*A-+&-3/(88-0'',-+4E,'&()*;-38(+-78',-&12a-0'&E4A-)',('',-(0'4A4'4-&(+-7)3/
4)'-)*-*'7*-'-+64)-&14'(2434'/87+&0+--)4)E87+.(+'404.('47)4)+-&-(+0,.+7'7073&9U,-&-(0'4A4'4-&
0713*)7'.+(0'40(23/2-0(++4-*71';4',71'',-;(A4-+(&0-)'+(3+-0+14'4)E&-+A40-&51'434<-*4)',-^Z_


	
  !"#!#"#"$%
&'()(*+'&,)-,./0,.12.30.,45*.,,)()6+*-(7(-(,512.38'-(0',5-89(,5+)92:-+()()6*2)5,)-12.,+*;2),(5:,<2)9-;,(..,528.*,5=>;,58:?,*-5@('':,0.27(9,9@(-;+99(-(2)+'0,.-(),)-()12.3+-(2)+1-,.0+.-(*(0+-(2)+5-;,<@('':,()12.3,9@;,-;,.2.)2--;,<+.,,'(6(:',-25(6)+*2)5,)-12.+99(-(2)+'5*.,,)()6=
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
&(.*835-+)*,5-;+-3+<@+..+)--,.3()+-(2)2.5850,)5(2)()*'89,/:8-+.,)2-'(3(-,9-2_` X,-,.3()+-(2)218),b0,*-,9/5(6)(1(*+)-/2.8)+**,0-+:',.(5c-20+.-(*(0+)-5` X,32)5-.+-(2)21,11(*+*<-;+-@28'9@+..+)-5-200()6` V)5811(*(,)-*230'(+)*,-20.2-2*2'.,d8(.,3,)-5` X+-+-;+-+.,)2-5811(*(,)-'<*230',-,+)9e2.,7+'8+:',` X,-,.3()+-(2)-;+--;,0.(3+.<,)902()-;+5:,,)3,-` X,-,.3()+-(2)2118-('(-<^-89<3+<.,583,2)*,*2)*,.)5+:28-5+1,-</0.2-2*2'*230'(+)*,/+)99+-+d8+'(-<+.,+99.,55,9/+)95+-(51<-;,502)52./V\]+)9+5+00'(*+:',/f229+)9X.86g93()(5-.+-(2)YfXgZ=ABTh iGIHQJLISSGDINREINOiGIHQJLRKNJDKH>;,*'()(*+'5(-,@(''0,.12.3()-,.)+'d8+'(-<3+)+6,3,)-215-89<*2)98*-/9+-++)9:(2'26(*+'50,*(3,)*2'',*-(2)/92*83,)-+-(2)+)9*230',-(2)=g)()9(7(98+'(j,9d8+'(-<3+)+6,3,)-0'+)@('':,9,7,'20,9-29,5*.(:,+5(-,k5d8+'(-<3+)+6,3,)-=l8+'(-<*2)-.2'Yl&Z0.2*,98.,5@('':,(30',3,)-,9:,6())()6@(-;-;,9+-+,)-.<5<5-,3+)99+-+l&*;,*c5-;+-@('':,.8)2)-;,9+-+:+5,@('':,6,),.+-,9=g)<3(55()69+-+2.9+-++)23+'(,5@('':,*2338)(*+-,9-2-;,5(-,Y5Z12.*'+.(1(*+-(2)e.,52'8-(2)=f2''2@()6@.(--,)^-+)9+.9m0,.+-()6[.2*,98.,5Y^m[5Z/-;,32)(-2.5@(''7,.(1<-;+--;,*'()(*+'-.(+'(5*2)98*-,9+)99+-++.,6,),.+-,9+)9:(2'26(*+'50,*(3,)5+.,*2'',*-,9/92*83,)-,9Y.,*2.9,9Z/+)9.,02.-,9()*230'(+)*,@(-;-;,0.2-2*2'/V)-,.)+-(2)+'&2)1,.,)*,2)n+.32)(5+-(2)o229&'()(*+'[.+*-(*,YV&no&[Z/+)9+00'(*+:',.,68'+-2.<.,d8(.,3,)-5Y,=6=/o229p+:2.+-2.<[.+*-(*,5Yop[Z/o229q+)81+*-8.()6[.+*-(*,5Yoq[ZZ=>;,()7,5-(6+-(2)+'5(-,@(''0.27(9,9(.,*-+**,55-2+''-.(+'.,'+-,95(-,5/528.*,9+-+e92*83,)-5/+)9.,02.-512.-;,08.025,2132)(-2.()6+)9+89(-()6:<-;,502)52./+)9()50,*-(2):<'2*+'+)9.,68'+-2.<+8-;2.(-(,5=


	
  !"#!#"#"$%
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`?GE<ZT_`[JG;<a?EE9NCHGA?EDGN9;>:9BFGD:;B=9>AGHH<?>CF9;ABG;<E9>?E<BE9PC:E9<A?K9FG:;AG:;9<KDA89:;I9BA:NGA?EJ:;>HC<:;NKCA;?AH:F:A9<A?JF9<:>GHE9>?E<BZ?@@:>9J>H:;:>J?E8?B=:AGH[G;<=8GEFG>DE9>?E<B@?EA89=GEA:>:=G;AB:;A8:BBAC<DL789>H:;:>GHBAC<DB:A9M:HH=9EF:AG>>9BBA?BC>8E9>?E<BL
789BAC<D=GEA:>:=G;AbB>?;AG>A:;@?EFGA:?;M:HHK9B9>CE9HDBA?E9<GA9G>8>H:;:>GHB:A9@?E:;A9E;GHCB9<CE:;NA89BAC<DL^AA899;<?@A89BAC<DJGHHE9>?E<BM:HH>?;A:;C9A?K9c9=A:;GB9>CE9H?>GA:?;@?EGBH?;NG=9E:?<GB<:>AGA9<KDA89E9I:9M:;NT_`JT;BA:ACA:?;GH=?H:>:9BJ?EB=?;B?EE9PC:E9F9;ABLdAC<D=GEA:>:=G;AE9B9GE>8<GAGJM8:>8:B@?E=CE=?B9B?@BAGA:BA:>GHG;GHDB:BG;<B>:9;A:@:>E9=?EA:;NJM:HHK9AEG;BF:AA9<A?G;<BA?E9<L78:BM:HH;?A:;>HC<9A89=GEA:>:=G;AbB>?;AG>A?E:<9;A:@D:;N:;@?EFGA:?;L_GA89EJ:;<:I:<CGH=GEA:>:=G;ABG;<A89:EE9B9GE>8<GAGM:HHK9:<9;A:@:9<KDGC;:PC9BAC<D:<9;A:@:>GA:?;;CFK9EL789BAC<D<GAG9;AEDG;<BAC<DFG;GN9F9;ABDBA9FBCB9<KDE9B9GE>8BAG@@M:HHK9B9>CE9<G;<=GBBM?E<=E?A9>A9<L^AA899;<?@A89BAC<DJGHHBAC<D<GAGKGB9BM:HHK9<9e:<9;A:@:9<G;<GE>8:I9<KDA89TSL
7?@CEA89E=E?A9>AA89=E:IG>D?@BAC<D=GEA:>:=G;ABJGS9EA:@:>GA9?@S?;@:<9;A:GH:AD8GBK99;:BBC9<KDA89RGA:?;GHT;BA:ACA9B?@f9GHA8ZRTf[L78:B>9EA:@:>GA9=E?A9>AB:<9;A:@:GKH9E9B9GE>8:;@?EFGA:?;@E?F@?E>9<<:B>H?BCE9LTAGHH?MBA89:;I9BA:NGA?EG;<?A89EBM8?8GI9G>>9BBA?E9B9GE>8E9>?E<BA?E9@CB9A?<:B>H?B9:<9;A:@D:;N:;@?EFGA:?;?;E9B9GE>8=GEA:>:=GA:?;:;G;D>:I:HJ>E:F:;GHJG<F:;:BAEGA:I9JH9N:BHGA:I9J?E?A89E=E?>99<:;NJM89A89EGAA89@9<9EGHJBAGA9J?EH?>GHH9I9HL`D=E?A9>A:;NE9B9GE>89EBG;<:;BA:ACA:?;B@E?FK9:;N>?F=9HH9<A?<:B>H?B9:;@?EFGA:?;A8GAM?CH<:<9;A:@DE9B9GE>8=GEA:>:=G;ABJS9EA:@:>GA9B?@S?;@:<9;A:GH:AD89H=G>8:9I9A89E9B9GE>8?KQ9>A:I9BG;<=E?F?A9=GEA:>:=GA:?;:;BAC<:9BKD89H=:;NGBBCE9>?;@:<9;A:GH:ADG;<=E:IG>DA?=GEA:>:=G;ABL

	
  !"#!#"#"$%
&' )*+,-+./012.+32567,-+1275&'8& -+,297-2:;25<&=>?==@ABCACAEFGHIJKLHMNFOMPMQLRMRSJQTMULTMFRLVWHGUCXYJZJRTJH[FHZLRIJH\JQJLHIY]ZZ\^_`LTMFRLVZLRIJHaRQTMTGTJ]`Za^bMVVEcFRQFHTYJa`d[FHTYMQQTGWeCKLHMNFOMPbMVVPJQGccVMJWPeTYJOLRG[LITGHJH]ZJVUJRJ^CABCAC%fGOLRXFgMIMTe\J[JHTFMRSJQTMULTFHPHFIYGHJ[FHWJTLMVJWTFgMIMTeMR[FHOLTMFRCABCAChiFHOGVLTMFRLRWcHJcLHLTMFRKLHMNFOMPjeFcYMVJLRWKLHMNFOMPjeFcYMVJdMVGJRTLHJQGccVMJWMR%SMLVQLQLkMTcVLIJWMRLQMRUVJPFgTYLTQYFGVWPJQTFHJWLT%lZTFmlZCKLHMNFOMPjeFcYMVJLRWKLHMNFOMPdMVGJRTLHJJLIYcHFSMWJWMRL%noIIIVJLHXecJaUVLQQSMLVbMTYLiVGHFoXJI
ppq
ppQTFccJHLRWLiVMcoF[[VMWCKLHMNFOMPjeFcYMVJMQQGccVMJWLQLbYMTJTFF[[bYMTJILkJFHcFbWJHF[%OUOLHMNFOMPLRWrnOUQGIHFQJcJHSMLVCKLHMNFOMPjeFcYMVJdMVGJRTMQcHFSMWJWLQLIVJLHQFVGTMFR]%nOj^IFOcHMQMRU$$scHFceVJRJUVeIFV_$sJTYLRFV_LRWBnsIMTHLTJPG[[JH]AnOK_cf$^CKLHMNFOMPjeFcYMVJSMLVQLHJWJQMURLTJW[FHQMRUVJGQJFRVeCiFHJLIYQGPtJITTHJLTOJRT_AkMTIFRTLMRMRUASMLVF[KLHMNFOMPjeFcYMVJLRWASMLVF[KLHMNFOMPdMVGJRTQYFGVWPJHJOFSJW[HFOTYJHJ[HMUJHLTFHCdFRFTbLHOTYJSMLVQLPFSJmuZCXYJcLHJRTJHLVWFQMRUQFVGTMFRF[OLHMNFOMPWHGUcHFWGIT[HFOTYJVeFcYMVJ[FHOGVLTMFRMQcHJcLHJWPeHJOFSMRUAnOjF[KLHMNFOMPdMVGJRTLRWLWWMRUMTTFTYJKLHMNFOMPjeFcYMVJSMLVC]`FTJvjeFcYMVJSMLVQLHJQJLVJWGRWJHSLIGGOLRWOLecGVVQeHMRUJWdMVGJRTMRTFTYJSMLVL[TJHRJJWVJMRQJHTMFR^C\JIFRQTMTGTMFRQYFGVWPJcJH[FHOJWGRWJHIFRTHFVVJW_LQJcTMIIFRWMTMFRQCXYMQHJQGVTQMRLOLHMNFOMPIFRIJRTHLTMFRF[nC%OUwOj]%CnOUMRAnOjwSMLV^CXYJHJQGVTMRUHJIFRQTMTGTJWQFVGTMFRQYFGVWPJTYFHFGUYVeOMgJWPeSMUFHFGQQYLkMRUCABCACBETLPMVMTeLRWETFHLUJKLHMNFOMPjeFcYMVJLRWKLHMNFOMPdMVGJRTSMLVQQYFGVWPJQTFHJWLT%uZTFmuZCXYJHJIFRQTMTGTJWOLHMNFOMPQFVGTMFRQYFGVWPJTYFHFGUYVeOMgJWPeSMUFHFGQQYLkMRULRWQTFHJWLT%lZTFmlZxTYJcHFWGITQYFGVWRFTPJ[GHTYJHWMVGTJWCXYJHJIFRQTMTGTJWK\yWFQMRUQFVGTMFRMQQTLPVJMRTYJWFQMRUQeHMRUJ[FHGcTF%YFGHQMRHJ[HMUJHLTJWIFRWMTMFRQ]%omuZ^_z`dGcTFLRLWWMTMFRLVAYFGHbYJRQTFHJWLT\FFOXJOcJHLTGHJ]\X^IFRWMTMFRQ]%no%$uZ^CzWFQMRUQeHMRUJIFRTLMRMRUK\yWFQMRUQFVGTMFRHJOFSJW[HFOHJ[HMUJHLTMFRLRWcVLIJWFRLRLOPMJRTQGH[LIJbMVVHJLIY\FFOXJOcJHLTGHJMRLccHFgMOLTJVeAno
A$OMRGTJQC
ABCAC$zWOMRMQTHLTMFRcHFIJWGHJQKLHMNFOMPQYFGVWPJUMSJRLQLRMRTHLSJRFGQMR[GQMFRLTnCmOUwO
pp%FSJHLTVJLQTAnOMRGTJQ]{AnOMRGTJQ^CC
ABCACraRIFOcLTMPMVMTMJQKLHMNFOMPMQLQJIFRWo|}~}~}}}}}~o~}oVLITLOQTHGITGHJLQPJVFbCKLHMNFOMPQVMcFcYMVMIQTHGITGHJLVVFbQMTTFIHFQQTYJPVFFWoPHLMRoPLHHMJHArCaT
MRYMPMTQTYJ%nEcHFTJLQFOJ_LITMSLTJQILQcLQJQLRWPGMVWQGcHJLITMSJFgeUJRQcJIMJQTFMRWGIJLcFcTFQMQ
MRTGOFHIJVVQArC


	
  !"#!#"#"$%
&'(&()+,-./01231.-13456780687-9:&;<';<$=>?'?:@?0,2A7A-6,B2>?&?::&=>?0B02A,-C?@?-3B2:,B47ACB2>.-6,B2>?$?.-6,B2?D?AC1?@?
1E1F/0B02AG%(@(HI,-J613-?%<)?4/A3-KA7.-72B L3AM3159D?NC1?@?1E1F/0B02AG%(@(HI,-J613-?%<)?4/A3-<'?:@?0,2A7A-6,B2>?&?G:=>?G:&=>?@?
0B02A,-C-3?&?B2I,B47ACB.-6,B2I?$?.-6,B2?<:&;<';<$=>+O=;-P/567BQ8.F-79'%))'@?%'?@+,-./012021559RSTUTVSTX?VYTZY[\?2106A3-N6,-70,-./012/4-36/]/-79 =12/3A5JA71./4-O^-3-7/031.-9_17/EA./F`714-31.-9 QA6155/P3-4OFF7-a/16-431.-9 Qbc?HH$@<_;d_A2-08217]A7.8219 +
ee&$
eef
ee@H
ee+2QN
ee'_A2-08217M-/P,69 %&%()gb,B5/0124-507/J6/A39h,/6-07B56122/3-5A2/4b,17.10A2AP/012021559b7A6-15A.-/3,/F/6A7=A28F/2/6B/3N7P13/05A2a-3659c5AJ7AJ13A2:$.Pi.j><-6,13A2:&H.Pi.j><.-6,13A2:&).Pi.j><10-6A3/67/2-:&%.Pi.j><J7AJB2-3-P2B0A2:D.Pi.j>< 6-76?F8613A2:@.Pi.j>=A28F/2/6B/3Ok8-A85F8]]-79$($lPi.j<Jf$+,-./01256780687-9
:=A870-9_1<j134n/1A<O-612(O36/0130-7OP-365_-4+,-.(@H&'G&gI>


	
  !"#!#"#"$%
&'()*+,)-'../'(01+2'3/'3/(45+6.+1/71)'58+(9(:;<9(:;)71/('=1)+70'0)1)07/)12/('7)72)-)1+(7+('7)79:=/(+82/.'1)=>?@08(+,9)88/(/710./=)/0A)1)07+1)785:/7=/9-4,:51).5/9(:;(/0)01'71BCD@E-)79)7;='00/11/1('70.+(1/(0'79)0)7'=1)3/)7'-(+'9'(('4+8/7*4,/A)+7=2'77/5A0/=+79,/00/7;/(A'79(/=/.1+('00'40F

	
  !"#!#"#"$$
%& ()*)()+,)-/0
123456780907:;2407<=>?>@A>>BA@C==DABDA@A>>BEAFAC=GHI2JK:6K:447LMM$0NOPQRS0TLTUTT$0L0
VW7X0710Y0Z6[\;65J]72J^80_0`a4b:6;7c>?GC=C?AACDEAFAC=GBHd:W65eJK547LM/f0%NOgQRS0hMLU/T0T0
9WJK2J7X02J^i0i5jj[2J7CD@C>AFAC=GBHk62aJ1W[56\0l^aJbW6]mRImW6Kma44naoaJ]\;5J:7/hh$RS0PhTU$MP0P0
8K`Wa6:7I0Y07p0n0Y2aJ2Ja72J^q0`0ra\m:67C@=AC@AFDDACBEAFAC=GstuvA>>C@AwF=A>?GwC=C=<ABu>DBBDu=Gsx>C@>D@>AHX5W6J245jJ:W65\W6]:637LMMh0%%yOPQRS0gL$UgLh0$0
YKmajj:67907cCDuBs>?GwFD>?GC=@>C@>AEAAC@AB0LM/LRYS6aJ]:6YKa:JK:zkW\aJ:\\8:^a20f0
q26{:67807:;2407x  E|}~<EuBCB=vAC@?AC@~FFcB?C>>C?CAFAC=GHd2;W6:7LM/P0&yOgPhQRS0P$/U$0g0
I2ma447p0l07_0Z0856\m:^72J^k02[aJa7u@>AE@D~BDsCB?DBCDA?u>DBC=D?ADA=DAFGHd:W65UeJK545]37LM/f0%NOTQRS0TLhUTTh00
i23^:J780Y02J^Y0`m5\m7~FFcwDAEBDuDA~@ACDuGsA>AF?ABBC=uDBDC=C?uABDCBH`:J:\9:o7LM/L0OTQRS0LMTUTP0h0
8:4a\a7902J^q0X0Ima257~FFcBD?ADE@C@ADAFGHlS:6;eSaJ1m:6126]:;\7LMMg0%%OLQRS0/TTUPP0/M0
1\W{2[5;57Y07tA@ECDBEDAuDC~DABAtGBDAEDu>tu@ABExC@AAFGHIm:[qm26[kW44O15{35Q7LM/f0OLQRS0//LU0//0
Z^2[\7X070X0q245[b:44272J^q0X0l44a5;;7DABACDCsCABDDA?GC@C@ADADACDHJo:\;d:96W]\7LMMM0%NOLQRS0/MhUL/0/L0
I62j56^7n0X07k0V24{:672J^Z0l06oaJ:7DABACDBC@C@ADAFGHXI:44I5[[WJYa]J247LM//0&OLQRS0/M/U/M0/T0
[25mUem[a7Y07:;2407@D@GBDCwBFA@E@CDEDAFDABAwC=u@ABFFDBBCuCC>BD|@A>>BHka5Km:[ka5Sm3\_:\I5[[WJ7/hh$0%OTQRS0/MgMUg0/P0
96:4:67i0I07@DvDCEDA@A>>=ADF?GCDCEFDABAEuC@DCHq65Kd2;4ZK2^YKaYZ7/hhg0 OTQRS0$$UfM0/$0
e645\{a7_0¡07:;2407u?DCDCC=u@A=CuCA=A>EuCcuDD¢B>GFGFDABACDHI2JK:6_:\7/hh0&NO/hQRS0PTPLU0/f0
9a7p07:;2407@DvDGBBC?>A?ACDC>?CCD?>Bs>DGD@BBDA>=~CAHd:W65eJK547LM/f0%NOfQRS0PMU0/g0
Z^2[\7X07:;2407DABACDBsCvA>@>BBEFDACDC=AEEA@DvACDDu?ACDBHI2JK:66:\:26Km7/hhh0& O//QRS0Lf/$ULfLL0/0
X5mJ\5J790k07:;2407GBDAC?vBC=u@A=GF>uCFDACDBDADBDD@A>CHX5W6J245jI4aJaK24eJK545]37LM/$0££OTTQRS0:/LLU:/LP0/h0
Z;{aJ\5J7X0807:;2407CCDA?DA=CvDC=Cvv?~Du?FuDB@AAC=ACDEABDADACD>A=BEAFAC=GHI2JK:6I:447LM//0yOTQRS0TPUhh0LM0
i266a\5J7Y0X07:;2407BAx>C@>>E¤~""}#¥CDACDBD=vC@A=>?CC@ABC@>u=C?u>DF>AGA>stDu=G~""}#~ "#C><ABu>DBHI4aJI2JK:6_:\7LM/f0
L/0
_aKm26^\5J7q0`07:;2407BA BDu=GECA>FBA=A>FBA=C=AE@DG
u>DF>AGA>s~""}#~ " D Hk455^7LM/f0%OLLQRS0LfhTULgMM0


	
  !"#!#"#"$%
&&'
()*+,-./+0.123'2)4+/'25678689:;7<=>;::7?@;;:9AA6@<96B7B8767<:=76;=;7<C=B;7B:DE)F*.G0H./2&IJ$'KLMNOPQ'RRI,S'&N'
T*U//2V'2)4+/'2:B=;BA;8;B;=CWB9B<B7@;=;7<C786<;797<;XC;:@>;Y96B8;7B;B6@B;Z;78[8;BC@;<B8\786>CDV.F*0+/.]^/U0UH+/G0H./._`2&IIJ'KaM$OPQ'J&bb,J&c%'&R'
d)*He+042f'3'+0gd'h.F/+gU2=;7<CY7;WB;=;9B8==8;:7869<7><B77<8;B;=CDVE)F*..0H./2&II$'LiMNOPQ'&bS,cc'&$'
j*k14*.0_2f'l'2)4+/'2m6<B7@B;DnDo7<;:7[C=B7A;7BCp7q9<96;rno[?pqsDVE)F*..0H./2&II%'tuMJOPQ'&S,N$'&%'
v)02w'x'2)4+/'2y=<B;<;:=7:;::;::;7B8B;@>?><;>6:Y;:=7:;::;::;7B77;9?786>CWz7>>9=DV^/U0G0H./2&IJI'{tMJJOPQ'Jc%N,S&'&S'
|+0_2x'+0gx'xF+02\=B6:;}9;7B6;78;7B<;:>7:@=:;86786B6:Dl4+4U14UH1U0d)gUHU0)2&IJ%'&b'
~UHe+*g1.02w'T'2)4+/'2:; 86786;A69B7@BW8;?W;;z6Cr?""X#s7A;6=B;:;7B7=B;7B:WB;6=:;<!;@8BC96B=6;C;6rsD-/..g2&IJJ'KKtM&JOPQ'NI&,NI&'&c'
+k/U02w'2)4+/'2Z:B?7?97=:;:B9<C@B;7A;6:B98B9;=B;:;7B?
""X#DV.F*0+/.]^/U0UH+/G0H./._`2&IIc'{LMJ$1FQQ/OPQ'N$J%,N$J%'NI'
f.01)0g2j'2)4+/'256786B6@?""X#7<A78;<6>778;:7869<7>6C=7<6;9z;r<A78;<6>778;:sDV.F*0+/.]^/U0UH+/G0H./._`2&IIc'{LMJ$1FQQ/OPQ'N$b&,N$b&'NJ'
v.0_23'^'2~'-'-F4.02+0g'~'h*+02=6;;7BB7@}97BBBA;=;@9:7>7>B;87}9;:@@978B767==7>9:7>=96:;<B;6:=76;67>DEd~U0-U.k)gUHU0)2JccS'KuMR$OPQ'&NS,&Rc'N&'
()04F*+2V'2)4+/'2796@B;;=7<;<;@=:C8B8B7>:86;D04)*0+4U.0+/.F*0+/.]k)4e.g1U0Q1`HeU+4*UH*)1)+*He2JccN'MNOPQ'&&S,&RR'

	
  !"#!#"#"$%
&' )**+,-./+0&'2& )**+,-.3)4
5)6,78059*+6876:),/+0;);<0),-,+<67=7>./)=8<,/;.7,?@ABCDAE
FGCHIJHK@DLCFA@AMF@DNOCMHJPJQBLRMDLABJDFSBPPTCQH@NCN@LLJHNBDQAJAUCIJPPJSBDQFL@PCFV5WXYZ[\]^*_X[ZX`WYa_0aWb_?CHLCDAcCFLHBGABJDdeeOJHK@PfDJLJKGP@BDAFfDJCgBNCDLCJINBFC@FChiejTPCAJL@HHkJDDJHK@P@LABgBAklKBDJHFBQDFJHFkKGAJKFJINBFC@FChmeOJHK@P@LABgBAkSBAUCIIJHAlFJKCFBQDFJHFkKGAJKFJINBFC@FCh%en@HCFIJHFCPIfMD@TPCAJL@HHkJDDJHK@P@LABgBAkJHAJNJ@LABgCSJHohpeqCrMBHCFJLL@FBJD@P@FFBFA@DLCfTMABF@TPCAJL@HCIJHKJFAJIUBFsUCHDCCNFh$eqCrMBHCFLJDFBNCH@TPC@FFBFA@DLC@DNIHCrMCDAKCNBL@PL@HChtecBF@TPCNfHCrMBHCFFGCLB@PL@HC@DN@FFBFA@DLChuevCgCHCPkNBF@TPCNfUJFGBA@PBw@ABJDBDNBL@ACNhcC@AUDJABKKBDCDAhxeyCHkFBLofUJFGBA@PBw@ABJDBDNBL@ACNhcC@AUDJABKKBDCDAhdezJHBTMDNfI@A@PGHJLCFFCFGHJQHCFFBDQH@GBNPkhe
cC@Nh

	
  !"#!#"#"$%
'()*+,+-./0)1/2.+13/+*(456789:5;<;=>9?@;A;B6C9DEA?E:6;>>;:97:59F@979>C9;@EG79>C9;=>9?@;A;B6C7H8F:;87I45679JE86>E:6;>75;?A<C;6>C6<9K6:5;GL9C:6D989E7?@989>:6>:?8;@76M9IN
O;>9?@;A;B6C7H8F:;87P
Q6>;@>9?@;A;B6C7H8F:;87R
Q;<9@E:9>9?@;A;B6C7H8F:;87S=?AAHEC:6D9T
Q;<9@E:9>9?@;A;B6C7H8F:;87SA977:5E>=?AAHEC:6D9U
V9D9@9>9?@;A;B6C7H8F:;87'()*+,+-./0)1/2.+1WRX9=6>6:9AHY9::9@WPZ;776GAHY9::9@N[>C5E>B9<\PZ;776GAH];@79\RX9=6>6:9AH];@79YYE79A6>9

	
  !"#!#"#"$%
&'() +,,-./0134
560+7890:0;0<.,6<;<7<=+>?@ABACADEFGDCD>DHJKLMNOPQRSTUVNLMWXYRTZJ[\]OVNTM\PUM^_ WXYRTZJ`RSa\]UNQLMRNT^XbNQLY]W$YRTZJcdKefWgYRTZJhidjkKldWmnopZW_qYRTZJ[\]OVNTM\PUMrP\RPsQ]tQRuPTSQ]^_YPuU W_YRTZJ[]\Y]PsRQRMvW^_wvTPYRVZWxYRTZJ[NUMOVNTM\PUMrP\RPsQ]tQRuPTSQ]^_YPuUW_YRTZJjRttLURNT^]TUN\eYPSRTSWyYRTZJ[]\tLURNTW^Xk^XzZWgYRTZJgj[NUMOVNTM\PUMW$YRTZJ[NUMOVNTM\PUM^_ WXYRTZiL\u\NuNU]wPV{LRURMRNTu\NMNVNQRUw]UV\Rs]wRTMa]sN|}PTwVNTURUMUNtPuu\N|RYPM]Qvx$YRTLM]UNtRYPSRTSMRY]WMvuRVPQQv%~MN_X~YRTLM]UNtMRY]MaPMMa]ULs]VMRURTMa]YPST]M}VNLTMRTSU]MLuPTwUVPTw]QPvUZPVaNtMa]U]wPMPU]MURQQs]PTPQv]wLURTSMNNQUMaPMP\]uLsQRUa]wPTw]QQTNTRTMa]T]L\N\PwRNQNSRVVNYYLTRMvKs\R]tNLMQRT]NtNL\PTPQvURUM]VaTR{L]UtNQQNUoonnooonooojOfeRQQs]LU]wMNYNTRMN\Ma]]tt]VMUNTMLYN\rPUVLQPML\]Ma\NLSauP\PY]M]\U\]tQ]VMRTSsNMaMLYN\u]\tLURNTPTwu]\Y]PsRQRMv^aRUU]{L]TV]LU]UPsNQLURT]VMRNTNt~_YYNQkSNtwOj^[KjPMPRQQs]PTPQv]wLURTSMa]UMPTwP\w^NtMUk]\YNw]YNw]QRMaMa]MvuRVPQPuu\NPVaNt[PMQP]MPQX_
#nonnoomonoKU]VNTwwNU]NtwOj^[KWMvuRVPQQv~_O~XYYNQkSZRUPwYRTRUM]\]wtN\tR\UMOuPUU^Xk^XO]RSaM]wRYPSRTS]LU]PVNYsRTPMRNTS\PwR]TMO]VaNkUuRT]VaNPuu\NPVaMNPQQN]UMRYPMRNTNtMLYN\rPUVLQP\UR]sPU]wNTMa]]{LPMRNTURTMa]sN|KUUaNTRTNL\]P\QR]\N\XX}MaRUVPTs]LU]wMN]UMRYPM]Pr]\PS]r]UU]QwRPY]M]\}aRVa]s]QR]r]YPvVaPTS]RMa]tt]VMRr]PTMROPTSRNS]TRVMa]\Puv^aRUPuu\NPVaPQUNu\NrRw]U]UMRYPM]UNtV]\]s\PQsQNNwrNQLY]WhbZ}V]\]s\PQsQNNwtQNWhcZ}Y]PTM\PTURMMRY]W^^Z}PTwu]\tLURNT]ttRVR]TVvW_k^^Zooo]RQQY]PUL\]Ma]tLQQPM]\U]QtOwRttLURNTM]TUN\s]tN\]PTwPtM]\M\]PMY]TMRTMaRUuPMR]TMuNuLQPMRNT^a]M]TUN\t\PVMRNTPQPTRUNM\NuvWcKZRQQs]VPQVLQPM]wPTwVPTs]LU]wMNw]tRT]aRM]YPMM]\M\PVMwR\]VMRNTUPTwMLYN\RTrPURNTKuuP\]TMwRttLURNTVN]ttRVR]TMWKjZYPuURQQPQUNs]VPQVLQPM]wpno p¡¢ono£¤pmoon ¡£o¥npmo£po¥£o¡mnop
NYsRT]whidjkKldRYPSRTSRUPTNTOVNTM\PUMPuu\NPVaMNURYLQMPT]NLUQvY]PUL\RTSV]\]s\PQsQNNw
tQNWKldZPTwV]\]s\PQY]MPsNQRV\PM]NtN|vS]TVNTULYuMRNTWhidjZg_


	
  !"#!#"#"$%
&'()*+,-+(-+..(/+012/(*13)3)*/')4+.'5)4-678)49'4,042/55/:4-;<+)3,=54>)1/*?=(+-34,*401/@ABC401/.5+,+(3D+=3,=+09'3)3*3/,EF:/401/4)+(4+09'3(4GHJKLMNOPKLQRSTUUVJWXLMYZ[Q\]^V_`JW_aGbLacOMOPKLQRSTdeVJWXLM]f[ghi_NjOaNJ_MO_GVjajJNOMOG(//D+3(+,-k%%l/m<=4,+*n+(<3,=*3D4./3,*)*1(/'=1/'**14)0+,EF14=+).+(+-3=D3)+)2/55/:)o;+)453,4(//D+3(@pD3,Cqk%%l&
rrs
rr@tD3,Cq:+)1/'*(//D+3(@sD3,C+*+0/,)*+,*uvw8xD3,25/:(+*4Ey5//-/m<=4,54n45)+(40/,*3,'/')5<D/,3*/(4-*1(/'=1/'**14)0+,:3*1+.'5)4/m3D4*4(E

	
  !"#!#"#"$%
&'() +,,-./0134
5+66730.+809.:-;-<08=:3+6->?@AABCBD?CDCEF@AGFHIFFGF?CJKLMA@C@HFNDHAFAODH@PPKLIQ@?@AABCBD?@PH@CB?RDOCEFIFGFHBCSDOE@PPTNB?@CBD?IUBPPVFHFNDHAFAB?CEFWXYTIB?RCEFODPPDUB?RNHBCFHB@Z[\]^_B?NFE@PPTNB?@CBD?I@HF@?KLDOB?CFHFICQCEFCS`FDOE@PPTNB?@CBD?QIC@HC@?AICD`A@CFQ@?AIFGFHBCS@HFCDVFHFNDHAFAB?CEFWXY^:abacdef/agdhdedih;acfjdklmEBPFHFICB?RDHRDB?RCDIPFF`QIFFIGBIBD?IQInFPPIDADHIDHEF@HIGDBNFIQIDT?AIQDHUEBI`FHIB?CEF@VIF?NFDOFoCFH?@PICBnTP@CBD?QVTC?DBn`@BHnF?CB?OT?NCBD?B?R^pdkl
mEBPFB?@NPF@HIC@CFDOND?INBDTI?FIIQEF@HI@GDBNFN@PPB?RCEFB?ABGBAT@Pq
I?@nFQFo`FHBF?NFI?D?rGFHV@P@TABCDHSE@PPTNB?@CBD?IJF^R^QIDT?AIDHUEBI`FHIMQODHnPFIIGBIT@PE@PPTNB?@CBD?IDHE@IIF?IDHSFo`FHBF?NFIB?CEF`HFIF?NFDO@nDA@PBCSHFPFG@?CICBnTPTIJF^R^QGBIT@PBPPTIBD?IMB?OHFsTF?CPSJF^R^Q%r\CBnFI`FHUFFtM@?AUBCE?DOT?NCBD?@PBn`@BHnF?C^pilacueavNN@IBD?@PGFHV@PQGBIT@PQRTIC@CDHSQDPO@NCDHSDHC@NCBPFE@PPTNB?@CBD?IUBCE?DOT?NCBD?@PBn`@BHnF?CvX?D?rGFHV@P@TABCDHSE@PPTNB?@CBD?IwGBIT@PBPPTIBD?InDHFCE@?B?OHFsTF?CPSDHUBCEBn`@BHnF?C^pilacueakf:abacaLo`FHBF?NFIA@BPSE@PPTNB?@CBD?IvXIDnF@HF@IDOOT?NCBD?B?R@HFABIHT`CFAVSE@PPTNB?@CBD?I^:abaca
Lo`FHBF?NFIGFHV@PDHGBIT@PE@PPTNB?@CBD?IIFGFH@PCBnFI@A@SvXn@?S@HF@IDOOT?NCBD?B?R@HFABIHT`CFAVSCEFIFE@PPTNB?@CBD?I^-xecajakf:abacayFHIBICF?CGFHV@PDHGBIT@PE@PPTNB?@CBD?ICEHDTREDTCCEFA@SvXnDIC@HF@IDOOT?NCBD?B?R@HFABIHT`CFAVSCEFIFE@PPTNB?@CBD?I^

	
  !"#!#"#"$%
&'() +,,-./01/3
4-56-.-0.070+5,8-6.+.498-,:87;:8<

	
  !"#!#"#"$%


	
  !"#!#"#"$%


	
  !"#!#"#"$%


	
  !"#!#"#"$$


	
  !"#!#"#"$%


	
  !"#!#"#"$%

ICF_001.pdf: 
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 1 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PRINCIPAL INVESTIGATOR:
Mark Gilbert, M.D.
STUDY TITLE:
Phase II Clinical Trial of Marizomib for Recurrent Low-
Grade and Anaplastic Supratentorial, Infratentorial and 
Spinal Cord Ependymoma
STUDY SITE: 
NIH Clinical Center
Cohort: 
Affected Patient  
Consent Version:
11/02/2020
WHO DO YOU CONTACT ABOUT THIS STUDY? 
Mark Gilbert, M.D.
Telephone: 240-760-6023
Email: mark.gilbert@nih.gov
 
This consent form describes a research study and is designed to help you decide if you would like 
to be a part of the research study.  
You are being asked to take part in a research study at the National Institutes of Health (NIH). 
Members of the study team will talk with you about the information described in this document. 
Some people have personal, religious, or ethical beliefs that may limit the kinds of medical or 
research treatments they would want to receive (such as blood transfusions). Take the time needed 
to ask any questions and discuss this study with NIH staff, and with your family, friends, and 
personal health care providers. Taking part in research at the NIH is your choice.
If the individual being asked to participate in this research study is not able to give consent to be 
in this study, you are being asked to give permission for this person as their decision-maker. The 
term “you” refers to you as the decision-maker and/or the individual being asked to participate in 
this research, throughout the remainder of this document.
IT IS YOUR CHOICE TO TAKE PART IN THE STUDY
You may choose not to take part in this study for any reason. If you join this study, you may change 
your mind and stop participating in the study at any time and for any reason. In either case, you 
will not lose any benefits to which you are otherwise entitled. However, to be seen at the NIH, you 
must be taking part in a study or are being considered for a study. If you do choose to leave the 
study, please inform your study team to ensure a safe withdrawal from the research.  
WHY IS THIS STUDY BEING DONE?
In this study we will investigate if marizomib can increase the time it takes for your disease to get 
worse. 
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 2 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Marizomib is in a class of medications call ‘proteasome inhibitors’ and works by slowing the 
spread of cancer cells. The proteasome is a part of the cell that is responsible for using proteins. In 
cancer cells proteasomes destroys “good proteins” responsible for killing cancer cells. Marizomib 
interacts with proteasomes and prevents them from eliminating proteins that are blocking or 
inhibiting cancer growth. Marizomib is not approved by the U.S. Food and Drug Administration 
(FDA) and is experimental. 
Ependymomas are classified by location, grade, clinical and molecular features. One of the 
molecular features is RELA-fusion status of the tumor. It can be positive or negative. We believe 
that marizomib can be more effective in patients with RELA-fusion positive ependymomas, but 
we do not know for sure. Considering this, we first will enroll people with RELA-fusion positive 
ependymomas. If we see that marizomib treatment is effective, we will continue enrollment of 
people with RELA-fusion negative ependymomas.
WHY ARE YOU BEING ASKED TO TAKE PART IN THIS STUDY?
You are being asked to take part in this study because you have been diagnosed with ependymoma 
already treated with standard therapies.
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY? 
Up 70 patients will be enrolled on the study, but because not everyone will be eligible, it is 
expected that 18 with RELA-fusion positive ependymoma will be treated in the first part and 
approximately 32 participants with RELA-fusion negative ependymoma will be treated in the 
second part.
DESCRIPTION OF RESEARCH STUDY
Before you begin the study
Before you begin this study, you will need to have the following exams and tests to make sure you 
are eligible for this study. The exams and tests are part of regular cancer care. If you recently had 
some of the tests, they may not need to be repeated. You will be removed from the study if you 
are not eligible. 

A review of any past or current medical conditions, medicines you are taking and cancer 
history.

Physical examination, including height, weight, neurologic assessment and vital signs.

Electrocardiogram (EKG – a record of your heartbeat) to evaluate your heart.

Review of your symptoms and your ability to perform your normal activities.

Imaging Assessments – magnetic resonance imaging (MRI) that uses a magnetic field to 
produce an image of your body. 

Routine blood tests to find out if you are anemic, have low blood counts, and if your liver, 
kidneys, and other organs are working well;

Routine urine tests

Pregnancy test if you are a woman who can have children
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 3 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

You will be asked to provide samples of your tumor to confirm your diagnosis. If a tumor 
sample from a previous surgery/biopsy is not available, we will perform a biopsy (collect 
a sample of your tumor) to confirm your diagnosis and RELA fusion status.

If you have had prior placement of radioactive seeds or non-surgical radiation therapy, we 
might need to do a fresh biopsy to confirm that your disease has gotten worse even if you 
have sample from prior surgery/biopsy.  
During the study
Marizomib will be administered to you IV (through an intravenous catheter, a small plastic tube 
that is put into a vein, usually in your arm) on days 1, 8 and 15 of each cycle (1 Cycle = 4 weeks).
You will continue treatment with marizomib until your disease gets worse, you have unacceptable 
side effects or you have completed 24 months of study therapy, whichever comes first.
Ongoing Procedures before treatment on the days 1, 8 and 15 of each cycle 

Review of your medications, your symptoms and vital signs

Routine blood tests to find out if you are anemic, have low blood counts, and if your liver, 
kidneys, and other organs are working well

Weight always will be measured on Day 1 and might be measured on Days 8 and 15 if loss 
or gain is observed during a cycle. 
Ongoing Procedures after treatment on the days 1, 8 and 15 of each cycle

Electrocardiogram (EKG – a record of your heartbeat) to evaluate your heart after drug 
infusion.
Additional Procedures before treatment on first day of cycles:

Physical exam and neurologic assessment 

Review of your ability to perform your normal activities

Blood tests to evaluate if your muscles are damaged

Pregnancy test if you are a woman who can have children

Imaging Assessments – MRI of brain or spine– every 8 weeks. If a scan identifies objective 
response, a confirmatory clinical MRI will be obtained 4-8 weeks following initial 
documentation of objective response.
Research tests
In addition to the tests that we will conduct to determine whether you are having side effects or if 
you are responding to the study therapy, we will also collect samples from you for purposes of 
research only. These studies include:

Blood samples before initiation of treatment to study if specific markers in your blood can 
be connected with the outcome of treatment and side effects caused by treatment.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 4 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

Collecting of tumor samples from prior surgery/biopsy to study genetic markers of your 
tumor.

You will be asked to complete questionnaires to determine your general well-being and 
function - before start of the treatment and approximately every 8 weeks after that (before 
imaging studies). It will take you about 5 minutes and will only be done if you can complete 
the surveys in English.

Genetic testing – Your tissue samples contain genes, which are made up of DNA 
(deoxyribonucleic acid) which serves as the "instruction book" for the cells that make up 
our bodies. We will use the tissue samples and blood you provided to learn about how the 
genes in your tumor compare to genes in normal tissue. Your tissue will help us study how 
genes might play a role in pancreatic cancer and other diseases. We will not share the 
results of these research tests with you.
When we are conducting the above genetic tests, it is possible that we could identify changes in 
other parts of your DNA that are not related to this research. These are known as “incidental 
medical findings”.
However, the analyses that we perform in our laboratory are for research purposes only; they are 
not nearly as sensitive as the tests that are performed in a laboratory that is certified to perform 
genetic testing. Changes that we observe unrelated to our research may or may not be valid. 
Therefore, we do not plan to inform you of the results of testing on your tissue and blood that is 
performed in our research lab. However, in the unlikely event that we discover a finding that is 
believed to be clinically important based on medical standards at the time that we first analyze 
your results, we will contact you. This could be many years in the future. We will ask you to have 
an additional tube of blood drawn to verify the findings we have seen in our lab. If the results are 
verified, you will be re-contacted and offered a referral to a genetic healthcare provider to discuss 
the results.
When you are finished taking the drugs
About 4 – 5 weeks after you have finished taking the study drugs, you will be asked to return for 
a safety follow up visit. At this visit, your will be asked questions about your health, get a physical 
and neurological exam, undergo blood tests and might have an MRI. 
If you still have unresolved health issues, caused by study drug, you will be invited to NIH for 
additional tests and treatment.
If your disease got worse, after the safety visit, we will call or e-mail you approximately once 
every 6 months to ask about your health and about any other medications you may have taken for 
your cancer. 
If your disease did not get worse, but you finished taking marizomib, we will invite you for 
imaging studies every 2 months for 1 year; then, every 3 months for 1 year; then, every 4 months 
for 1 year; then, every 6 months. During these visits you will be asked questions about your 
health, get a physical and neurological exam and asked to complete questionnaires to determine 
you general well-being and function. If your disease gets worse, these visits will be canceled.
If you are unable to return for these visits, we will obtain the information from you by telephone 
or e-mail.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 5 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
BIRTH CONTROL
If you are a woman who is breast feeding or pregnant, you will not take part in the study because 
we don’t know how this medicine would affect your baby or your unborn child. If you are a woman 
who can become pregnant, or are the partner of a woman who can become pregnant, you will need 
to practice an effective form of birth control before starting study treatment, during study 
treatment, and for 1 month after the last drug infusion. If you think that you or your partner is 
pregnant, you should tell your study doctor or nurse at once. 
Effective forms of birth control include: 

abstinence 

intrauterine device (IUD)

hormonal [birth control pills, injections, or implants]

tubal ligation

vasectomy
RISKS OR DISCOMFORTS OF PARTICIPATION
If you choose to take part in this study, there is a risk that:

You may lose time at work or home and spend more time in the hospital or doctor’s office 
than usual

You may be asked sensitive or private questions which you normally do not discuss
Marizomib used in this study may affect how different parts of your body work such as your liver, 
kidneys, heart, blood and brain. The study doctor will be testing your blood and perform 
neurological exam and will let you know if changes occur that may affect your health.
Here are important points about side effects:

The study doctors do not know who will or will not have side effects.

Some side effects may go away soon, some may last a long time, or some may never go 
away.

Some side effects may interfere with your ability to have children.

Some side effects may be serious and may even result in death.
Here are important points about how you and the study doctor can make side effects less of a 
problem:

Tell the study doctor if you notice or feel anything different so they can see if you are 
having any symptoms.

The study doctor may be able to treat some side effects.

The study doctor may adjust the study drugs to try to reduce side effects.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 6 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Late side effects of the investigational agents may affect your ability to tolerate subsequent 
regimens of standard of care chemotherapy.
Below we show the most common and the most serious side effects that researchers know about. 
There might be other side effects that researchers do not yet know about. If important new side 
effects are found, the study doctor will discuss these with you.
Risks from study therapy
Marizomib
Common (occurring in more than 10 % of patients)

Constipation

Peripheral edema (swelling)

Muscular Weakness

Dizziness

Headache

Hallucinations

Difficulty sleeping

Change of taste

Fatigue (tiredness) 

Nausea 

Diarrhea

Vomiting

Decreased appetite

Infusion-related pain

Hypertension (high blood pressure)

Memory impairment
Occasional, but serious (occurring in less than 10% of patients)

Confusion

Seizure

Difficulty to speak or understand speaking

Loss of consciousness

Feeling drunk

Elevated mood
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 7 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

Gait imbalance and incoordination

Difficulty breathing

Lung infection

Low blood counts

Double Vision
Allergic reactions or reactions in the context with the infusions might occur during treatment. In 
general, these reactions are mild and can be handled with appropriate drugs. 
For the prevention of nausea or vomiting you will receive a premedication of ondansetron or 
prochlorperazine 30-90 minutes before the infusion.
If any of these side effects occur, you must inform your study doctor immediately.  
Marizomib may cause psychiatric symptoms in some participants, please call your study doctor if 
you experience any worrisome change in mood, behavior or thoughts.
Poor fluid intake with vomiting and/or diarrhea may hurt your kidneys,  contact your study doctors 
immediately if this is occurring.
Very important: please, do not drive or operate machinery if you develop central nervous system 
side effects while receiving marizomib.
Risk from Biopsy
If a tumor sample from a previous surgery/biopsy is not available, we will perform a biopsy 
(collect a sample of your tumor) to confirm your diagnosis and RELA fusion status.
The biopsy procedure usually causes only brief discomfort at the site from which the biopsy is 
taken.  Rarely, infection or bleeding may occur at the needle site.
Risks for MRI:
People are at risk for injury from the MRI magnet if they have some kinds of metal in their body.  
It may be unsafe for you to have an MRI scan if you have pacemakers or other implanted electrical 
devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall 
of a large artery), metal prostheses (including metal pins and rods, heart valves, and cochlear 
implants), permanent eyeliner, tattoos, an implanted delivery pump, or shrapnel fragments. 
Welders and metal workers may have small metal fragments in the eye. You will be screened for 
these conditions before having any MRI scan.  If you have a question about metal in your body, 
you should inform the staff. You will be asked to complete an MRI screening form before each 
MRI scan you have. 
In addition, all magnetic objects (like watches, coins, jewelry, and credit cards) must be removed 
before entering the MRI scan room.
People with fear of confined spaces may become anxious during an MRI. Those with back 
problems may have back pain or discomfort from lying in the scanner.  The noise from the scanner 
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 8 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
is loud enough to damage hearing, especially in people who already have hearing loss. Everyone 
having a research MRI scan will be fitted with hearing protection. If the hearing protection comes 
loose during the scan, you should let us know right away.
There are no known long-term risks of MRI scans.
Additional risk for gadolinium enhanced MRI:
Procedure
During part of the MRI you may receive gadolinium, a contrast agent, through an intravenous (iv) 
catheter. It will be done for medical purposes. 
It is not known if MRI with contrast is completely safe for a developing fetus. Therefore, all 
women of childbearing potential will have a pregnancy test performed no more than 24 hours 
before each MRI scan with contrast. The scan will not be done if the pregnancy test is positive. 
Risks
The risks of an IV catheter include bleeding, infection, or inflammation of the skin and vein with 
pain and swelling.  
Mild symptoms from gadolinium infusion occur in fewer than 1% of those who receive it and 
usually go away quickly.  Mild symptoms may include coldness in the arm during the injection, a 
metallic taste, headache, and nausea.  In an extremely small number, fewer than one in 300,000 
people, more severe symptoms have been reported including shortness of breath, wheezing, hives, 
and lowering of blood pressure. You should not receive gadolinium if you previously had an 
allergic reaction to it.  You will be asked about such allergic reactions before gadolinium is given.   
People with kidney disease are at risk for a serious reaction to gadolinium contrast called 
“nephrogenic systemic fibrosis” which has resulted in a very small number of deaths.  A blood test 
of your kidney function may be done within the month before an MRI scan with gadolinium 
contrast. You will not receive gadolinium for a research MRI scan if your kidney function is not 
normal or if you received gadolinium within the previous month. 
Most of the gadolinium contrast leaves the body in the urine.  However, the FDA recently issued 
a safety alert that indicates small amounts of gadolinium may remain in the body for months to 
years.  The effects of the retained gadolinium are not clear. At this time, retained gadolinium has 
not been linked to health risks in people whose kidneys work well. 
Some types of gadolinium contrast drugs are less likely to remain than others.  In this study, we 
will use the gadolinium contrast drugs that are less likely to remain. 
Please tell your research team if you have had any MRI scans in the past 12 months. We will 
also give you additional information called a “Medication Guide.”  Upon request, we will give you 
individual information about retained gadolinium we see on your studies. 
Risks from Blood Collection 
Side effects of blood draws include pain and bruising in the area where the needle was placed, 
lightheadedness, and rarely, fainting. When large amounts of blood are collected, low red blood 
cell count (anemia) can develop.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 9 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Risks from Questionnaires 
Questionnaires contain questions that can be sensitive for you to answer.  
Privacy Risks:
The following general points are indirectly related to your participation in the research study.
Privacy Risks Associated with Genetic Testing
It may be possible that genetic information from you could be used by law enforcement agencies 
or other entities to identify you or your blood relatives
Psychological or Social Risks Associated with Return of Incidental or Secondary Findings
As part of the research study, it is possible that you could learn that you have genetic risks for 
another disease or disability. This may be upsetting and, depending on what you learn, might create 
a need to make challenging decisions about how to respond. 
Although your genomic information is unique to you, you share some genomic similarities with 
your children, parents, brothers, sisters, and other blood relatives. Therefore, learning your 
research results could mean something about your family members and might cause you or your 
family distress. Before joining the study, it may be beneficial to talk with your family members 
about whether and how they want you to share your results with them. 
Protections against misuse of genetic information 
This study involves genetic testing on samples.  Some genetic information can help predict future 
health problems of you and your family and this information might be of interest to your employers 
or insurers. The Genetic Information Nondiscrimination Act (GINA) is a federal law that prohibits 
plans and health insurers from requesting genetic information or using genetic information. It also 
prohibits employment discrimination based on your health information. However, GINA does not 
address discrimination by companies that sell life insurance, disability insurance, or long-term care 
insurance. GINA also does not protect you against discrimination based on an already-diagnosed 
condition or disease that has a genetic component.
POTENTIAL BENEFITS OF PARTICIPATION
Are there benefits to taking part in this study? 
The aim of this study is to find out whether the experimental treatment can increase the time it 
takes for your disease to get worse. We do not know if you will receive personal, medical benefit 
from taking part in this study. Potential benefits could include shrinking of your tumor or lessening 
of your symptoms, such as pain, that are caused by the cancer. Because there is not much 
information about the drug’s effect on your cancer, we do not know if you will benefit from taking 
part in this study, although the knowledge gained from this study may help others in the future 
who have cancer. 
ALTERNATIVE APPROACHES OR TREATMENTS
Instead of being in this study, you have these options:

Getting standard FDA approved treatment or care for your cancer without being in a study

Taking part in another study
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 10 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

Getting comfort care, also called palliative care. This type of care helps reduce pain, 
tiredness, appetite problems and other problems caused by the cancer. It does not treat the 
cancer directly. Instead, it tries to improve how you feel. Comfort care tries to keep you as 
active and comfortable as possible.
Please talk to your doctor about these and other options.
STOPPING THERAPY
Your doctor may decide to stop your therapy for the following reasons:

if he/she believes that it is in your best interest

if your disease comes back during treatment

if you need to take medication that is not allowed on the study

if you become pregnant

if you have side effects from the treatment that your doctor thinks are too severe

if new information shows that another treatment would be better for you

if the investigator decides to end the study
In this case, you will be informed of the reason therapy is being stopped.
You can stop taking part in the study at any time. However, if you decide to stop taking part in the 
study, we would like you to talk to the study doctor and your regular doctor first.
If you decide at any time to withdraw your consent to participate in the trial, we will not collect 
any additional medical information about you. However, according to FDA guidelines, 
information collected on you up to that point may still be provided to Celgene or designated 
representatives. If you withdraw your consent and leave the trial, any samples of yours that have 
been obtained for the study and stored at the NCI can be destroyed upon request. However, any 
samples and data generated from the samples that have already been distributed to other 
researchers or placed in the research databases cannot be recalled and destroyed.
CONFLICT OF INTEREST
The National Institutes of Health (NIH) reviews NIH staff researchers at least yearly for conflicts 
of interest. This process is detailed in a Protocol Review Guide. You may ask your research team 
for a copy of the Protocol Review Guide or for more information. Members of the research team 
who do not work for NIH are expected to follow these guidelines but they do not need to report 
their personal finances to the NIH.
Members of the research team working on this study may have up to $15,000 of stock in the 
companies that make products used in this study. This is allowed under federal rules and is not a 
conflict of interest. 
The National Institutes of Health and the research team for this study are using therapies developed 
by Celgene through a joint study with your researchers and the companies. The company also 
provide financial support for this study. 
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 11 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
USE OF SPECIMENS AND DATA FOR FUTURE RESEARCH
To advance science, it is helpful for researchers to share information they get from studying human 
samples. They do this by putting it into one or more scientific databases, where it is stored along 
with information from other studies. A researcher who wants to study the information must apply 
to the database and be approved. Researchers use specimens and data stored in scientific databases 
to advance science and learn about health and disease. 
These specimens and data will be used for future research and shared with other researchers. We 
will not contact you to ask about each of these future uses. These specimens and data will be 
stripped of identifiers such as name, address or account number, so that they may be used for future 
research on any topic and shared broadly for research purposes. Your specimens and data will be 
used for research purposes only and will not benefit you. It is also possible that the stored 
specimens and data may never be used. Results of research done on your specimens and data will 
not be available to you or your doctor. It might help people who have cancer and other diseases in 
the future. 
If you do not want your stored specimens and data used for future research, please contact us in 
writing and let us know that you do not want us to use your specimens and/or data. Then any 
specimens that have not already been used or shared will be destroyed and your data will not be 
used for future research. However, it may not be possible to withdraw or delete materials or data 
once they have been shared with other researchers.
Genomic Data Sharing
As part of this research study, we will put your genomic data in a large database for broad sharing 
with the research community. These databases are commonly called data repositories. The 
information in this database will include but is not limited to genetic information, race and 
ethnicity, and sex.  If your individual data are placed in one of these repositories, they will be 
labeled with a code and not with your name or other information that could be used to easily 
identify you, and only qualified researchers will be able to access them. These researchers must 
receive prior approval from individuals or committees with authority to determine whether these 
researchers can access the data.
Summary information about all of the participants included in this study (including you) is being 
placed in a database and will be available through open access. That means that researchers and 
non-researchers will be able to access summary information about all the participants included in 
the study, or summary information combined from multiple studies, without applying for 
permission. The risk of anyone identifying you with this information is very low.
NIH policies require that genomic data be placed in a repository for sharing. Therefore, we cannot 
offer you a choice of whether your data will be shared.  If you do not wish to have your data placed 
in a repository, you should not enroll in this study.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 12 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
COMPENSATION, REIMBURSEMENT, AND PAYMENT
Will you receive compensation for participation in the study?
Some NIH Clinical Center studies offer compensation for participation in research. The amount 
of compensation, if any, is guided by NIH policies and guidelines.
You will not receive compensation for participation in this study. 
Will you receive reimbursement or direct payment by NIH as part of your participation?
Some NIH Clinical Center studies offer reimbursement or payment for travel, lodging or meals 
while participating in the research. The amount, if any, is guided by NIH policies and guidelines.
The NCI generally does not cover expenses during screening.  If you are scheduled for and begin 
treatment, the NCI will cover the cost for some of your expenses. Some of these costs may be paid 
directly by the NIH and some may be reimbursed after you have paid.  Someone will work with 
you to provide more information.
Will taking part in this research study cost you anything? 
NIH does not bill health insurance companies or participants for any research or related clinical 
care that you receive at the NIH Clinical Center. 

If some tests and procedures are performed outside the NIH Clinical Center, you may have 
to pay for these costs if they are not covered by your insurance company.

Medicines that are not part of the study treatment will not be provided or paid for by the 
NIH Clinical Center.

Once you have completed taking part in the study, medical care will no longer be provided 
by the NIH Clinical Center.
CLINICAL TRIAL REGISTRATION AND RESULTS REPORTING 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time.
CONFIDENTIALITY PROTECTIONS PROVIDED IN THIS STUDY  
Will your medical information be kept private? 
We will do our best to make sure that the personal information in your medical record will be kept 
private.  However, we cannot guarantee total privacy.  Organizations that may look at and/or copy 
your medical records for research, quality assurance, and data analysis include:

The NIH and other government agencies, like the Food and Drug Administration (FDA), 
which are involved in keeping research safe for people.

National Institutes of Health Intramural Institutional Review Board

The study Sponsor, Center for Cancer Research, NCI, or their agents

Qualified representatives from Celgene, the pharmaceutical company who produces 
marizomib.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 13 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
When results of an NIH research study are reported in medical journals or at scientific meetings, 
the people who take part are not named and identified.  In most cases, the NIH will not release any 
information about your research involvement without your written permission.  However, if you 
sign a release of information form, for example, for an insurance company, the NIH will give the 
insurance company information from your medical record.  This information might affect (either 
favorably or unfavorably) the willingness of the insurance company to sell you insurance.
If we share your specimens or data with other researchers, in most circumstances we will remove 
your identifiers before sharing your specimens or data. You should be aware that there is a slight 
possibility that someone could figure out the information is about you. 
Further, the information collected for this study is protected by NIH under a Certificate of 
Confidentiality and the Privacy Act. 
Certificate of Confidentiality
To help us protect your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
NIH researchers must not share information that may identify you in any federal, state, or local 
civil, criminal, administrative, legislative, or other proceedings, for example, if requested by a 
court.  
The Certificate does not protect your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by the NIH; or 
2. is required to be disclosed by Federal, State, or local laws, for example, when information 
must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or 
others including, for example, child abuse and neglect, and by signing below you consent to those 
disclosures. Other permissions for release may be made by signing NIH forms, such as the Notice 
and Acknowledgement of Information Practices consent.
Privacy Act
The Federal Privacy Act generally protects the confidentiality of your NIH medical records we 
collect under the authority of the Public Health Service Act.  In some cases, the Privacy Act 
protections differ from the Certificate of Confidentiality.  For example, sometimes the Privacy Act 
allows release of information from your medical record without your permission, for example, if 
it is requested by Congress. Information may also be released for certain research purposes with 
due consideration and protection, to those engaged by the agency for research purposes, to certain 
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 14 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
federal and state agencies, for HIV partner notification, for infectious disease or abuse or neglect 
reporting, to tumor registries, for quality assessment and medical audits, or when the NIH is 
involved in a lawsuit.  However, NIH will only release information from your medical record if it 
is permitted by both the Certificate of Confidentiality and the Privacy Act.
POLICY REGARDING RESEARCH-RELATED INJURIES  
The NIH Clinical Center will provide short-term medical care for any injury resulting from your 
participation in research here. In general, no long-term medical care or financial compensation for 
research-related injuries will be provided by the NIH, the NIH Clinical Center, or the Federal 
Government. However, you have the right to pursue legal remedy if you believe that your injury 
justifies such action.
PROBLEMS OR QUESTIONS
If you have any problems or questions about this study, or about your rights as a research 
participant, or about any research-related injury, contact the Principal Investigator, Mark Gilbert, 
MD, Telephone: 240-760-6023, Email: mark.gilbert@nih.gov. You may also call the NIH Clinical 
Center Patient Representative at 301-496-2626, or the NIH Office of IRB Operations at 301-402-
3713, if you have a research-related complaint or concern.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021


PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/02/2020
Page 15 of  15
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Adult Research Participant: I have read the explanation about this study and have been given the opportunity 
to discuss it and to ask questions. I consent to participate in this study.
Signature of Research Participant
Print Name of Research Participant
Date
Legally Authorized Representative (LAR) for an Adult Unable to Consent: I have read the explanation 
about this study and have been given the opportunity to discuss it and to ask questions. I am legally authorized 
to make research decisions on behalf of the adult participant unable to consent and have the authority to provide 
consent to this study. As applicable, the information in the above consent was described to the adult participant 
unable to consent who agrees to participate in the study.
Signature of LAR
Print Name of LAR
Date
Investigator:
Signature of Investigator
Print Name of Investigator
Date
Witness to the oral short-form consent process only: This section is only required if you are doing the oral 
short-consent process and this English consent form has been approved by the IRB for use as the basis of 
translation.
Witness:
Signature of Witness*
Print Name of Witness
Date
*NIH ADMINISTRATIVE SECTION TO BE COMPLETED REGARDING THE USE OF AN 
INTERPRETER:
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent and served as a witness. The investigator obtaining consent may not 
also serve as the witness.
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent but did not serve as a witness. The name or ID code of the person 
providing interpretive support is:
.
IRB NUMBER: 19C0011
IRB APPROVAL DATE: 01/27/2021